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General introduction
Rheumatoid Arthritis (RA) is a common disease, the most prominent feature of which 
is a symmetric chronic polyarthritis. This leads to pain, stiffness and functional 
limitations and can also lead to structural damage of the cartilage and the underlying 
bone in the joint. Treatment of RA has traditionally consisted of Disease Modifying 
Anti-Rheumatic Drugs (DMARDs), a divers group of drugs, the disease modifying 
properties of which have often been discovered by chance. These agents are 
however not effective in all patients and in addition their usefulness is limited by side 
effects (1).
In the last decade, the knowledge about the pathogenesis of RA has increased. 
Proinflammatory cytokines like Tumour Necrosis Factor a (TNFa) and interleukin ß 
(IL-1ß) are known to play a pivotal role in the inflammation in RA and other chronic 
inflammatory diseases (2-4). Based on these insights, new - so-called biological - 
agents have been developed. These agents have specifically been designed to block 
the action of immune cells or to antagonise cytokines and other mediators produced 
by these cells (5). Among these new therapies, strategies to neutralise the function of 
TNFa seem the most promising. Blockade of the actions of TNFa can be 
accomplished with monoclonal antibodies directed against TNFa or with TNF 
receptor fusion proteins that bind with TNFa, preventing its binding with signalling 
receptors. Both modalities have been shown to be effective in the treatment of RA 
(6,7).
One monoclonal antibody that recently has been approved for treatment of RA 
(infliximab) has been constructed using both human and murine protein sequences. 
The use of such chimeric antibodies is potentially limited by the formation of human 
anti-chimeric antibodies (HACA), which may lead to a shortened half-life time or 
adverse reactions (8). Adalimumab (D2E7, Knoll) is a fully human monoclonal 
antibody against TNFa, developed using phage display techniques (9) undergoing 
phase III studies.
The main subject of this thesis is the evaluation of several aspects of treatment of 
patient with RA with the human anti-TNFa MoAb adalimumab. These aspects include 
efficacy, mode of action, safety and use in daily clinical practice. Chapter 6 and 7 
also include data derived from patients treated with a TNF p55 receptor fusion 
protein (Ro 45-2081, lenercept, Roche) (10,11).
To study the effects of any treatment intervention in patients with RA, the impact on 
disease activity has to be measured. As no single variable can be considered the 
"golden standard” for disease assessment in RA, a wide variety of variables have 
traditionally been used in rheumatoid arthritis clinical trials. In the last decade much 
progress has been made in the assessment of disease activity in RA. Consensus has 
been reached on a minimum set of variables that should be measured in clinical trials 
and powerfull combined disease activity indices have been developed (12,13).
In chapter two, the current state-of-the-art in disease assessment in RA is reviewed. 
In addition, the level of compliance in recently published clinical studies towards the
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guidelines that have been developed was assessed. To this aim, all clinical studies 
comparing two or more interventions that have been published in 1999 were 
reviewed.
Aspects of efficacy of treatment with anti-TNFa are discussed in chapter three and 
four. In chapter three the short-term efficacy, toxicity and pharmacokinetics of i.v. 
treatment with increasing doses of adalimumab were studied in a randomised, 
placebo-controlled study in 120 patients. These patients with a longstanding disease 
had previously been treated with a large number of DMARDs. The patients were 
randomly assigned to one of five dose groups or placebo. The American College of 
Rheumatology (ACR) improvement criteria and the European League Against 
Rheumatism (EULAR) response criteria were used to judge individual response 
percentages and the toxicity was assessed using the Common Toxicity Criteria.
The goals of treatment of RA are not only ameliorating the signs and symptoms of 
the disease, but also preventing radiologic damage and development of functional 
disability. The first reports on the effect of TNFa blocking strategies on this important 
outcome variable show that these therapies retard radiologic progression (6,7,14). 
Since radiologic progression is a slow process, the effect of a treatment intervention 
on radiologic damage can only be judged after a substantial period of time. This way 
an undesired delay will occur. Therefore, the search for markers that can predict 
radiologic outcome at an early timepoint has been intensified in recent years (15). In 
chapter four the effect of long-term treatment with monotherapy with anti-TNFa on 
radiological outcome is studied in 47 patients. Radiological outcome is compared 
between patients that have been treated with anti-TNFa for two years and patients 
that dropped out earlier because of toxicity or lack of efficacy and were treated with 
other DMARDs. In addition, a number of biological markers were tested at baseline 
to assess their predictive value for radiologic progression. These markers were 
chosen since they reflect bone and cartilage turnover (HC gp-39, COMP and the 
metalloproteinases 1 and 3) (16-18) or because they are involved in endothelial 
activation (sE-selectin and sICAM-1), which plays an important role in the 
inflammation that characterises RA (19).
The mode of action of TNFa blockade in RA has not been unravelled yet. This 
subject is targeted in chapter five to seven. Several studies with another IgG1 anti- 
TNFa MoAb (infliximab) have shown that blocking TNFa reduces the acute phase 
reaction and decreases the local and systemic levels of adhesion molecules in RA 
patients (20-22). In vitro studies have also shown that neutralisation of TNFa reduces 
the production of IL-1 ß in synovial cultures (23). Whether such therapies also 
downregulate the synovial expression of I L-1 and TNFa in RA has not been fully 
elucidated yet, although some data exist supporting this theory (24,25). In chapter 
five the short-term effects of the first dose of adalimumab or placebo on the 
homeostasis of the two main pro-inflammatory cytokines I L-1 ß and TNFa at the 
systemic and the synovial level are investigated.
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The HPA axis could also play a role in the mechanism of action. Although acute 
TNFa or IL-1 administration is known to stimulate the hypothalamus-pituitary-adrenal 
axis (HPA-axis) (26,27), the HPA axis in patients with RA does not seem to be 
activated and has even been reported to be impaired (28). Glucocorticoids, both 
endogenous and exogenous, are strong inhibitors of TNFa production (29). 
Therefore, it can be hypothesised that TNFa production in RA is enhanced by 
relative deficit of glucosteroid activity. Alternatively, it could be that TNFa has a 
suppressive effect on the HPA axis in this chronic inflammatory state, in contrast to 
the effects of TNFa in acute models. In this scenario, blockade of TNFa could lead to 
increased activity of the HPA axis. The latter would be concordant with the clinical 
and laboratory effects of anti-TNFa treatment that occur very rapidly and mimic 
treatment with corticosteroids. In chapter six the effect of treatment with anti-TNFa 
on the HPA axis is assessed. Eighteen patients receiving adalimumab, lenercept or 
placebo were studied. Several variables that reflect the activity of the HPA axis were 
measured.
RA can be accompanied by pathology occurring outside the joints. One of the 
common extra-articular manifestations of RA is vasculitis. Vasculitis in RA usually 
affects small vessels and commonly involves the skin, causing nail-fold infarcts, and 
in more severe cases digital gangrene and leg ulcers (30). Vasculitis can also affect 
larger vessels leading to organ damage. The effect of TNFa-blockade on RA related 
vasculitis is unknown. Chapter seven describes the positive effect of treatment with 
lenercept on skin vasculitis in one patient with RA.
Neutrophilic granulocytes (neutrophils) play an important role in the inflammation that 
characterises RA. These cells are abundantly present in RA synovial fluid and 
increased production of reactive oxygen species (ROS) by these cells can induce 
cartilage damage (31,32). Modulation of neutrophil functions could therefore be 
beneficial in RA. TNFa is involved in the in-vivo priming of neutrophils and in the 
induction of ROS production and chemotaxis (33-35). It has been suggested that 
reduction of neutrophil priming and ROS production may be implicated in the 
mechanism of action of several antirheumatic drugs, including methotrexate and 
leflunomide (36-39). Whether this also holds true for TNFa blocking agents is still 
unknown.
On the other side, alteration of neutrophil function by TNFa blocking agents could 
yield adverse effects. Data derived from experimental animal models suggest 
increased susceptibility for infections (40-42) and impaired clearance of (pre) 
malignant cells (43-45) after TNFa neutralisation. These adverse effects are partially 
mediated through an impaired function of phagocytic cells, including neutrophils.
In chapter eight the effect of treatment with anti-TNFa on neutrophil function is 
assessed. Neutrophil ROS production and chemotactic capacity were measured ex­
vivo. Moreover, two in vivo models were used to study neutrophil migration. Migration 
into the synovial joints was measured using scintigraphy with radiolabelled
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autologous leukocytes. Neutrophil migration to a non-target organ (the skin) was 
assessed using an ultraviolet type B skin inflammation model.
Except for local injection site reactions (46) and infusion reactions (47,48), no clearly 
related specific adverse effects of anti-TNFa treatment have been published, 
although it is suggested that blockade of TNFa could possibly lead to reactivation of 
prior tuberculosis infections. In chapter nine a patient is described that develops a 
nephrotic syndrome during treatment with anti-TNFa. The possible pathofysiological 
pathways are discussed.
Two anti-TNFa agents have recently reached clinical practice, but their exact place in 
the treatment of RA has yet to be established (49). Anti-TNFa strategies share some 
unique characteristics compared to standard DMARD therapies. The onset of action 
is very rapid, especially after intravenous administration. Also, based on the blocking 
characteristics of these agents -  blocking TNF with a fixed ratio - (50) and the huge 
differences in cytokine levels in patients with RA (51), it is conceivable that the inter­
individual variation in effective dose of anti-TNFa is large. If present, this large inter­
patient variation could result in gross over- or undertreatment when standard dosing 
schedules are applied. In addition, treatment with TNFa blocking strategies is 
characterised by very high costs. For prevention of possible adverse effects resulting 
from overtreatment and to diminish costs, individual dosing is warranted.
To this aim, we developed a treatment protocol that can be used in daily clinical 
practice (chapter ten). This protocol was tested in patients that had been treated 
with anti-TNFa for two years and had stable disease activity. The disease activity 
was monitored using the Disease Activity Score (DAS28) (52), a combined disease 
activity index, ranging from 0-10. The dose of anti-TNFa was lowered in steps and 
adjusted for each individual patient based on the DAS28.
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Abstract
For many years the clinical evaluation of patients with rheumatoid arthritis (RA) has 
been hampered by the lack of consensus about variables that should be used to 
follow the course of the disease. We summarise the progress that has been made in 
the last decade in assessment of rheumatoid arthritis; the core set variables, the 
Disease Activity Score (DAS), and the EULAR and ACR improvement criteria. 
Furthermore the compliance towards the use of the core set criteria and improvement 
criteria was reviewed in clinical studies published in 1999.
Although consensus has been reached on the core set variables and powerful 
improvement criteria have been developed, our results show that standardisation of 
the instruments to measure these variables has not taken place. Prudent 
implementation of these tools in clinical studies is not yet common practice. This 
observation warrants further attention.
Introduction
For many years the clinical evaluation of patients with rheumatoid arthritis (RA) has 
been hampered by the lack of consensus about variables that should be used to 
follow the course of the disease. This has led to the use of a broad spectrum of 
variables to measure disease activity. These include clinical variables like joint 
scores, grip strength, walking time, morning stiffness, questionnaires to assess 
functional capacity, and patient’s and observer’s judgement of pain and disease 
activity using Visual Analogue Scales (VAS). Laboratory variables often employed 
are acute phase reactants or viscosity. Also different outcome measures are being 
used including radiographic damage, and recently also magnetic resonance imaging, 
ultrasound and bone density.
The validity and test characteristics of many of these variables, however, are poor or 
unknown. Also for both practical and economical reasons the variables that are being 
employed in a clinical study should not yield redundant information, e.g. should not 
give information already provided by another measure. Furthermore, it is difficult to 
compare the results of clinical studies or to perform meta-analyses when different 
measures are used. The same holds true for comparison of baseline patient 
characteristics.
In the last decade much effort has been directed towards refining and validating 
disease assessment to overcome the aforementioned problems. In this report, first 
an overview is given of the current existing guidelines for measuring disease activity 
in RA. In addition, the level of compliance towards these recommendations is 
assessed by reviewing clinical studies concerning RA published in 1999 in seven 
journals.
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Overview of existing guidelines
Both the American College of Rheumatology (ACR) and the European League 
Against Rheumatism (EULAR) have created core sets based on a minimal set of 
validated variables that needs to be measured in Rheumatoid Arthritis Clinical Trials 
(RACT) (1,2). The variables included in the core set are the following: number of 
tender joints, number of swollen joints, patient’s pain score, patient’s global 
assessment of disease activity, observer’s global assessment of disease activity, an 
acute phase reactant, a physical function score, and a radiologic evaluation when the 
study duration is equal to or exceeds one year. Consensus regarding these core sets 
has been reached based on the validity and the sensitivity to change for the variables 
used in clinical trials. Those measures that do not show good test characteristics and 
those that give redundant information have been excluded. It has still to be 
determined whether these core sets have to be extended in the future with other 
variables such as socio-economic status and psychological variables.
To assess individual respondership in RACT, composite improvement criteria based 
on these core set variables were developed. The ACR has proposed the preliminary 
revised criteria for response (table 1), dichotomous criteria for response that include 
all the core set variables excluding radiologic outcome (3). The EULAR has adopted 
the Disease Activity Score (DAS), a continuous score of disease activity ranging from
0 to 10 that is calculated using three or four core set variables. Using the DAS, the 
EULAR respondership criteria (table 1) have been created, defining response in three 
groups: no, moderate and good response (4). Both improvement criteria, although 
designed using a different approach, demonstrate good validity, are sensitive to 
change and can discriminate between placebo and effective treatment (5).
Table 1. Improvement/respondership criteria developed by the ACR and the EULAR
ACR criteria* EULAR criteria**
20% improvement swollen and tender joint counts DAS28=0.56VT28+ 0.28S28+ 0.7lnESR +
20% improvement in 3 out of 5 variables 0.014GH
Acute phase reactant Good response : DAS28 below 3.2 and
Patient’s assessment of pain improvement with 1.2
Patient’s assessment of global disease activity Moderate response = DAS28 below 5.1 and
Observer’s assessment of global disease activity improvement with 0.6-1.2 or DAS28 above 5.1
Patient’s assessment of physical function and improvement>1.2
* ACR 50% and 70% should read 50% or 70% respectively instead of 20%.
** The equation shown is the calculation of the Disease Activity Score from the components: tender 
joint count (T28), swollen joint count (S28), the Erythrocyte Sedimentation Rate (ESR) and the 100 
mm VAS for the patients global disease activity (GH).
The original DAS score is calculated with another formula including the Ritchie Articular Index and 
44 swollen joint count instead of 28 tender and swollen joint counts.
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Although it is clear now which variables to assess in RACT, the methods used to 
measure these variables still lack standardisation. Several joint counts for example 
have been and are still being used, ranging from 68/66 joint counts to 28 joint counts. 
Because the latter have been demonstrated on several occasions to give as much 
information as the more comprehensive joint counts, it makes sense to use these 
simple counts (6,7,8). Consensus is leaning towards the use of these simple joint 
counts, and these have been included now in the EULAR core set recommendations 
(9).
For other core set variables, however, standardisation is further away. Both different 
semi-quantitative scores (e.g. Likert) and different VAS (horizontal/vertical, different 
sizes, with or without marks) are being used to determine patient’s and observer’s 
global assessment of disease activity and pain. Also for assessment of radiologic 
damage different scores (e.g. Larsen, Sharp, modified Sharp/van der Heijde, 
Kellgren) exist. Functional status is often assessed by the Health Assessment 
Questionnaire (HAQ), of which several translations and versions (for example 
modified HAQ) have been developed, but also other questionnaires are being used. 
Even for laboratory variables standardisation has not reached an optimum. The ESR 
is usually measured according to the Westergren method (although this is often not 
mentioned) but CRP levels are still not interchangeable between different 
laboratories. All the different instruments that are being used to measure core set 
variables yield different results that are not interchangeable in the majority of cases. 
To prevent the “Babylonian confusion of languages” in the comparison of results of 
RACT, further standardisation of the instruments for measuring these core set 
variables should be reached.
Compliance towards existing guidelines
Methods
To investigate whether the aforementioned guidelines are being followed, all the 
clinical studies concerning therapeutic interventions in RA patients published in 1999 
in the following seven Journals were reviewed: Lancet, New England journal of 
Medicine, Arthritis and Rheumatism, Annals of Rheumatic Diseases, Rheumatology, 
Journal of Rheumatology and the Scandinavian journal of Rheumatology. Inclusion 
criteria were comparison of two or more treatment modalities for RA (including 
placebo) and a study duration > 3 months. Studies that compared treatment with 
analgesics or NSAIDs were excluded. The primary study measure on which the 
conclusions were based (individual response criteria), the variables assessed in the 
study, and the method of assessment and references were determined.
Deviations from the current recommendations for disease assessments that were 
found were classified as either major or minor deviations. Major deviations are those 
that do not allow valid conclusions to be made regarding the number of patients that 
show individual response. This includes the absence of individual response criteria or 
the use of not validated response criteria. The absence of one or more core set
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variables is also regarded as major deviation because this severely hampers the 
possibility of comparison with other studies. The second group, labelled minor 
deviations, includes the use of not recommended instruments to measure a particular 
variable with, missing references regarding the instruments that were used (e.g. HAQ 
version or translation). Differences in radiologic score were not taken into account, as 
radiologic evaluation is only recommended in clinical studies with a follow-up equal to 
or exceeding one year.
Results
Twelve studies fulfilled the inclusion criteria (appendix A). Results are depicted in 
table 2. For each study, the primary outcome measure is shown. Furthermore, the 
core set variables that are assessed are listed with the method used for evaluation of 
that particular variable.
Major deviations were found in seven studies. These consisted of the lack of an 
individual response measure (study 1, 4 and 6) and the use of non-validated or 
adjusted response criteria (study 2, 9 and 11). In five studies (study 1, 2, 4, 11 and 
12) not all core set variables were assessed although study 12 provides correct 
individual response percentages using the DAS and the EULAR response criteria. 
Minor deviations from the guidelines are seen in all studies. These included for 
example the use of the modified HAQ instead of the original HAQ and missing 
references or description of the methods used. The studies printed in bold (n=5) are 
complying with the existing guidelines.
Discussion
The last decade the methods available to follow the course of RA have been vastly 
improved. Consensus has been reached on a core set of variables to measure and 
powerful improvement criteria have been developed and validated. The results of the 
review of clinical studies, however, show that the guidelines that have been 
developed for measuring disease activity in RA are not being followed in the majority 
of studies in 1999. Only five of twelve studies are compliant with the current 
recommendations and even these studies differ in the instruments that are used to 
measure the core set variables with.
Regarding the use of composite response criteria, things seem clear. For individual 
improvement or response status, both the EULAR criteria using the DAS and the 
ACR criteria have been extensively validated and at least one of these response 
criteria should therefore be used. The use of alternative response criteria, for 
example ACR improvement criteria with 20% improvement in 2 out 4 variables 
instead of 3 out 5 variables is thus lacking rationale.
The same holds true for the core set of variables that should at least be included in 
RACT. The assessment of extra variables does not influence the primary endpoints 
for efficacy of a clinical study, but missing variables could hamper comparability with 
other clinical studies.
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Table 2. RA clinical studies published in 1999 (n=12); response criteria and core set variables.
Study no 1 2 3 4 5 6 7 8 9 10 11 12
Response criteria
DAS28(4) 
Core set variables
ACR20 
(2 of 3 
variables)
DAS(3)+
EULAR
ACR20
ACR20 ACR20 ACR20
ACR50
Paulus * ACR20
ACR50/70
ACR20 
(2 of 4 
variables)
DAS(3)+
EULAR
Tender # T28 T40 RAI T66 T68 T48, RAI T28 T68 T66 T68 T69 G RAI
Swollen # S28 S40 S44 S66 S66 S48 S28 S66 S64 S66 S66 G ?
Pain f ? - V 100mm V 100mm 0-10 V 100mm V 100mm V 100mm V 100mm V 100mm - 1-4
Pt’s global f ? 0-10 L 1-5 - 0-10 1-4 V 100mm V 100mm V 100mm V 100mm 1-5 ** -
Observer’s
globa lf
- 0-10 L 1-5 - 0-10 1-4 V 100mm V 100mm V 100mm V 100mm 1-5 ** -
ESR/CRP esr/crp Crp esr/crp esr/crp crp esr/crp esr esr crp/esr crp crp/esr Crp/Esr
Functional 
status §
? HAQ HAQ HAQ HAQ 
(no ref)
HAQ MHAQ HAQ MHAQ HAQ MHAQ HAQ
LEE
Paulus criteria need a change of 2 scales on a 5-point scale instead of a VAS
** 1 to 5, 1 being no improvement and 5 being excellent improvement
# RAI= Ritchie Articular Index, G = graded (0-3)
t  L= Likert scale, V=VAS
§ (M)HAQ = (modified) Health Assessment Questionnaire
not done
? the variable is assessed but the instrument is not mentioned
Consensus has, however, not been reached yet on the instruments to measure the 
core set variables with. The recommendations leave room for several different 
instruments to measure for example functional capacity and patients’ and observers’ 
opinion on disease activity and pain. Although it is possible that these instruments 
turn out to be interchangeable, the influences of the use of these different 
instruments on the individual response criteria are still unknown. The ACR 
improvement criteria for example have been developed using the original HAQ to 
measure functional capacity. Recently the modified HAQ is often used instead. The 
latter makes use of transition questions (is a function better, the same or worse 
compared to before) and it is not clear how these questions can be used to calculate 
20% improvement. This does not imply that the modified HAQ can never be used as 
part of the ACR improvement criteria. Rather, validation of this method has to take 
place prior to this substitution.
The question raises why support for the proposed core sets and response criteria is 
lacking. It can be argued that this is caused by the short time between publication of 
the core-sets (1992) and response criteria (1995) and the design of the studies 
included in our survey. Although the design of some of these clinical studies may 
date from before 1995 (publication of response criteria), the core set variables 
published in 1992 should however at least have been included.
In conclusion we would like to stress the importance of unambiguous and careful use 
and description of methods used for clinical assessment. There is a lot to gain if 
optimisation is reached at all levels: a smaller sample size needed to find significant 
differences, less work and costs due to fewer variables that need to be assessed and 
finally comparability between patient populations and responder percentages. To 
meet the goals mentioned above also the compliance towards the use of the 
proposed core sets and improvement criteria in RACT should be carefully monitored 
in the future, as there is still room for improvement.
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Abstract
Objectives This dose-ranging study assessed the pharmacokinetics, the safety 
profile, and efficacy of the fully human anti-TNFa monoclonal antibody adalimumab 
(D2E7) in patients with long-standing active rheumatoid arthritis.
Methods This was a randomised, double blind, placebo-controlled study of single 
intravenous injections of ascending doses (0.5 to 10 mg/kg) of adalimumab in 5 
cohorts of 24 patients each (18 adalimumab, 6 placebo). The clinical response was 
measured by changes in composite scores as defined by the criteria of the European 
League Against Rheumatism and the American College of Rheumatology.
Results Single doses of adalimumab showed a rapid onset of clinical effect (24 
hours to 1 week) with peak efficacy at 1 to 2 weeks which was sustained for at least
4 weeks and as long as 3 months in some patients. EULAR response was seen at 
least once during the 4 week period after study drug injection in 29% of patients in 
the placebo group as well as in 41%, 78%, 72%, 89%, and 100% in the 0.5, 1.0, 3.0,
5.0, and 10.0 mg/kg group, respectively. No dose-related increases in adverse 
events were observed in the adalimumab-treated patients when compared to that 
seen in the placebo group. Adalimumab systemic drug exposure (AUC0-inf) increased 
linearly with an increase in dose. The mean total serum clearance was 0.011 to 
0.017 L/h, and the steady state volume of distribution ranged from 4.7 to 5.5 L. The 
estimated mean terminal half-life ranged from 10.0 to 13.6 days for the five cohorts 
with an overall mean half-life of 12 days.
Conclusion Treatment with the fully human monoclonal antibody adalimumab is safe 
and well tolerated when administered as a single intravenous injection at doses up to
10 mg/kg and is associated with a clinically significant improvement in the signs and 
symptoms of active rheumatoid arthritis.
Introduction
Current treatments for rheumatoid arthritis (RA) have little impact on the long-term 
course of the disease (1). Recently the focus of novel therapies for RA has shifted 
towards attempts to target the cellular inflammatory mechanisms involved in long­
term tissue destruction in order to slow or prevent disease progression. The pro- 
inflammatory cytokines, interleukin (IL)-1 and tumour necrosis factor (TNF)-a, are 
known to play an important role in the induction and maintenance of inflammatory 
synovitis and articular matrix degradation and therefore modulation of their synovial 
activity provides the potential for novel therapeutic interventions in RA (2,3). 
Biological agents such as anti-cytokine antibodies and soluble receptors that bind 
and neutralise these mediators have been developed as potential therapies and 
several are currently being evaluated. These new biological treatment modalities 
include chimeric and humanised monoclonal antibodies (4-6), as well as fusion 
proteins of soluble TNF receptor proteins with human immunoglobulin Fc regions (7). 
Whilst therapy with these modalities has shown promising results in terms of 
tolerability and duration of clinical benefit, long-term use of non-human constructs
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may be limited by immune responses mounted against their foreign components 
thereby reducing their half-life and thus efficacy (8). In addition, there may be an 
increased risk of adverse events due to immune complex formation. Given these 
limitations, the development of a fully human (i.e., 100% human peptide sequences 
in a natural configuration) therapeutic antibody has considerable potential to provide 
improved safety and efficacy in long-term use (8).
Adalimumab is a fully human anti-TNFa monoclonal antibody (MoAb) consisting of 
100% human sequences and has been developed using phage display technology 
(9). The adalimumab antibody has been extensively tested in animal models of 
disease and in standard in vitro and in vivo safety and toxicity assays. Adalimumab 
has been shown to be both safe and highly effective in these experimental systems. 
The purpose of this dose-ranging study reported here was to assess the clinical 
pharmacology profile and evaluate the safety, tolerability and efficacy of adalimumab 
over a range of doses in patients with active rheumatoid arthritis. The study results 
have been previously reported in abstract form (10).
Patients and methods
This was a multicenter, double blind, randomised, placebo-controlled, ascending 
single-dose study in cohorts of patients with active RA carried out in one centre in the 
Netherlands and two in Germany. The study was conducted under GCP guidelines in 
accordance with the principles of the Declaration of Helsinki and followed Ethics 
Committee approval. All patients gave written informed consent to participate in the 
study.
Patients and study design
The study population included males and females > 18 years of age (women of 
childbearing potential required a negative pregnancy test and had to use a reliable 
method of contraception to be included in the study) with a diagnosis of RA and 
evidence of active inflammatory synovitis as defined by a disease activity score 
(DAS) of > 3.2 at study entry (11). Body weight of patients was limited to < 100 kg. 
Important exclusion criteria included intra-articular or intra-muscular corticosteroid 
treatment within 4 weeks prior to study screen, joint surgery within 2 months prior to 
study screen (if those joints were to be included in the study assessment), and 
treatment with any investigational drugs of a chemical or biological nature 2 months 
or 12 months (respectively) prior to pre-study screen.
After a 3-week washout period for DMARDs, a single intravenous injection lasting 3-5 
minutes of study drug was administered to qualified patients hospitalised for 24 
hours. The study had five ascending cohorts with 24 patients each. Within each 
cohort, 18 patients received adalimumab and 6 received matching placebo. Doses of 
adalimumab were 0.5, 1, 3, 5 and 10 mg/kg, respectively. The cohort with the next 
higher dose was started only if no dose-limiting adverse events were observed at the 
previous dose level.
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Concomitant treatment with anti-rheumatic/anti-inflammatory drugs was not allowed 
during the study with the exception of stable doses of NSAIDs and/or corticosteroids 
with a maximum daily dose equivalent to 10 mg of prednisolone. Analgesics including 
OTC preparations, propoxyphene, or codeine alone or in combinations were not 
allowed with the exception of infrequent acetylsalicylic acid (ASA: maximum daily 
dose of 500 mg) or equivalent treatments for mild pain. Regular intake of low-dose 
ASA for prophylaxis of myocardial infarction was allowed.
Patients were followed with weekly examinations for at least 4 weeks. If the study 
drug showed efficacy in individual patients beyond this 4-week period, they continued 
under observation until their disease status deteriorated in order to assess the 
duration of efficacy of single-dose administration up to month 3. After completion of 
this phase of the study, patients were offered the option to enter a continuation phase 
either at the end of the 4-week follow-up period (day 29) or upon clinical 
deterioration. The results of the continuation phase will be reported separately.
Pharmacokinetic assessments
Pharmacokinetic (PK) analysis was performed using a non-compartmental approach 
for intravenous (iv) bolus delivery. The PK analyses were performed using 
commercially available PK software (KINETICA TM 2000, Version 3.0, InnaPhase, 
France). The PK variables assessed were the model-dependent parameters for 
serum concentrations of drug: area under the serum concentration-time curve from 
time zero to infinity (AUC 0.inf); serum clearance (CL); volume of distribution at 
steady-state (Vss); and terminal log-linear phase half-life (t/2).
Blood samples were collected pre-dose, after end of injection (5 min) and 20 
minutes, 1, 4, 8, 12, and 24 hours post-dose. Additional samples were taken weekly 
for up to six weeks post-dose and bi-weekly thereafter up to a maximum of 12 weeks 
post-dose. Samples were assayed for adalimumab content using a validated double­
antigen, sandwich ELISA method. The assay is sensitive (limit of quantitation = 0.72 
^.g/rnL), precise (CV < 12%; interassay) and accurate (deviation from nominal < ± 20 
%; interassay).
Safety assessments
Safety and tolerability were evaluated based on reported adverse events, standard 
hematology and biochemistry parameters and urinalysis, vital signs and ECG. In 
addition, total immunoglobulins M, G, A, and E, as well as coagulation factors (aPTT, 
PT and fibrinogen) and complement activity (C1q, C3, C4) were assessed using 
standard methods. Pulse rate, blood pressure, body weight, and temperature were 
measured pre-dose and at various times up to day 29. A twelve lead ECG was 
recorded pre-dose and 4-6 hours post-dose as well as on day 29.
Efficacy assessments
Efficacy analyses up to day 29 were based on the intent-to-treat population within 
this period. Efficacy variables were determined at each patient visit. Tender joint
30
count (TJC) and Ritchie Articular Index were assessed in 53 joints or regions by 
pressure and joint manipulation on physical examination. Standard pain grading was 
used for calculation of the Ritchie Index (12). For swollen joint count (SJC), 44 joints 
were rated by physical examination as either swollen or not swollen. Patient’s global 
assessment of disease activity, pain and general health and physician’s assessment 
of disease activity were recorded using standard 100-mm visual analogue scales 
(VAS). Erythrocyte Sedimentation Rate/1hr (ESR) was assessed as a measure of the 
acute phase reaction.
From the above assessments, a Disease Activity Score (DAS) was calculated 
according to the formula: 0.53938 x V(Ritchie Index) + 0.06465 x swollen joint count + 
0.33 x ln(ESR mm/1st hour) + 0.00722 x patient’s general health assessment (11). 
The functional capacity was assessed using either the Dutch HAQ (Health 
Assessment Questionnaire) or the German HAQ depending on the center (13, 14). 
EULAR responses were compared to those defined by the American College of 
Rheumatology (ACR) at the 20% and 50% improvement levels (15). Responses 
based on EULAR criteria were defined as good response (DAS decrease from 
baseline > 1.20 and current DAS < 2.40), no response (DAS decrease from baseline 
< 0.6 or patients with an improvement of >0.6 but < 1.20 and DAS attaining >3.7). 
The improvement of the remaining patients is classified as moderate response (11). 
For the ACR 20 and 50 a positive response was considered to be 20 or 50% 
respectively for improvements in Ritchie Index, swollen joint count and at least three 
of five other variables (patient’s assessment of pain, patient’s or physician’s 
assessment of disease activity, HAQ score and ESR).
Statistical methodology
Descriptive statistics and simple linear regression analyses were performed to 
indicate variability in PK data and to establish dose-proportionality.
Analyses of efficacy data were descriptive. Accordingly, 95% confidence intervals 
(CI) were calculated for treatment group means or percentages, for differences 
between dose groups of adalimumab treatment versus placebo and actual or percent 
differences from pre-dose data. Safety data were also analysed using descriptive 
statistics.
Results
Patients
A total of 120 patients were randomised to receive study medication. No significant 
differences between study groups were detected in pre-treatment characteristics or 
baseline disease activity (Table 1). The mean age of patients in the study ranges 
from 53 to 59 years, and most were female (64%). Overall, the mean duration of RA 
was 11.5 years. All randomised patients had received therapies for RA prior to study 
entry. These included both drug treatment and surgery.
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Table 1. Demographic and baseline disease characteristics
Placebo
0.5
Adalimumab (mg/kg) 
1 3 5 10
Total
No. Patients 31 17 18 18 18 18 120
Sex, n (%) 
Male 9 (29) 7 (41) 8 (44) 10 (56) 3 (17) 6 (33) 43 (36)
Female 22 (71) 10 (59) 10 (56) 8 (44) 15 (83) 12 (67) 77 (64)
Age in yr. ± SD 55±11 54±15 58±8 54±11 59±12 53±16 55±12
(Mean (range)) (31-75) (26-72) (42-76) (24-71) (39-76) (24-80) (24-80)
Duration of RA 10.0 11.0 11.2 10.8 14.5 8.9 11.5
in yr. (mean)
Measures of arthritis activity (mean values) 
DAS 5.16 5.14 5.81 5.35 4.93 5.63 5.32
TJC [0-53] (no.) 23.5 23.8 27.1 21.8 20.7 27.0 23.9
SJC[0-44] (no.) 18.4 18.4 20.8 20.8 15.9 20.4 19.1
ESR (mm/hr) 39.0 36.3 55.3 47.1 43.1 47.2 44.2
CRP (mg/L) 41.4 37.5 85.8 51.6 53.4 57.0 53.7
Physician’s 62.1 59.1 68.3 70.2 64.2 65.5 65.7
global
assessment 
(mm on VAS) 
Patient’s global 60.5 66.0 78.1 63.0 64.9 63.8 66.3
assessment 
(mm on VAS) 
Patient’s 58.6 63.2 74.6 61.4 64.3 71.4 64.9
assessment of 
pain
(mm on VAS) 
Morning 132.9 106.8 143.3 130.0 115.0 132.9 128.7
stiffness (min) 
HAQ 1.57 1.57 1.85 1 .41 1.61 1 .68 1.65
DAS = Disease Activity Score; TJC = Tender Joint Count; SJC = Swollen Joint Count; ESR = 
Erythrocyte Sedimentation Rate; CRP = C-reactive protein; VAS = Visual Analogue Scale; 
HAQ = Health Assessment Questionnaire.
The most frequent drug treatments were with disease modifying anti-rheumatic drugs 
(DMARDs), glucocorticoids and non-steroidal anti-inflammatory drugs (NSAIDs). The 
mean number of previous DMARDs per patient was 3.6. The most frequently given 
DMARDs were methotrexate (88%), gold preparations (78%), sulfasalazine (71%), 
chloroquine/hydroxychloroquine (43%), azathioprine (40%), penicillamin (29%), 
cyclosporin A (10%) and cyclophosphamide (8%). All randomised patients completed 
the double-blind phase of the study except for one patient in the 0.5 mg/kg group
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who received study drug but withdrew from the study after 3 weeks due to a serious 
adverse event (necrotising pancreatitis).
Pharmacokinetic
Pharmacokinetic parameters derived using non-compartmental analyses are 
summarised in Table 2.
Table 2. Mean (S.D.) pharmacokinetic parameters (non-compartmental analyses) following a 
single intravenous injection of adalimumab_________________________________________
Dose Cmax O
O
UA t1/2 CL CL Vss Vss
(mg/kg) (^g/mL) (iag*h/mL) (h) (L/h) (mL/h/kg) (L) (L/kg)
0.5 25 2729 284 0.015 0.196 5.28 0.068
(22) (707) (119) (0.006) (0.068) (1.41) (0.013)
1 68 4363 242 0.017 0.261 4.97 0.075
(76) (1807) (170) (0.006) (0.089) (1.33) (0.020)
3 78 14229 267 0.015 0.225 5.46 0.082
(28) (3703) (90) (0.004) (0.061) (1.36) (0.022)
5 144 32963 326 0.012 0.071 4.73 0.070
(46) (11556) (129) (0.004) (0.065) (1.00) (0.017)
10 294 67115 321 0.011 0.158 4.70 0.065
(74) (17385) (117) (0.003) (0.038) (1.27) (0.018)
Cmax =peak serum adalimumab concentration immediately after end of injection; AUC0-inf 
=total area under the serum concentration-time curve ; t1/2 =half-life ; CL =serum clearance; 
Vss = volume of distribution at steady-state.
Mean serum concentration-time profiles (log-linear) following single IV bolus doses of 
0.5 to 10 mg/kg adalimumab are shown in Figure 1. Serum adalimumab 
concentrations appeared to have declined bi-exponentially. Mean serum adalimumab 
clearance ranged from 0.011 to 0.017 L/h (0.183 to 0.283 ml/min). The estimated 
mean steady-state volume of distribution ranged from 4.7 to 5.5 L (0.070 to 0.086 
L/kg), indicating that the drug mainly resides in the vascular compartment. The mean 
terminal half-life ranged from 242 to 326 h (10.0 to 13.6 days). The overall mean half­
life was 12 days for all dose groups. Systemic exposure (AUC0.inf) increased linearly 
with an increase in dose following single intravenous bolus doses ranging from 0.5 to
10.0 mg/kg (Figure 2). The clearance, terminal half-life, and steady-state volume of 
distribution appeared to be dose-independent, indicating linear kinetics.
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Time (h)
Figure 1. Mean serum profile of adalimumab following a single IV injection (semi-log plot)
Dose (mg/kg)
Figure 2. Relationship between area under the serum concentration-time curve and 
dose following single IV injections of adalimumab
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Safety and tolerability
The injections of adalimumab and placebo were well tolerated. All patients in both 
adalimumab- and placebo-treated groups experienced at least one adverse event 
(AE). In general, overall AE frequencies did not differ between the placebo and the 
adalimumab groups and no increased rate of AEs was seen with increasing doses of 
adalimumab (Table 3). This was also the case for individual AEs. The most frequently 
reported clinical AEs were fever (body temperature > 37°C), headache, and 
hypertension (Table 4). Pruritis and rash occurred in six and five patients, 
respectively, treated with adalimumab and none on placebo. No injection site 
reactions were reported. Two patients experienced serious adverse events (SAEs) 
following treatment with adalimumab. One had a necrotising pancreatitis with 
abdominal pain after 1 injection of 0.5 mg/kg adalimumab. Retrospectively, it was 
discovered that this patient had a strongly elevated serum lipase at baseline and had 
hidden a history of alcohol abuse. The second from the 1 mg/kg group had a known 
long history of epilepsy and had an epileptic seizure 5 days after injection of 
adalimumab. The plasma concentration of the concomitant medication phenytoin has 
been analysed retrospectively and proved to be much too low at the time of the 
event. The dosage of the anti-epileptic medication was adjusted and the patient was 
treated repeatedly with adalimumab in the continuation study without further adverse 
events.
Changes from baseline in clinical laboratory values, vital signs, and ECG were small 
in all treatment groups. There were only a few cases of clinical laboratory values 
meeting grade 3 or 4 of the common toxicity criteria (CTC). Most of these were low 
lymphocytes (29% placebo, 28% adalimumab), which was also a common condition 
at study entry (22%).
Table 3. Overview of numbers (%) of patients with treatment emergent adverse events
Placebo
0.5
Adalimumab (mg/kg)
1 3 5 10
Any
Adali-
mumab
No. Patients 31 17 18 18 18 18 89
Clinical AE 27 (87) 15 (88) 15 (83) 18 (100) 11 (61) 16 (89) 75 (84)
Laboratory AE 31 (100) 16 (94) 16 (89) 16 (89) 18 (100) 16 (89) 82 (92)
Possibly drug- 
related AE
18 (58) 12 (71) 12 (67) 11 (61) 8 (44) 9 (50) 52 (58)
Severe/life 
threatening AE
7 (23) 5 (29) 4 (22) 4 (22) 3 (17) 2 (11) 18 (20)
Serious AE 1 (0) 1 (6) 1 (6) 0 (0) 0 (0) 0 (0) 2 (2)
AE leading to 
withdrawal
0 (0) 1 (6) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1)
AE=adverse event
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Table 4. Most frequent (>2 patients) treatment emergent clinical adverse events
Adverse Event
Placebo
n=31
0.5
n=17
Adalimumab (mg/kg)
1.0 3.0 5.0 
n=18 n=18 n=18
10.0
n=18
Any Adali­
mumab 
n=89
Fever (no. [%]) 9 (29) 5 (29) 7 (39) 4 (22) 3 (17) 4 (22) 23 (26)
Headache 2 (6) 2 (12) 5 (28) 5 (28) 2 (11) 3 (17) 17 (19)
Hypertension 3 (10) 7 (41) 2 (11) 2 (11) 1 (6) 2 (11) 14 (16)
Asthenia 3 (10) 2 (12) 3 (17) 0 0 1 (6) 6 (7)
Rhinitis 2 (6) 1 (6) 2 (11) 2 (11) 1 (6) 0 6 (7)
Dizziness 2 (6) 0 3 (17) 1 (6) 0 1 (6) 5 (6)
Flu syndrome 1 (3) 2 (12) 0 1 (6) 0 2 (11) 5 (6)
Pruritis 0 1 (6) 0 2 (11) 1 (6) 2 (11) 6 (7)
Rash 0 2 (12) 0 0 2 (11) 1 (6) 5 (6)
Arthralgia 1 (3) 1 (6) 0 1 (6) 0 2 (11) 4 (4)
Nausea 1(3) 1(6) 0 1(6) 1(6) 1(6) 4(4)
Joint disorder 2 (6) 0 1 (6) 1 (6) 2 (11) 0 4 (4)
GI pain 2 (6) 0 0 2 (11) 0 0 (0) 2 (2)
Efficacy: primary efficacy variables
In all the adalimumab dose groups, reductions in DAS compared with baseline 
scores were observed. In the placebo group, by contrast, only slight mean changes 
in DAS from baseline were found at all evaluated time points. The improvement in 
DAS was smallest in the 0.5 mg/kg group. In the higher adalimumab dosage groups
1.0 to 10.0 mg/kg the improvement was much larger, but of similar magnitude 
between the groups (Table 5).
For the adalimumab dose groups, an initial decline in DAS was seen as early as 24 
hours after injection, further decreasing up to day 8, and returning toward baseline by 
days 22 and 29. For all doses other than 0.5 mg/kg, DAS remained below the pre­
treatment level up to day 29.
Relative to placebo, treatment with adalimumab 0.5 mg/kg resulted in statistically 
significantly greater decreases from baseline in DAS at days 8 and 15. For the 
adalimumab 1.0 mg/kg group, the change from baseline in DAS versus placebo was 
statistically significant at all evaluated time points up to day 29. This was also the 
case for the adalimumab 3.0 mg/kg, 5 mg/kg and 10.0 mg/kg groups.
Response rates based on EULAR and ACR 20 criteria (using ESR as the acute 
phase reactant variable) are shown in Figure 3. In the higher adalimumab dose 
groups, 60 to more than 80% of patients achieved EULAR and ACR 20 response 
status between 24 hours to 29 days of treatment.
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Table 5. Disease Activity Scores (DAS) over time. Mean (95% CI) baseline 
measurements and differences from baseline
Placebo
0.5
Adalimumab (mg/kg)
1 3 5 10
Patients 31 17 18 18 18 18
Baseline 5.16 5.14 5.81 5.35 4.93 5.63
(4.73,5.59) 
Difference from baseline
(4.72,5.55) (5.32,6.31) (4.93,5.77) (4.53,5.32) (5.09,6.17)
24 hours -0.16 -0.25 -0.81 -0.49 -0.33 -0.72
(-0.34,0.02) (-0.49,-0.01) (-1.10,-0.53) (-0.76,-0.22) (-0.64,-0.02) (-1.00,-0.43)
Day 8 -0.09 -0.76 -1.28 -1.50 -1.21 -1.29
(-0.38,0.20) (-1.12,-0.39) (-1.58,-0.97) (-1.88,-1.13) (-1.69,-0.74) (-1.85,-0.73)
Day 15 -0.03 -0.82 -1.37 -1.45 -1.19 -1.50
(-0.34,0.27) (-1.31,-0.33) (-1.77,-0.97) (-1.87,-1.04) (-1.69,-0.68) (-1.88,-1.13)
Day 22 0.24 -0.35 -1.14 -1.27 -1.56 -1.53
(0.00,0.48) (-0.88,0.18) (-1.58,-0.71) (-1.73,-0.81) (-2.13,-0.99) (-1.99,-1.08)
Day 29 0.26 0.16 -0.81 -1.05 -1.52 -1.08
(0.02,0.50) (-0.32,0.64) (-1.31,-0.31) (-1.54,-0.55) (-2.08,-0.96) (-1.54,-0.62)
Therapeutic effects became evident within 24 hours to 1 week after adalimumab 
administration and peaked after 1-2 weeks, with dose response seeming to reach a 
plateau at 1 mg/kg adalimumab. In contrast, only 29% of patients on placebo 
achieved EULAR response status. The ACR 50 responder rates at any time up to 
day 29 were 18%, 17%, 28%, 28% and 17% in the 0.5, 1, 3, 5, 10 mg/kg adalimumab 
groups, respectively.
100
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Placebo 0.5 1 3 5 10 mg/kg
Figure 3. Percentage of patients with EULAR/ACR 20 response at any time.
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The proportion of all patients with EULAR response to a single dose of adalimumab 
over time was also analysed. The adalimumab dose groups had consistently longer 
periods of response (defined as time from injection until non-responsiveness) 
compared to placebo. Duration of response was longer in the 1.0, 3.0, 5.0, and 10.0 
mg/kg groups compared with the 0.5 mg/kg group and the placebo group. Only 6% of 
the placebo and 0.5 mg/kg treated patients had a EULAR response lasting until day 
29, whereas 33%, 39%, 61% and 61% of the patients in the 1.0, 3.0, 5.0, and 10.0 
mg/kg group had responses lasting until day 29 or longer. In some patients the 
response lasted up to 3 months. There was no apparent difference in response- 
duration in the dose groups above 0.5 mg/kg.
Secondary efficacy variables
Further confirmation of the beneficial effects of adalimumab treatment on 
inflammatory synovitis during the trial was demonstrated by the reduction from 
baseline in the individual components of the EULAR and the ACR response criteria 
(Table 6). Following therapy with adalimumab, there were improvements in all these 
parameters with the least pronounced improvements being in the 0.5 mg/kg group. 
Improvements in the higher dose groups (1 -10 mg/kg) were of similar magnitude.
Table 6. Maximum median reduction (%) from baseline in individual components of EULAR 
or ACR response criteria at any time up to day 29 following single injection of adalimumab or 
placebo
Placebo Adalimumab (mg/kg)
0.5 1 3 5 10
No. Patients 31 17 18 18 18 18
TJC 5.6 29.4 49.4 54.8 51.1 51.4
SJC 0 31.3 29.3 28.4 48.4 39.1
ESR 0 27.5 36.2 47.4 43.8 39.1
CRP 4.8 49.5 75.7 71.3 82.2 63.2
HAQ 0 15.7 25.3 34.7 14.3 14.5
TJC = Tender Joint Count (Ritchie Index); SJC = Swollen Joint Count; ESR = Erythrocyte 
sedimentation rate; CRP = C reactive protein; HAQ = Health Assessment Questionnaire
The improvements were sustained with values for each parameter remaining below 
baseline at day 29, except the Ritchie articular index in 0.5 mg/kg group.
Patient’s and physician’s global assessments of disease activity and patient’s 
assessment of pain and general health measured using a 100-mm visual analogue 
scale largely paralleled the above findings. Placebo effects were minimal, and the 
effects of the 0.5 mg/kg dose were less marked than those resulting from treatment 
with the higher adalimumab doses. As with the other measures of efficacy, the 
effects with the higher adalimumab doses (1 mg/kg and higher) persisted at least up
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to the day 29 observation. Acute phase reactants CRP and ESR have shown an 
impressive drop within one week after injection of adalimumab for all dose groups.
Discussion
This is the first report of a clinical study of the fully human anti-TNFa monoclonal 
antibody adalimumab in patients with active RA. Analysis of pharmacokinetic data 
indicated that systemic drug exposure (AUC) increased proportionally with an 
increase in dose. The drug mainly resides in the vascular compartment (Vss = 4.7 to 
5.5 L) and is cleared very slowly from serum (CL = 0.011 to 0.017 L/h). The 
estimated mean terminal half-life ranged from 10.0 to 13.6 days for all the five 
cohorts with an overall half-life of 12 days for all doses.
The results of this double blind, placebo-controlled trial demonstrated that single 
intravenous doses of adalimumab from 0.5 to 10 mg/kg were safe and well tolerated. 
No dose-related increases in adverse events were observed, and the two reported 
SAEs did not appear to be treatment related. The relatively high rates of abnormal 
clinical laboratory findings in the study were to be expected given the patient 
population and there were no differences between placebo and adalimumab groups. 
Compared with placebo, treatment with adalimumab produced a statistically 
significant reduction in disease activity as assessed by standard clinical endpoints. 
Adalimumab produced rapid and sustained reductions in disease activity with the 
maximum clinical response seen within 1 to 2 weeks. The treatment effect became 
evident as early as 24 hours following adalimumab administration. Approximately 60­
80% of the patients in the higher adalimumab dose groups achieved a significant 
therapeutic response (EULAR and ACR20) with a single dose, which was sustained 
in some patients for up to 3 months. Considering the longstanding, therapeutically 
refractory nature of the disease in the RA patients studied and the relatively stringent 
primary efficacy parameters used (EULAR and ACR 20 and 50), it is noteworthy that 
such positive and sustained responses could be achieved following single doses of 
adalimumab. In this single dose study, the dose-response relationship was flat at 
doses between 1 and 10 mg/kg/day, whereas the lowest dose of adalimumab (0.5 
mg/kg) was less effective than the higher doses for all parameters evaluated.
In conclusion, single intravenous injections between 0.5 to 10 mg/kg of the fully 
human anti-TNFa monoclonal antibody adalimumab exhibited systemic drug 
exposure linearly related to dose and were well tolerated in patients with active RA. 
The results provide the first clinical evidence that the fully human antibody 
adalimumab can be safely and effectively used to treat RA. Patients from this study 
continue to be treated in long-term studies that will provide data on chronic safety 
and efficacy.
39
Acknowledgements
We would like to thank M Wibberg (Datamap GmbH, Freiburg, Germany) and Dr D Compagnone 
(Knoll AG) for data management and statistical support, Dr P Noertershäuser for pharmacokinetic 
analyses.
REFERENCES
1 Brooks P. Clinical management of rheumatoid arthritis. Lancet 1993; 341: 286­
290
2 Maini RN, Brennan F, Williams R, Chu CQ, Cope AP, Gibbons D, Elliot M, 
Feldmann M.TNF-a in rheumatoid arthritis and prospect for anti-TNF therapy. Clin 
Exp Rheumatol 1993; 11 (Suppl 8): S173-5
3 Feldmann M, Brennan F, Elliot MJ, Williams RO, Maini RN. TNF alpha is an 
effective therapeutic target for rheumatoid arthritis. Ann NY Acad Sci 1995; 766: 272­
278
4 Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsakis P, Brennan 
FH, Walker J, Bijl H, Ghrayeb J et al. Treatment of rheumatoid arthritis with chimeric 
monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 
1681-90
5 Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN. 
Repeated therapy with monoclonal antibody to tumor necrosis factor alpha (cA2) in 
patients with rheumatoid arthritis. Lancet 1994; 344: 1125-27
6 Rankin EC, Choy EH, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, 
Panayi GS. The therapeutic effects of an engineered human anti-tumour necrosis 
factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34: 
334-42
7 Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, 
Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch 
CM. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis 
factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7
8 Kavanaugh AF. Anti-tumor necrosis factor-alpha monoclonal antibody therapy 
for rheumatoid arthritis. Rheum Dis Clin North Am 1998; 24: 593-614
9 Jespers L, Roberts A, Mahler S, Winter G, Hoogenboom H. Guiding the 
selection of human antibodies from phage display repertoires to a single epitope of 
an antigen. Biotechnology (NY) 1994; 12: 899-903
10 van de Putte L, van Riel PLCM, den Broeder A, Sander O, Rau R, Binder C, 
Krüger K, Schattenkirchner M, Fenner H, Salfeld J, Bankmann Y, Kupper H, 
Kempeni J. A single dose placebo controlled Phase I study of the fully human anti- 
TNF antibody adalimumab in patients with rheumatoid arthritis. Arthritis Rheum 1998;
41 (Suppl): 57
40
11 van Gestel A, Prevoo M, van’T Hoff MA, van Rijswijk MH, van de Putte LB, Riel 
PL. Development and validation of the European League Against Rheumatism 
response criteria for rheumatoid arthritis. Arthritis Rheum 1996; 39: 34-40
12 Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, 
Buchanan WW. Clinical studies with an articular index for the assessment of joint 
tenderness in patients with rheumatoid arthritis. Quarterly J Med 1968; 37 (147): 393­
406
13 van der Heijde DM, van Riel PL, van de Putte LB. Sensitivity of a Dutch Health 
Assessment Questionnaire in a trial comparing hydroxychloroquine vs 
sulphasalazine. Scand J Rheumatol 1990; 19: 407-12
14 Brühlmann P, Stucki G, Michel BA. Evaluation of a German version of the 
physical dimensions of the Health Assessment Questionnaire in patients with 
rheumatoid arthritis. J Rheumatol 1994; 21: 1245-9
15 American College of Rheumatology: Preliminary definition of improvement in 
rheumatoid arthritis. Arthritis Rheum 1995; 36: 727-735
41
42
Chapter IV
Long-term anti-TNFa monotherapy in rheumatoid arthritis. Effect on radiologic course 
and prognostic value of markers of cartilage turnover and endothelial activation.
Alfons A den Broeder, Leo AB Joosten, Tore Saxne, Dick Heinegàrd, Helmut Fenner, 
Andre MM Miltenburg, W  LH Frasa, Wim A Buurman, Piet LCM van Riel, Leo BA van de
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Abstract
Aims To investigate the effect of prolonged neutralisation of tumour necrosis factor 
alpha (TNFa) on the radiologic course in rheumatoid arthritis (RA). To assess whether 
the radiologic course can be predicted by clinical variables or biological markers of 
cartilage and synovium turnover and of endothelial activation.
Patients and methods Forty-seven patients with active RA enrolled at our centre in 
monotherapy trials with adalimumab (D2E7), a fully human anti-TNFa monoclonal 
antibody, were studied for two years. X-rays of hands and feet obtained at baseline and 
after 1 and 2 years were scored in chronological order by a single, blinded observer 
using the modified Sharp method. Radiologic course was classified as stable or 
progressive using the smallest detectable difference as cut-off. The relationship between 
radiologic course and serum markers of cartilage and synovium turnover 
(metalloproteinases MMPs 1 and 3), cartilage oligomeric matrix protein (COMP), human 
cartilage glycoprotein-39 (HC gp-39)), endothelial activation (soluble E-selectin and 
ICAM-1) and integrated measures of disease activity were assessed using univariate 
and multivariate analysis.
Results At study completion, 42% of the patients presented no radiological progression. 
In this group, more patients were still on anti-TNFa therapy (87% versus 51%; P  = 0.03) 
and baseline COMP and sICAM-1 levels were lower (P = 0.01 and 0.04, respectively) 
compared to the group with progressive disease. In a logistic regression model these 
three factors in combination were predictive for radiologic outcome (P = 0.03). CRP and 
DAS area under the curve were significantly correlated with changes in radiologic scores 
after two years (r=0.40 and 0.37, P  < 0.05). Long-term TNFa neutralisation decreased 
the levels of COMP, sICAM, MMPs and HC gp-39. sE-selectin was not decreased after 
two years.
Conclusion Our results suggest that long-term monotherapy with anti-TNFa has a 
positive effect on radiologic outcome and modulates cartilage and synovium turnover as 
measured by biological markers. Baseline serum sICAM-1 levels and moreover baseline 
COMP levels may be helpful to identify patients with progressive or non-progressive 
radiologic outcome.
Introduction
Rheumatoid Arthritis (RA) is characterised by a chronic polyarthritis leading to 
irreversible cartilage damage. In the last decade therapeutic options for the treatment of 
RA have been broadened by the development of specifically targeted biological agents. 
Among these, strategies aimed at specific neutralisation of pro-inflammatory cytokines, 
such as tumour necrosis factor alpha (TNFa) and interleukin-1 (IL-1) seem the most 
promising. Studies with monoclonal antibodies (MoAb) against TNFa and with TNF
44
receptor fusion proteins have proven the clinical efficacy of TNFa neutralisation in RA 
(1,2) and these treatment modalities have been introduced in clinical practice. 
Adalimumab (D2E7) is a fully human IgG1 anti-TNFa MoAb developed using phage 
display techniques (3). Studies in more than 1200 patients have demonstrated the 
efficacy and safety of prolonged administration of this compound either alone (4-7) or in 
combination with methotrexate (8).
Adalimumab and other TNFa blocking agents have a very short lag-time to clinical 
response and induce a rapid decrease in non-specific acute phase reactants such as C- 
reactive protein (CRP) and ESR (9,10). Based on the short-term effects of TNFa 
neutralisation on several other biological markers, it has been proposed that this therapy 
reduces endothelial activation (11,12) and angiogenesis (13) and might be 
chondroprotective (14,15). Whether these effects are maintained during long-term anti- 
TNFa therapy and whether they correlate with outcome variables has not been 
elucidated yet.
The first reports with one-year follow-up indeed suggest that TNFa neutralisation retards 
radiological progression (16-18). Tissue derived molecular markers have been 
suggested as possible prognostic factors for future joint damage (19). If this can be 
verified, such markers could be attractive tools for treatment decisions and patient 
selection and also for monitoring of therapy aimed at slowing joint damage progression.
In the present study, the influence of long-term treatment with anti-TNFa therapy with 
adalimumab on radiological course was assessed. Furthermore early and long-term 
effects of this treatment on biological markers of cartilage and synovium turnover 
(cartilage oligomeric matrix protein (COMP), metalloproteinases 1 and 3 (MMPs) and 
human cartilage glycoprotein-39 (HC gp-39, also known as YKL-40)) and on markers of 
endothelial activation (sE-selectin and intercellular adhesion molecule-1 (sICAM-1)) 
were examined. The interrelationships and potential prognostic value of these markers 
on the radiological outcome after 2 years were also investigated.
Patients and Methods
Patients
All patients with RA included in phase I clinical studies with adalimumab monotherapy at 
our center were studied. Patients fulfilled the 1987 ACR criteria (20), had an active 
disease, defined by a disease activity score (DAS (21)) > 3.2 at baseline and underwent 
a washout period for DMARDs of at least 3 weeks prior to study initiation. Stable 
dosages of NSAIDs and steroids (dose <10mg/day prednisone equivalent) were allowed 
during the study. The 2-year follow-up encompassed a 6 to 8 weeks placebo-controlled, 
randomised, dose ranging (0.5 -  10 mg/kg) trial followed by an ongoing open label 
phase. In the latter, all patients, including those initially randomised to placebo, received 
adalimumab, at dosages of 3 mg/kg i.v. biweekly (5,6) or 1 mg/kg s.c. weekly (4). In the
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intravenous clinical studies with adalimumab, a plateau in response was seen at the 
level of 1.0 mg/kg biweekly and beyond. The pharmacokinetics of subcutaneously 
administered adalimumab are the same three to four weeks after therapy start (4-7). 
Therefore, it was decided to pool data derived from these two treatment modalities. 
Anti-TNFa therapy was withheld in case of adverse events or lack of efficacy. The latter 
was defined as a DAS decrease of less than 1.2 in the placebo-controlled phase and 
according to the judgement of the clinical rheumatologist in the subsequent open phase. 
In case of withdrawal, patients were treated using the best available choice of DMARDs 
taking previous therapies into account.
Methods
Radiological and clinical assessments
Standard X-rays of hands and feet were obtained at baseline and after 1 and 2 years. 
Erosions, joint space narrowing (JSN) and total scores (erosion plus narrowing) were 
evaluated in sequential order by a single observer (AdB) blinded for therapy and clinical 
response using the Sharp/van der Heijde method (22). Readings were performed in 
chronological order since this method has been shown to be more sensitive to change 
than random readings (23). Moreover, instead of using an arbitrary cut-off point, the 
radiologic course of each patient was classified as stable or progressive using the 
smallest detectable difference (SDD) calculated according to Lassere et al (24,25). The 
SDD is the smallest change a measuring instrument can detect, taking the measurement 
error (in our case the intra-observer variation) into account. The SDD was calculated 
using a set of 75 radiographs from 25 patients assessed twice by the same observer 
within an interval of 9 months.
The area under the curve (AUC) for DAS and CRP were calculated using measurements 
obtained at baseline and every twelve weeks during the 2-year follow-up period. For 
patients who dropped out before study completion, data was collected during an 
additional post study follow up period of 12 months. If patients dropped out before the 
end of year one, data collected at the last clinical observation were carried forward. 
Radiograph data were then separately obtained at year 2.
Markers o f cartilage and synovium turnover and endothelial activation.
Serum samples had been collected during the study and stored at -8 0 C 0 until assay. 
For all markers, short-term changes after the first administration of anti-TNFa MoAb or 
placebo were analysed in samples collected at baseline, day 1 and day 14. Long-term 
changes were assessed using samples collected after a 2-year follow-up for all markers 
with exception of the MMPs. The latter were assessed at month 6 due to technical 
reasons. All samples from the same patient were analysed simultaneously to minimise 
inter-assay variations.
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Systemic levels of COMP were measured using a previously described ELISA with an 
intra-assay variation of < 5% (26,27). The concentrations of collagenase (MMP-1) and 
stromelysin-1 (MMP-3) were measured by ELISA according to the manufacturer’s 
instructions (Binding Site, Birmingham; intra-assay variation <13%) (28). The adhesion 
molecules sE-selectin and intercellular adhesion molecule-1 (sICAM-1) were measured by 
ELISA as previously described (29,30). Intra-assay variation for both essays is < 10%.
HC gp-39 levels were assessed as follows. Polystyrene 96-well microplates (Nunc 
Maxisorb C12) were coated overnight at 4 °C with 150 ^L/well of 1.0 ^g/ml mouse anti- 
HC gp-39 capture antibodies (HC gp-39 8B) in coat buffer (CB). The supernatant was 
discarded and the wells were incubated for one hour at room temperature with 200 mL 
PBS, 1.0 % BSA to block excess free binding sites. Subsequently, plates were washed 
three times with 500 mL PBST and incubated for one hour at room temperature with 100 
ML sample, 100 mL recombinant HC gp-39 standard in assay buffer (PBS, 10 % FCS), 
100 mL REF in assay buffer (ten times the highest STD) and 100 mL recombinant HC gp-
39 control samples (at 5.0, 25.0 and 75.0 ng/ml) in assay buffer. Plasma samples were 
diluted 1:10 in assay buffer (10% FCS, 0.1% Triton-X, 0.2% Kathon CG in PBS) After 
this incubation the plates were washed three times with 500 mL PBST and incubated for 
one hour at room temperature with horseradish peroxidase labeled with mouse anti-HC 
gp-39 detection antibodies (HC gp-39 10B) at a dilution of 1:10.000 in assay buffer. 
Then, the plates were washed three times with 500 mL PBST and incubated for five 
minutes with 100 mL tetramethylbenzidine/ureum peroxide substrate solution (Organon 
Teknika). The enzyme reaction was stopped by addition of 50 mL 4 mol/L sulfuric acid to 
each well. The a 450-a 690 absorbencies were measured with a microplate reader. 
Calibration curves (0.15-24 ng/ml) for recombinant HC gp-39 were constructed using 4- 
parameter-logistic regression, and HC gp-39 concentrations in study samples and 
quality control samples were calculated with the data reduction package PhIRSt 
(Phoenix International Reporting System, version 2.1). The LOQ was determined at 0.15 
ng/ml. The assay has been validated and the accuracy of the quality control samples 
was higher than 94.7% and the CV% was lower than 9.7%.
Statistical analysis:
Within-groups comparisons were made using paired Student’s t-test and Wilcoxon 
signed rank test. For comparisons between groups Mann Whitney U tests and chi- 
square test were used as appropriate. Correlations were tested with Pearson or 
Spearman correlation tests. The use of parametric or non-parametric test was 
dependent on the data distribution. P-values are reported without adjustments for 
multiple comparisons.
Multiple logistic regression analysis was performed to elucidate whether markers of 
cartilage and synovium turnover and endothelial activation had prognostic value using 
the radiologic progression from 0 to 2 years and from 1 to 2 years as dependent
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variable. Additional independent variables considered were treatment status at study 
completion (0 = on therapy, 1 = withdrawal), IgM rheumatoid factor (0 = negative, 1 = 
positive) and the DAS and Sharp scores at baseline. Potential interactions between 
independent variables were tested prior to inclusion in the model. Analysis was 
performed using the Astute Base Module version 1.50 Package and SAS version 6.12.
Results
Clinical course
A total of 47 patients were studied whose characteristics are shown in Table 1. At 
inclusion, patients had active disease, long disease duration and had been refractory to 
a large number of DMARDs prior to anti-TNFa therapy. No significant differences 
between patients randomised to adalimumab or placebo were observed in the blinded 
study. The course of the follow-up is depicted in Figure 1.
Table 1. Patient characteristics at baseline; patients with and without radiologic progression. 
Data expressed as mean ± SD unless otherwise stated.
Radiologic course All patients Stable course Progression P
(n=47) (n=24) (n=12)
Age (yr) 56 ± 15 53 ± 15 60 ± 15 0.10
Female sex (%) 57 73 48 0.12
Disease duration (yr) 13 ± 8 15 ± 10 13 ± 9 ns
RF positive (%) 98 100 96 ns
Previous DMARDs (nr) 4.7 ± 1.9 4.5 ± 2.3 4.9 ± 1.6 ns
Concomitant steroids (%) 53 40 53 ns
DAS 5.2 ± 1.0 5.0 ± 0.8 5.2 ± 1.0 0.43
Ritchie Articular Index 25 ± 10 25 ± 10 25 ± 12 ns
Swollen Joints (nr) 18 ± 5 18 ± 4 18 ± 6 ns
ESR (mm) 34 ± 25 29 ± 26 38 ± 25 0.26
CRP (mg/L) 64 ± 55 50 ± 46 67 ± 58 0.44
Sharp score, median (25-75 perc) 111 (55-151) 66 (46-145) 114 (64-151) 0.31
As shown, a total of 41 (87%), 33 (70%) and 26 (55%) patients were still on therapy and 
maintained responder status after 6 months, 1 and 2 year follow-up respectively. Clinical 
improvement occurred rapidly after initiation of therapy. Two weeks from baseline 16 out
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of 35 patients (46%) treated with adalimumab but none in the placebo group (0/12) had 
achieved responses according to the EULAR definitions. The course of the DAS and 
CRP in the whole patient group is shown in Figure 2.
Figure 2. Course of the median DAS and CRP during two-year follow-up in this study. 
Intention-to-treat analysis.
Radiologic Course
As expected from the long disease course, most patients had high radiologic scores at 
baseline (Table 1). In the whole patient group (radiographic data present at all timepoints in
36 patients), the median changes in radiologic scores after 1 and 2 years were 5 and 9 
for erosions and 3 and 5 for narrowing respectively.
For this study, the smallest detectable difference (SDD) in total Sharp/van der Heijde 
scores were 8 and 13 after 1 and 2 years, respectively. Using these cut-off points, a total 
of 53% (n=19/36) and 42% (n=21/36) of the patients presented no signs of radiological 
progression after 1 and 2 years follow-up respectively.
Comparison between the groups with stable radiologic course and those with 
radiological progression showed that the former group encompassed more patients still 
on therapy at study completion than the latter (87% [n= 13/15] versus 51% [n=11/21] 
respectively; P  = 0.03). The Sharp scores at baseline tended to be lower and the
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percentage of females higher among patients with stable radiological course but this did 
not reach statistical significance (Table 1).
Characteristics of patients who still received anti-TNFa treatment at study completion 
were similar to those who had switched to other therapies (data not shown) with the 
exception of the radiological course, which was stable in 54% (n=31/24) of the former 
but in only 17% (2/12) of the latter (P = 0.03).
Relationship between radiologic course, disease activity and biological markers 
The serum levels of the biological markers at baseline were compared between patients 
with stable and progressive radiologic course. These groups only differed in baseline 
COMP and sICAM-1 levels, which were higher in the progressive group (P = 0.01 and P  
= 0.04 respectively; figure 3.). After two years, COMP and sICAM-1 had decreased in 
patients with X-ray progression (P = 0.0003 and P  = 0.03 compared to baseline for 
COMP and sICAM-1 respectively) and remained low and unchanged in patients with 
stable radiologic course.
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Figure 3. Concentrations of COMP [A] and sICAM-1 [B] in patients with and without radiologic 
progression. The boxes illustrate the mean (horizontal bar), 25 and 75 percentile (box) and 5 
and 95 percentile (bars). Significance is shown as p<0.05, tested between groups (t).
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Figure 1.
baseline 6 months
Adverse event, n=5
Lack of efficacy, n=5 --------
Required by protocol, n=31
Death, n=1
The primary reason for withdral is mentioned
1 patients that did not reach respondership after three administrations of 
adalimumab were withdrawn according to the study protocol.
12 months 2 years
adalimumab, n=26
n=7
Adverse events, n=3 
Lack of efficacy, n=2 
Remission, n=1 
Death, n=1
Other Treatments, n=19
Methotrexate 6
Sulfasalazin 1
Cyclophosfamide 3
Steroids 2
Leflunomide 2
Gold salts 1
Azathioprine 2
DMARDs comb. 1
No therapy 1 
Concomitant steroids 9
Correlations between baseline radiological and clinical variables and biological markers 
are outlined in Table 2. As shown, the classical acute phase reactant CRP correlated 
with both MMPs, HC gp-39 and, to a lesser extent, also with sICAM-1 but importantly 
not with COMP levels. COMP and HC gp-39, were significantly correlated with age and 
this was not due to a confounding effect of disease duration (data not shown).
We performed univariate analysis to assess which variables could be prognostic for 
changes in radiologic scores over time. The changes in total Sharp/van der Heijde 
scores between 0 and 2 years showed modest correlations with the AUC for CRP and 
DAS (r = 0.40 and 0.37 respectively; P  < 0.05) and with baseline COMP and sICAM-1 
levels (r = 0.30 and 0.37; P  = 0.06 and 0.04 respectively). None of the biological 
markers or clinical parameters at baseline showed a significant correlation with the 
radiologic changes between 1 and 2 years follow-up (data not shown). All analyses were 
also performed for both patient groups (adalimumab treated patients and patient that 
dropped out) separately. This approach did not yield different results (data not shown).
Table 2. Correlations between radiologic score, acute phase and markers at baseline
Duration SE-select sICAM-1 MMP-1 MMP-3 HC gp-39 COMP
Sharp score 0.49 t ns ns 0.50 t ns 0.39 * ns
Age 0.48 t ns ns 0.33 * ns 0.56 t 0.57 t
CRP 0.33 * 0.46 t 0.65 t 0.53 t 0.56 t ns
sE-selectin 0.35 * 0.36 * ns ns ns
sICAM-1 0.35 * ns ns ns
MMP-1 0.45 t 0.39 * ns
MMP-3 0.37 * ns
HC gp-39 ns
R is shown
P < 0.05 (* ); P < 0.01 (t); P < 0.001 (t); not significant (ns).
Multiple Logistic Regression analysis results.
Two models, using the radiological changes between 0 and 2 years and between 1 and
2 years respectively as dependent variable were initially considered. The latter was 
abandoned after the negative results of the univariate analysis. The final logistic 
regression model using presence/absence of radiologic progression from 0 to 2 years as 
dependent variable included the following independent variables: treatment status (on 
therapy or dropout; 0 or 1), baseline sICAM-1 and baseline COMP. Rheumatoid factor 
(RF) was not included as explanatory variables, since all but one patient were RF
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positive. The DAS and CRP at baseline were also left out of the model since they did not 
differ between patients with stable and progressive course (Table 1). Although baseline 
Sharp scores were not associated with progression using univariate tests (r = 0.28, P  = 
0.09), this variable was tested in the model, because differences - although not 
significant - were found at baseline between patients with and without progression 
(Table 1).
The logistic regression model is shown in Table 3. Patients remaining on anti-TNFa 
therapy had a four-fold higher chance to have stable radiologic course. Higher COMP 
levels at baseline were associated with worse radiologic outcome independently from 
the effect from the treatment. The association of baseline sICAM levels with radiologic 
outcome largely disappeared. As shown, none of these three individual variables 
reached significance, but the complete model had a significant explanatory effect on the 
radiologic progression as indicated by the P value for the chi-square for covariates 
(0.03). The disappearance of significance for the individual independent variables 
between the two treatment groups in the logistic regression model is caused by listwise 
deletion of missing values at baseline (1 COMP level and 1 sICAM level). Inclusion of 
baseline Sharp in the model scores did not change these results (data not shown).
Table 3. Multiple Logistic Regression results of predictors for radiologic progression
Dependent variable Progression 0 -  2 year
ß OR CI P
Chi-square for covariates 0.03
Independent variables
Treatment at two years (0=on therapy, 1=drop-out) 3.99 0.60 ; 26.30 0.15
Baseline sICAM-1 0.09 -0.15 ; 0.33 0.43
Baseline COMP 0.41 -0.02 ; 0.84 0.06
Intercept -5.64
Parameter estimate (ß), standard error (SE), confidence interva (CI), independent variables
(x1_ x k), dependent variable is 1
1 + exp [- (ß 0 + ß 1x 1 + ß 2x2 + ß 3x3 )]
Markers o f endothelial activation and cartilage turnover
Short-term and long-term changes in the marker levels during anti-TNFa therapy are 
outlined in Figure 4. Short-term measurements within 2 weeks after the first dose, 
allowed comparison between anti-TNFa and administration of placebo. As observed,
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none of the markers showed significant changes after placebo. In contrast, the levels of 
MMP-1, HC gp-39 and the adhesion molecules sE-selectin and sICAM-1 decreased 
significantly (P < 0.05) and MMP-3 also tended to drop (NS) within two weeks after 
starting anti-TNFa therapy. This was not the case for COMP levels that remained stable 
during the first two weeks.
Long-term measurements allowed comparison between patients still on anti-TNFa 
treatment and those who dropped-out and were treated with DMARDs. HC gp-39 and 
COMP levels were significantly decreased after 2 years (P < 0.0001 and < 0.001 
respectively) irrespective of the therapy that patients received at this time point (Figure 4 
lower panel). The levels of sICAM-1 values showed a modest decrease only in patients 
who were still on anti-TNFa therapy (P < 0.05) but not in those patients who had 
switched to other treatments. In contrast, the final concentrations of sE-selectin did not 
differ from baseline values (Figure 4 mid panel). Further reductions in MMP-1 and 3 
concentrations (P < 0.05) were found after 6 months of therapy in the whole patient 
group (Figure 4 upper panel). At this time point, the number of patients who had 
switched to other therapies was too small to allow for comparisons with those still on 
anti-TNFa.
Discussion
Radiologic assessment remains the cornerstone of outcome assessment in RA, but has 
important drawbacks such as the extensive lag-time to change after therapeutic 
interventions. This has resulted in an intensified search for predictors of outcome in RA 
in recent years. The need for better monitoring of clinical decisions and aspects of cost- 
effectiveness is especially high for novel and expensive biological agents such as those 
directed against TNFa. Potential predictors for outcome could be used a priori for 
adequate patient selection or for adjustment of therapy.
This is, to our knowledge, the first long-term follow-up study on both the effect of anti- 
TNFa monotherapy on radiologic course and on prognostic value of biological markers 
of cartilage and synovium turnover and endothelial activation.
Concerning the radiological assessments, our findings support the notion that sustained 
TNFa neutralisation can modulate the outcome in advanced RA. First, a stable 
radiologic course was observed in 54% of the patients who were still receiving anti- 
TNFa therapy after two years compared to only 17% of the patients who had to switch 
from anti-TNFa to the best available choice of antirheumatic drugs during the same 
observation period. Although dropout patients had been treated for variable amounts of 
time with adalimumab, this fact should most likely have made differences between the 
two groups only smaller. The same holds true for the possible positive effect of 
treatment with DMARDs in patients that had dropped out. Switching was mostly due to 
other reasons than lack of response (Figure 1), which suggests a positive effect of anti-
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TNFa in modulating the radiologic course. Also, our results show that blocking TNFa 
resulted in a rapid and sustained reduction of CRP and DAS and that radiologic 
progression is associated with time-integrated measures of these variables. Such a 
relationship has been previously described in patients with RA receiving conventional 
DMARD therapy (31) but not in patients with longstanding disease treated with anti- 
TNFa.
Recently published reports on random X-ray readings after one-year treatment with this 
(18) and other anti-TNFa strategies in patients with advanced disease (17) and early RA 
(16) have suggested that blocking TNFa can arrest radiological progression in RA. Our 
findings show that this may be the case in most patients who remain on therapy for 
prolonged periods. It should be stressed that the follow-up in our study was longer than 
in previous reports and that X-rays were scored in chronological order as originally 
described and recently recommended (32). In contrast to random readings, this method 
assumes that radiological damage is irreversible and thus detects more progression but 
is also more sensitive to change (23). Moreover, we addressed recent OMERACT 
recommendations (33,34) by taking intraobserver reproducibility into account.
Regarding the effect of anti-TNFa therapy on biological markers, we observed a rapid 
and sustained down-modulation of non-specific acute phase reactants such as CRP. 
With the notable exception of COMP, all markers studied correlated positively with CRP 
levels and most of them dropped within two weeks of therapy initiation. This is in line 
with previous data on the kinetics (35,36) and on the effect of anti-TNFa on these 
markers in patients with RA (11,14,15). COMP levels in contrast, did not change over 
the short term and our results confirmed the acute-phase-independent nature of this 
marker (37,38).
Our study was directed to identify potential predictors of radiologic outcome. Analysis of 
the relationship between biological markers and radiologic course yielded some 
interesting findings. Among the biological markers studied, univariate analysis showed 
that only baseline COMP and sICAM-1 had moderate correlations with radiologic course 
over the 2-years follow-up. This was corroborated by the fact that patients with X-ray 
progression had significantly higher levels of COMP and sICAM-1 compared to those 
with stable radiologic course (P = 0.01 and 0.04 respectively). These findings are of 
interest since previous studies have found that high COMP levels were prognostic for 
large joint destruction in RA (37), Mànsson thesis, Lund 1999. Our data suggest that, in 
contrast to data published concerning early RA (38),COMP levels might also predict 
small joint damage in RA. sICAM-1 is known to be upregulated in synovial tissue and its 
soluble form is found in high concentrations in patients with RA (39). Down-regulation of 
the expression of this and other adhesion molecules has also been implicated in the 
mechanism of action of anti-TNFa (11,12) and other antirheumatic drugs (40,41).
55
D=0 D=14 Long-term
150 T
100 --
50
D=0 D=14 Long-term
Figure 3. Short and long-term changes in markers of endothelial activation (sE-selectin [C], sICAM-1 
[D]) and cartilage and synovium turnover (metalloproteinases MMP-1 [A] and MMP-3 [B], cartilage 
oligomeric matrix protein or COMP [E] and human cartilage glycoprotein-39 or HC gp-39 [F]).
The boxes illustrate the mean (horizontal bar), 25 and 75 percentile (box) and 5 and 95 percentile 
(bars). Short-time changes: changes observed within two weeks after the first dose of anti-TNFa 
(continuous line) or placebo (dashed line) in the double-blind phase. Long-term changes : changes 
occurring between baseline and the two years follow up, patients still on therapy (gray boxes) or drop­
out (white boxes).
MMP-1, MMP-3, sE-selectin and sICAM-1 levels are displayed in |jg/l, COMP and HC gp-39 levels are 
shown in mg/l. Significance is shown as p<0.05, tested within groups (t) and between groups (t).
t
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In addition, antibodies that block ICAM-1 have been tested with favourable results in RA 
patients (42). The relation of baseline sICAM-1 levels with radiological course has 
however not been previously described, although higher sICAM-1 levels have been 
found in patients with radiologic damage in a cross-sectional study (43).
Circulating MMPs were associated with acute phase parameters but not found to be 
prognostic for radiologic course up to two years or between one and two years in our 
study. This relationship has been previously suggested in patients with early RA (44,45). 
The long median disease duration of our study population is most likely the reason for 
this difference, as also another study including patients with longstanding RA yielded a 
negative result (46). Whether differences in therapies used in our and above-mentioned 
studies also contribute to this apparent contrast is not clear.
Besides the higher baseline levels of COMP and s-ICAM-1 (Figure 4) and the higher 
drop-out rate observed among patients with progressive radiologic course, this group 
tended to have higher baseline X-ray scores than those showing no progression (Table 
2). This difference was, however, not significant and neither disease activity nor 
radiologic damage at baseline were prognostic for radiologic course. Inclusion of the 
latter in the regression model did not change the results of the model.
Logistic regression using baseline COMP, sICAM-1 and therapy status at completion 
demonstrated that these independent variables together had significant prognostic value 
for the radiologic outcome after two years, although each individual variable failed to 
reach significance in this statistical model. This could be due to the size of the sample 
and confirmation of these data is therefor needed in a larger cohort. The model, 
however, shows that both the treatment with anti-TNFa and baseline COMP levels are 
independently associated with radiologic outcome.
Although this was not the main goal of our study, the levels of biological markers at 
study completion were compared with those at baseline. Interestingly, decreases in 
COMP levels were observed irrespective of the therapy at study completion whereas 
sICAM-1 levels were lower than baseline only in patients still on anti-TNFa therapy 
(Figure 3, panel D for sICAM-1 and E for COMP). This association with therapy at study 
end might explain the disappearance of the prognostic value of sICAM-1 in the 
multivariate analyses. In patients with a stable radiologic course COMP and sICAM-1 
levels remained low and unchanged. Of note, both MMPs and HC gp-39 levels but not 
E-selectin showed further decreases on the long term. Earlier studies showed that 
sICAM-1, but not sE-selectin levels were elevated in patients with RA (39). This shows 
that the endothelial markers sICAM-1 and sE-selectin are differentially regulated and do 
not possess the same properties as disease markers.
In conclusion, our study indicates that sustained anti-TNFa monotherapy with 
adalimumab has a positive effect on radiologic outcome. This intervention has rapid 
effects on biological markers of cartilage and synovial turnover and endothelial
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activation, which are associated with the acute phase reaction but not on COMP levels, 
which strengthens the importance of serum COMP as a selective cartilage marker. 
Besides sustained anti-TNFa therapy during study period, only baseline COMP and to a 
lesser extent sICAM-1 levels were prognostic of the radiological course. These markers 
could potentially be used to identify patients at risk for development of radiological 
damage.
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Chapter V
Effects of therapy with a fully human anti-tumour necrosis factor a monoclonal antibody 
on the local and systemic homeostasis of interleukin-1  ß and tumour necrosis factor a in
patients with rheumatoid arthritis
Pilar Barrera, Leo AB Joosten, Alfons A den Broeder, Leo BA van de Putte, Piet LCM
van Riel, Wim B van den Berg
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Abstract
Objectives To study the short-term effects of a single dose of adalimumab, a fully 
human anti tumour necrosis factor (TNFa monoclonal antibody (MoAb), on the local 
and systemic homeostasis of interleukin-1 ß (IL-1ß) and TNFa in patients with 
rheumatoid arthritis (RA).
Methods All patients with RA enrolled in a phase I, single-dose, placebo-controlled 
study with adalimumab in our centre were studied. Systemic cytokine levels, acute 
phase reactants and leukocyte counts were studied at day 0, 1 and 14 after the first 
administration of anti-TNFa MoAb (n = 39) or placebo (n = 11). The cellularity and the 
expression of IL-1 ß and TNFa in synovial tissue were studied in knee biopsies obtained 
at baseline and at day 14 in 25 consenting patients.
Results A single dose of anti-TNFa MoAb induced a rapid clinical improvement, a 
decrease in acute phase reaction and increased lymphocyte counts in patients with 
active RA. The protein levels of I L-1 ß in the circulation were low and remained 
unchanged but the systemic levels of IL-1 ß mRNA, (P = 0.002) and the concentrations 
of IL-1 ß receptor antagonist (IL-1ra) and IL- 6  (P = 0.0001) dropped already within 24 
hours and this persisted up to day 14. Systemic levels of TNFa mRNA were low and 
remained unchanged though total TNFa (free and bound) in the circulation increased 
after adalimumab, reflecting most likely the presence of TNF:anti-TNFa complexes (P 
<0.005 at day 1 and 14). Both TNF receptors dropped below baseline levels at day 14 
(P <0.005).
Despite clinical improvement of arthritis, no consistent immunohistological changes were 
observed two weeks after anti-TNFa administration. Endothelial staining for IL-1 ß 
tended to decrease in treated patients (P = 0.06) but not in responders. The staining for 
IL-1 ß and TNFa in sublining layers and vessels were mutually correlated (r = 0.47 and 
0.58 respectively, P < 0.0005) and the microscopic scores for inflammation correlated 
with sublining TNFa and IL-1 ß scores (r = 0.65 and 0.54 respectively, P < 0.0001) 
though none of these showed significant changes during the study.
Conclusions Blocking TNFa in RA results in downregulation of IL-1 ß mRNA at the 
systemic level and in reduction of the endogenous antagonists for IL-1 ß and TNFa and 
of other cytokines related to the acute phase response, such as IL-6 , within days. At the 
synovial level, anti-TNFa therapy does not modulate IL-1 ß and TNFa on the short term. 
The synovial expression of these cytokines does not reflect clinical response to TNFa 
neutralisation.
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Introduction
In recent years, several approaches aimed at specific neutralisation of 
proinflammatory cytokines such as interleukin-1 ß (IL-1 ß) and tumour necrosis factor 
a (TNFa) have proven successful in chronic inflammatory diseases, such as 
rheumatoid arthritis (RA) (1-4) and Crohn’s disease (5,6).
In patients with RA, TNFa has been targeted using monoclonal antibodies (MoAb), 
either chimeric (2,3) or humanised (4), and TNF receptor-fusion proteins (7,8). Some 
of these TNFa antagonists have shown their efficacy in multicenter, placebo­
controlled trials and have been approved by the FDA. A potential drawback of some 
TNFa blocking agents is the development of human anti-chimeric antibodies (HACA), 
which may hamper or shorten the therapeutic effects in the long-term. This 
complication could be overcome using MoAb devoid of murine regions.
Adalimumab (D2E7, Knoll-BASF Germany) is a fully human IgG1 MoAb anti-TNFa 
with high specificity for recombinant and natural TNFa and it is generated with phage 
display techniques (9). Studies in more than 1200 patients show that repeated 
intravenous or subcutaneous administration of adalimumab is safe and result in rapid 
clinical improvement in patients with active RA (10-13).
Several studies with another IgG1 anti-TNFa MoAb have clearly shown that blocking 
TNFa reduces the acute phase reaction and decreases the local and systemic levels 
of adhesion molecule in RA patients (14-17). In vitro studies have also shown that 
neutralisation of TNFa reduces the production of I L-1 ß in synovial cultures (18). 
Whether such therapies also downregulate the synovial expression of IL-1 and TNFa 
in RA has not been fully elucidated yet. Observations in small numbers of patients 
suggest that this might be the case (14,19,20). In the present study we investigated 
the short-term effects of the first dose of adalimumab or placebo on the homeostasis 
of the two main pro-inflammatory cytokines IL-1 ß and TNFa at the systemic and the 
synovial level.
Patients and Methods
Patients
Patients with RA according to the ACR criteria (21) and with active disease, defined 
by a disease activity score (DAS (22) > 3.2, enrolled in a double-blind multicenter 
clinical trial with adalimumab at our centre were studied. DMARD therapy was 
withheld and NSAIDs and/or low-dose oral steroids (< 10 mg/day) were kept constant 
in a 3-week washout period prior to and during the study. Patients were randomly 
assigned to receive 0.5, 1, 3, 5 or 10 mg/kg of adalimumab and each dose group 
included 2  patients treated with placebo, who received active drug at 6  weeks if they 
still fulfilled the entry criteria (11,13).
Adalimumab or placebo was administered as a slow i.v. infusion over 3 to 5 minutes. 
The preparation consists of a non-pyrogenic solution of 25 mg/ml adalimumab MoAb 
in 1.2% mannitol, 0.12% citric acid, 0.02% sodium citrate. The placebo consists of 
the same ingredients, except for the exclusion of adalimumab.
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Results of the multicenter study including 120 patients in three centres show that 
clinical response is already apparent within 24 hours and maximal between 1 to 2 
weeks after adalimumab administration (11,13). The clinical effect is maximal at a 
dose of 1mg/kg and shows a plateau in the dose response curve thereafter (11,13). 
Therefore, for the aims of this study, we focused on the short-time effects observed 
the first 2  weeks after infusion of adalimumab/placebo and subdivided the patients in 
three dose groups consisting of placebo (n = 11), 0.5 mg/kg (n = 8 ) and 1-10 mg/kg 
adalimumab (n = 31).
Concentrations and gene expression of cytokines in peripheral blood 
Blood samples were drawn at 8-9 a.m. on day 0, 1 and 14 after infusion in endotoxin­
free Vacutainer tubes with 15% EDTA-K3 (Becton&Dickinson, Rutherford, NJ). 
Samples were directly centrifuged (2250 g, 10 min and 15000 g, 5min) to assess 
circulating cytokine concentrations in platelet-free plasma. Aliquots were stored at -20 
oC until assay.
IL-1 ß was measured using a high sensitivity ELISA (sensitivity 0.1 pg/ml; Quantikine 
HS, R&D, Minneapolis, USA) according to the manufacturer’s instructions. IL-1ra was 
measured by radioimmunoassays (RIA) (sensitivity 40 pg/ml; inter- and intra-assay 
variation < 10% respectively). IL- 6  and both soluble TNF receptors (sTNFR) were 
measured by ELISA (sensitivity 8  pg/ml and 0.1 ng/ml respectively) as previously 
described (23,24). Total TNFa was measured by ELISA (sensitivity 10 pg/ml). The 
latter had been validated in spiking experiments showing adequate TNFa recovery 
and no hampering by therapeutic concentrations of adalimumab (range 25 to 250 
mg/l) (1 1 ).
Aliquots of 500 .^L blood aimed for RNA isolation were mixed with 
guanidiumisothiocyanate (GITC) at 1:1 ratio and stored at -70 oC. Isolation of whole- 
blood mRNA and reverse transcriptase polymerase chain reaction (RT-PCR) analysis 
were performed as previously described by Netea et al (25). Briefly, aliquots of 0.5 .^g 
total RNA were diluted in 20 ^l RT buffer (50mM Tris-HCL pH 8.3, 75 mM KCl, 3 mM 
MgCh) containing 10 mM dithiothreitol, 5 .^M random hexamers, 250 .^M dNTPs, 20 
U RNAsin and 200 M-MLV RT. RT reaction was performed for 10 minutes at 20oC,
45 minutes at 42oC and 10 minutes at 95oC in a Mastercycler 5330 (Eppendorf, 
Hamburg, Germany). PCR reaction mixtures consisted of 3 ^l cDNA in 50 ^l PCR 
buffer (20mM Tris-HCL pH 8.4, 50 mM KCl, 1.5 mM MgCh, 0.001% gelatine) 
containing 100 .^M dNTPs, 1.25 U Taq polymerase and 0.3 .^M of each primer (25). A 
total of 29 PCR cycles (denaturation 30 sec at 92oC, annealing 30 sec at 55oC and 
extension 90 sec at 72oC) were performed for IL-1 ß mRNA and TNFa mRNA and 24 
cycles were performed for ß2-microglobulin. PCR products underwent electrophoresis 
on 2% agarose gel and were stained with ethidium bromide. Gels were scanned on a 
densitometer and analysed using the Molecular Analyst™ software. Results are 
expressed as ratio IL-1 ß or TNFa mRNA to the housekeeping gene.
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Synovial biopsies and immunohistochemistry
Percutaneous synovial biopsies of the knee were obtained with a Parker Pearson 
needle at baseline and 14 days after the first dose of adalimumab/placebo in all 
consenting patients. Biopsy was preceded by knee joint examination for tenderness 
(0 = none, 1 = response on questioning, 2 = spontaneous response, 3 = withdrawal) 
and swelling ( 0  = none, 1 = thickening without loss of bony contours; bulge sign, 2  = 
loss of bony contours; palpable but not tightly distending effusions, 3 = bulging 
synovial proliferation; tightly distending effusions). Macroscopic knee joint scores 
were calculated by adding up the tenderness and swelling scores. An average of 30 
biopsies was obtained at each occasion and immediately fixed in 1 0 % formalin and 
embedded in paraffin. Serial 7 .^M microtome sections were mounted on superfrost 
slides and either stained with haematoxylin and eosin (HE) or used for histochemical 
staining as previously described (26,27). For each marker, all sections were stained 
in the same run to minimise interassay variations. Slides were incubated with anti- 
TNFa (IgG1, Monosan, Uden, The Netherlands) or anti-IL-1 ß MoAbs (IgM, 12E9, 
Oncogene Science, Manhasset, NY, USA). This primary step was followed by 
incubation with normal horse serum and with biotinylated horse anti-murine IgG. 
Slices were stained with avidin peroxidase (Elite kit, Vector, Burlingame, CA), 
developed with diaminobenzidin (DAB) and counterstained with haematoxylin for 3 
minutes. Controls consisted of a) irrelevant primary isotype-specific IgG1 and IgM 
antibodies obtained from normal horse serum and b) by omitting the secondary 
antibodies.
All areas of each section were randomly analysed by two blinded observers using 
semiquantitative five point scales. HE sections were scored for the presence of 
lymphocytes, plasma cells and polymorphonuclear cells (PMN) with a scale ranging 
from 0 (no or minimal infiltration) to 4 (abundant inflammatory infiltrate), the lining 
hyperplasia was also scored (0 : 1-2, 1 : 3-4, 2 : 5-6 and 3 : > 6  layers). An 
“inflammation score” was calculated by adding these four components (range 0-15) 
as previously described by Tak et al (14). The staining for IL-1 ß and TNFa in lining, 
sublining and vessels was also scored semiquantitatively on a five-point scale ( 0  to 
4). Differences in readings of 1 point were taken as the average, differences 
exceeding 1 point were resolved by mutual agreement.
Statistical Analyses
Analysis was performed using the SAS statistical package (SAS 6.04 PC version). 
Data are expressed as mean ± SD or as median (p25-p75) if appropriate. Within 
groups comparisons were analysed by paired Student’s t or Mann Whitney rank sum 
test. Baseline comparisons between groups were performed using one-way ANOVA 
or Kruskal Wallis tests. Correlations are expressed using the Spearman’s rank 
correlation coefficient.
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Results
Clinical results, acute phase reaction and leukocyte subsets
The baseline characteristics of the patients included in the present study are 
summarised in Table1. Patients were subdivided in placebo, 0.5 mg/kg and 1-10 
mg/kg since, as previously mentioned, the dose-response curve in the multicenter 
study (n = 120) showed a plateau at doses of 1 mg/kg adalimumab (11, 13). 
Administration of adalimumab, but not placebo, resulted in a rapid reduction of 
disease activity as measured by the DAS, a composite disease activity score (22) 
(Figure 1 upper panel), and its individual components including swollen and tender 
joint counts, patient wellbeing (data not shown) and ESR (Figure 1 mid panel). In the 
group treated with 1-10 mg/kg adalimumab, the decrease in DAS was already 
significant within 24 hours post-infusion (mean ± SD 4.87 ± 0.79 versus 5.25 ± 0.95; 
P < 0.002) and reached a nadir at week 2 (mean ± SD 4.06 ± 0.85, P < 0.0001). The 
0.5 mg/kg group showed a drop in DAS values significant at week 2 (P < 0.01). At 
this time point, 65% and 37.5% of the patients treated with 1 - 10 and 0.5 mg/kg 
adalimumab respectively fulfilled the EULAR criteria for clinical response (28) in 
contrast to only one patient (9%) receiving placebo. Sixteen percent of the patients in 
the 1-10 mg/kg group showed clinical response already 24 hours after infusion. 
Baseline acute phase reaction parameters such as the ESR, C-reactive protein 
(CRP) and platelet counts tended to be higher in the 1-10 mg/kg group (Table 1) and 
were also significantly decreased 2 weeks after administration of anti-TNFa MoAb 
but unchanged or increased in the placebo group (Figure 1 mid and lower panel). 
The 0.5 mg/kg group which included fewer patients (n = 8 ) also showed a clear 
decrease in ESR and CRP after 2 weeks.
Baseline white blood cell (WBC) and leukocyte subset counts were similar in all 
groups (Table 1). Total WBC counts did not change during the study (data not 
shown) but a rise in day 1 lymphocyte counts was observed in all groups, being more 
marked in patients receiving 1- of 10 mg/kg adalimumab (median 14.5% pre-infusion 
versus 22% at day 1; P < 0.01). Only in this group, the lymphocyte counts were still 
higher than baseline at day 14. Conversely, there was a drop in day 1 
polymorphonuclear cells (PMN) counts in all groups which only reached significance 
in the 1-10 mg/kg group at day 1 (median 77% at baseline and 66.5% at day 1; P = 
0 .0 2 ).
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Table 1. Baseline characteristics and response percentages according to the dose group.
Placebo 
n = 11
0.5 mg/kg 
n = 8
1 to 10 mg/kg 
n = 31
P
Age, mean ± SD (years) 60 ± 8 53 ± 18 57 ± 14)
Female (%) 73 75 55
RF positivity (%) 100 100 97
Disease duration, median (p25-p75) (years) 13 (4 -  23) 8 (4 -  15) 10 (5 -  19)
Previous DMARDs (n) 4.5 ± 1.6 4.5 ± 2.6 5 ± 1.7
Prednisone (%) 72 38 52
DAS, mean ± SD 4.8 ± 1.1 5.2 ± 1.3 5.2 ± 1
Ritchie Articular Index, mean ± SD 22 ± 13 25 ± 11 26 ± 11
Swollen joint count, mean ± SD 18 ± 5 18 ± 5 18 ± 6
ESR, median (p25-p75) (mm/h) 24 (7- 39) 15 (9 - 38) 36 (23 - 55) 0.05
CRP, median (p25-p75) (mg/l) 23 (6 - 90) 22 (12 - 42) 63 (33 -  115) 0.05
Haemoglobin (mmol/l) 7.6 ± 0.9 7.4 ± 1.2 7.2 ± 1.0
Leukocytes, median (p25-p75) (x109/l) 8.1 (6.3-10.5) 7.5 (6.5-8.9) 7.2 (5.9-10.4)
Polymorphonuclears 5.77 (4.76-8.12) 5.07 (4.55-6.51) 4.78 (4.05-8.16)
Lymphocytes 1.16 (0.85-1.60) 1.37 (1.08-2.26) 1.14 (0.85-1.31)
Monocytes 0.52 (0.40-0.58 0.42 (0.38-0.49) 0.46 (0.38-0.63)
Platelets mean ± SD (x109/l) 329 ± 48 306 ± 65 3 7 7 ± 130
Responders t  at (%)
2 weeks 9 37.5 65 t
12 weeks - 50 76.6
24 weeks - 87.5 70
t  Response according to the EULAR criteria for moderate and good response.
t  16 % of the patients showed clinical response already 24 hours after 1-10 mg/kg adalimumab 
administration.
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Figure 1. Disease activity score (DAS; upper panel), ESR (mid panel) and CRP (lower panel) in 
patients receiving a single dose of placebo or anti-TNFa MoAb (0.5 mg/kg or 1-10 mg/kg doses; 
bottom). Boxes represent percentiles P25, P50 and P75; vertical lines indicate the P5 and P95 
percentiles. Measurements on day 0, 1 and 14 after infusion (x-axis).
Comparisons versus baseline shown as *, **, *** representing P < 0.05, < 0.005 and < 0.0005 
respectively.
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Systemic cytokine measurements
Baseline IL-1 ß and TNFa levels were below or around the detection limit of the RIAs 
currently used in our lab and similar to those found in healthy individuals (data not 
shown). Using a high sensitivity ELISA (Quantikine HS, R&D, Minneapolis, USA), IL- 
1 ß protein levels were very low and did not show significant changes after the first 
dose of adalimumab or placebo (median levels at baseline, day 1 and day 14 were 
0.55, 0.4 and 0.5 pg/ml after 1 to 10 mg/kg adalimumab and remained 0.6 pg/m 
before and after placebo administration).
Mean baseline TNFa levels (free and bound) measured by ELISA did not change 
after infusion of placebo but increased after adalimumab administration (41 pg/ml at 
baseline versus 76 and 63 pg/ml at day 1 (P<0.0001) and day 14 (P<0.01) 
respectively) which may reflect the formation of circulating TNF-anti-TNF complexes. 
To complement the data at the protein level, systemic IL-1 ß and TNFa mRNA levels 
in whole blood were measured in the placebo and 1 - 1 0  mg/kg adalimumab group 
using RT-PCR. Baseline IL-1ß/ß2m ratios in patients with RA were elevated in 
relation to healthy controls (median [range] 1.45 [0.57-2.95] versus 0.35 [<0.10­
0.69]). As shown in Figure 2, I L-1 ß mRNA expression decreased within 24 hours 
after adalimumab administration (P = 0.002) and remained lower than baseline at day 
14 (P = 0.007) whereas no significant changes occurred after placebo. Systemic 
TNFa mRNA levels were lower than those of I L-1 ß overlapped largely with those 
found in healthy controls (median [range] 0.13 [<0.10 -  0.85] in RA versus <0.10 
[<0.10 - 0.30] in controls) and remained unchanged during the study. Systemic levels 
of IL-1 ß and TNFa mRNA were not correlated (r [95%CI] = 0.13 [-0.18; 0.43])
The concentrations of IL-1 ra and IL- 6  decreased sharply after adalimumab 
administration (P<0.0001 and <0.005 at day 1 and 14 respectively in the 1-10 mg/kg 
group). Both sTNFR types decreased also after therapy. In patients receiving 1-10 
mg/kg adalimumab, the p75 levels dropped from median baseline values of 5 ng/ml 
to 4.3 (P < 0.005) and 3.7ng/ml (P = 0.0001) after 1 and 14 days respectively and the 
p55 sTNFR levels fell from median baseline values of 3.1 ng/ml to 2.5 ng/ml at day
14 (P < 0.002) (Figure 2).
There were positive correlations between acute phase reactants and the endogenous 
antagonists of IL-1 ß and TNFa. CRP measurements correlated with the levels of IL- 
1ra (r = 0.47; P < 0.001), p55 sTNFR (r = 0.66; P < 0.0001) and IL- 6  (r = 0.65; P < 
0.0001) while ESR levels correlated with p75 sTNFR (r = 0.51; P < 0.002). In 
contrast, neither TNFa nor IL-1 ß at protein or mRNA level was related to acute phase 
parameters.
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p55 sTNFR (ng/ml)
Placebo 0.5 mg/kg 1-10 mg/kg
IL-6 (pg/ml)
p75 sTNFR (ng/ml)
Placebo 0.5 mg/kg 1-10 mg/kg
IL-1ß/ß2M ratio
Placebo 1-10 mg/kg
TNFa/ß2M ratio
Placebo 1-10 mg/kg
Figure 2. Circulating concentrations of IL-1 ra, IL-6 (upper panel), p55 and p75 sTNFR 
(central panel). IL-1 ß and TNFa mRNA in whole blood (lower panel) normalised for the 
presence of ß2 microglobulin. Boxes represent P25, P50 and P75 percentiles; vertical lines 
indicate the P5 and P95 percentiles. Measurements on day 0, 1 and 14 after infusion (x- 
axis). Comparisons versus baseline shown as *, **, *** representing P < 0.5, < 0.005 and < 
0.0005 respectively.
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Immunohistological findings
A total of 25 patients underwent synovial biopsies at baseline and 14 days post­
infusion of placebo (n = 8 ) or 1-10 mg/kg adalimumab (n = 17). At this time in the 
treated group, the DAS had dropped from 5.0 ± 1.0 to 4.0 ± 1.1 (P < 0.0005) and 11 
patients fulfilled the EULAR criteria for clinical response (28). Conversely, DAS 
scores remained unchanged or increased (4.8 ± 1.3 at baseline versus 5.1 ± 1.6) in 
the placebo group where only one patient fulfilled the EULAR response criteria (28) 
(Figure 3, upper panel). The macroscopic joint scores for swelling and pain at the 
biopsied joint were unchanged 2  weeks after placebo but decreased in treated 
patients (P = 0.02; Figure 3, mid panel). The microscopic scores for inflammation
(14) showed a more scattered pattern and no significant changes in either group 
(Figure 3, lower panel). Baseline microscopic inflammation scores were weakly 
related with the macroscopic scores for pain and swelling (r = 0.3; P <0.05).
TNFa and IL-1 ß staining were observed in all layers of most biopsies. The scores for 
both cytokines in the lining, sublining and especially in vessels were mutually 
correlated (r = 0.43; P = 0.002 for the lining and r = 0.47 and 0.58; P < 0.0005 for the 
sublining and vessels respectively). Nevertheless some differences were found in the 
staining patterns of both cytokines: TNFa showed a more dense and intense staining 
in sublining layers, lymphocyte aggregates and vessels whereas IL-1 ß tended to be 
more diffuse (Figure 4). The microscopic scores for inflammation were positively 
correlated with the scores for TNFa and IL-1 ß in the sublining (r = 0.65 and 0.54 
respectively; P < 0.0001) and to a lesser extent with the TNFa staining in the lining (r 
= 0.38; P = 0.005).
The individual synovial scores for IL-1 ß and TNFa after administration of anti-TNFa 
MoAb or placebo are shown in Figure 5. As shown, there was a marked inter- and 
intra-individual variation in the synovial staining for these cytokines. Decreases larger 
than 1 point in the scores for I L-1 ß or TNFa were rare among placebo treated 
patients. On the other side, both increased and decreased scores for IL-1 ß and TNFa 
were detected in the lining and sublining of patients treated with anti-TNFa. With the 
exception of a trend to decrease in the IL-1 ß staining in vessels among the treated 
patients (P < 0.06), no significant changes were observed.
Additionally, analysis was performed according to the clinical response achieved at 
day 14 after infusion. At this time point, a total of 12 patients (all but one in the group 
treated with anti-TNFa) were responders according to the EULAR criteria (28) (DAS 
decreased from 4.9 ± 1.1 to 3.4 ± 0.6; P < 0.0001) whereas 13 patients, 7 among 
them after receiving placebo, were non-responders (mean ± SD DAS 5.1 ± 1.2 
versus 5.2 ± 1.2). Macroscopic knee joint score for swelling and pain dropped from 2 
± 2.3 to 0.8 ± 1.1 (P < 0.05) among responders but remained unchanged (2.2 ± 2.0 
versus 2 . 2  ± 2 ) in the non-responders.
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Figure 3. DAS, pain and swelling scores and histologic scores for 
inflammation in 25 patients undergoing serial biopsies. Time in 
weeks and placebo (n = 8) or anti-TNFa therapy (n = 17) shown in 
the x-axis.
Scores for n > 1 patient (x exact number) shown in bold lines.
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Figure 5. Semiquantitative scores for IL-1 ß (left columns) and TNFa (right 
columns). Staining in lining, sublining and vessels in biopsies taken at baseline 
and at day 14 after administration of placebo (n = 8) or anti-TNFa therapy (n = 
17). Scores for n > 1 patient (x exact number) shown in bold lines.
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In contrast with the clinical improvement observed in responders, the microscopic 
inflammation scores (HE) and the staining for IL-1 ß or TNFa in lining, sublining and 
vessels were not significant changed from baseline as compared to day 14 (data not 
shown). Subgroup analysis considering the individual dose of adalimumab 
administered yielded the same results.
Discussion
Our study demonstrates that in patients with active RA, a single dose of human anti- 
TNFa antibody in clinically effective and results in rapid downregulation of I L-1 ß 
mRNA at the systemic level. Such effect was observed in unstimulated conditions, 
using a sensitive PCR, normalised for the presence of ß2 microglobulin, which 
corrects for fluctuations in peripheral blood mononuclear cells (PBMNC) counts. The 
inhibition of I L-1 ß by anti-TNFa MoAb therapy occurred at the transcriptional level 
and seemed rather specific. TNFa neutralisation did not alter the levels of TNFa 
mRNA in the circulation and no change in I L-1 ß or TNFa mRNA expression was 
observed in the placebo group.
The production of both IL-1 ß and TNFa is transcriptionally regulated (29,30) and both 
cytokines share many pro-inflammatory effects. Therefore, a decrease in I L-1 ß 
message might be involved in at least a part of the downstream changes observed 
after therapy with this and other anti-TNFa MoAb. These include inhibition of IL- 6  and 
acute phase reaction, chemokines and nitric oxide production and decrease in 
angiogenesis, endothelial activation and cartilage breakdown markers (16,17,31).
In our study, baseline mRNA levels of I L-1 ß in whole blood were elevated in RA 
patients compared with normal controls. Elevated levels of messenger RNA for IL-1 ß 
and other pro-inflammatory cytokines such as IL- 8  have also been measured in 
isolated PBMNC of patients with RA (32, 33) and these may reflect an increased 
activation status of PBMNC in the circulation. Systemic TNFa mRNA levels were 
lower, and not correlated with those of IL-1 mRNA, which is in line with the earlier 
reported differential regulation of I L-1 ß and TNFa in PBMNC (30,32) and in whole 
blood (29).
Inhibition of the synthesis of I L-1 ß after blocking TNFa has been shown to occur in 
rheumatoid synovial cultures (18,34). Direct evidence for such effect in patients with 
RA has been hard to find since, as we and others have shown (17), protein levels of 
IL-1 ß in the circulation are mostly low or undetectable.
Indirect evidence for an effect of blocking TNFa on the homeostasis of IL-1 ß can be 
sought in the effects of such therapy on the concentrations of its natural antagonist
I L-1 ra. This and other studies (35) have shown that the levels of IL-1 ra are elevated 
in patients with RA and positively correlated with acute phase reaction parameters 
and with IL- 6  levels. It has been proposed that in RA, the elevated levels of IL-1 ra 
may reflect an increased production and/or activity of I L-1 ß (35). Therapy with 
adalimumab diminished the levels of IL-1ra and IL- 6  with similar kinetics and such
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effects have also been reported after the administration of cA2, a chimeric anti-TNFa 
monoclonal antibody, in patients with RA (15,36).
The fully human anti-TNFa antibody used in this study is of the same isotype and 
clinically as efficacious and has other systemic effects common with the chimeric 
IgG1 anti-TNFa MoAb infliximab. One of those is the reduction of circulating levels of 
both soluble TNFa receptors after therapy. This has led to the hypothesis that anti- 
TNFa MoAbs act mainly through neutralisation of TNFa since this cytokine is a major 
regulator of TNFR release (17). However, decreases in circulating sTNFR levels are 
not specific for anti-TNFa MoAb therapy and probably mirror the acute phase 
reaction (24). Another common effect of both anti-TNFa antibodies was a transient 
rise in lymphocyte counts and a reciprocal drop in granulocyte counts (17) which has 
not been reported after blocking TNFa with TNFR:Fc fusion proteins. Whether this 
raise in lymphocytes is due to a deactivation of vascular endothelium, as proposed 
(37), or is a non-specific phenomenon as suggested by the similar trends seen in 
placebo group remains to be elucidated.
At the target organ level, significant reductions of pain and swelling at the biopsied 
joint occurred concomitantly with the systemic improvement observed 2  weeks after 
adalimumab but not after placebo. The improvement in the macroscopic inflammation 
scores was also evident when analysed according to the clinical response. The 
microscopic inflammation scores (HE) and the staining for IL-1 ß and TNFa in lining, 
sublining and vessels showed large intra-individual variations. Except for a trend to 
decrease in the endothelial staining for IL-1 ß among treated patients we observed no 
consistent changes two weeks after initiation of anti-TNFa therapy.
Previously Tak et al. reported a reduction in T cells and in the expression of adhesion 
molecules in RA synovial tissue after TNFa neutralisation (14, 20). It has also been 
suggested that the synovial expression of I L-1 ß and TNFa decreases four weeks 
after an initial dose of anti-TNFa using other TNFa blocking strategies. This was 
either reported in a very limited number of patients (14) and/or in abstract form (19, 
2 0 ), which precludes firm conclusions.
Our results are in line with recent observations in experimental arthritis also show 
that anti-TNFa therapy does significantly reduce joint swelling (38) but leaves the 
production of I L-1 ß in synovium unaltered (39). That the local production and 
expression of I L-1 ß during arthritis is not driven by TNFa has been elegantly 
demonstrated in TNFa knockout mice (39). After induction of arthritis in the latter, 
there is a lack of joint swelling and a marked reduction in the late synovial infiltrate 
but an ongoing local production of I L-1 ß. Interestingly, the amelioration in swelling 
and infiltrate in these mice are abolished if the membrane-bound TNFa is 
reintroduced in the model (40).
Taken together, our results confirm that TNFa neutralisation with anti-TNFa MoAb in 
RA is very effective in controlling clinical inflammation and decreasing the acute 
phase reaction in patients with active RA. Blocking TNFa inhibits IL-1 ß at the trans­
criptional level in the circulation and this may be implicated in its mechanism of 
action. Our study further confirms that the effect of anti-TNFa MoAb is not due to
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upregulation of the endogenous antagonists for I L-1 ß and TNFa since these 
decrease during therapy mirroring the acute phase reaction.
TNFa neutralisation has a very rapid clinical effect and our goal was to analyse short­
term systemic and local changes in the homeostasis of IL-1 ß and TNFa. In the short 
term, blocking TNFa did not modify the local expression of I L-1 ß or TNFa or the 
histological inflammation scores in the joint. Local changes therefore do not precede, 
or occur concomitantly, with systemic improvement. Whether such changes occur in 
a delayed fashion is now subjected to further studies.
Our results corroborate the discordance in macro- and microscopic signs of synovial 
inflammation. Moreover, they suggest that the synovial expression of TNFa and IL-
1 ß, does not relate to concomitant signs of synovitis. Whether the former is predictive 
for future joint damage has not been elucidated yet. Nonetheless, in view of the 
independent regulation of these cytokines, future therapeutic efforts that combine 
neutralisation of IL-1 ß and TNFa are warranted in patients with RA.
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Figure 4 Immunohistochemical staining in the same patient at baseline (TNFa [A]; IL-1 ß [B]) 
and 14 days (TNFa [C]; IL-1 ß [D]) after the first dose of anti-TNFa. Note the unchanged 
expression of cytokines in synovial lining (s, arrows), sublining and blood vessels (bv). No IL- 
1ß or TNFa staining was observed in controls with an irrelevant primary antibody (E) and 
omitting the secondary antibody (F). Original magnification 200x.
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Chapter VI
Anti-TNFa treatment does not affect hypothalamic-pituitary-adrenal axis activity in
patients with rheumatoid arthritis
Agnes MM Eijsbouts, Alfons A den Broeder, Roland FJM Laan, Fred CGJ Sweep, 
Oliver Sander, Rolf Rau, Leo BA van de Putte, Frank HJ van den Hoogen
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Abstract
Objective Treatment with TNFa neutralising agents yields rapid improvement of 
disease activity in patients with RA, and it has been suggested that this may be a 
cortisol-mediated effect. In this study we examined the effect of anti-TNF treatment on 
the activity of the HPA-axis in these patients.
Methods Eighteen patients with active RA were studied before and after an i.v. 
injection with a TNFa neutralising agent or placebo. Five patients were treated with the 
TNFR:FC receptor fusion protein Ro 45-2081 in a study by F. Hoffmann-La Roche, and 
eight were treated with the human monoclonal antibody adalimumab in a study by Knoll 
AG. Five patients were studied before and after an injection with placebo in the latter 
study.
Before the first injection with anti-TNFa, and on the day after injection, plasma ACTH, 
plasma cortisol and ESR were determined. Before and after injection 24 hrs urinary 
cortisol excretion was measured, circadian cortisol rhythm was measured in salivary 
samples, and a composite disease activity score (DAS) was determined 
Results DAS improved in the group of patients treated with anti-TNFa (mean decrease 
of DAS ± SD: 0.64 ± 0.46, P=0.0007), but not in the placebo group (0.09 ± 0.35). No 
changes were observed in the treatment group in plasma ACTH and plasma cortisol 
before and after injection. Neither were there significant changes in 24 hrs urinary 
cortisol excretion or in the circadian cortisol rhythm.
Conclusion Treatment with TNFa neutralising agents does not influence the activity of 
the HPA-axis and the achieved improvement is not due to changes in cortisol levels.
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease characterised by chronic 
inflammation, predominantly affecting the joints. Although its aetiology still remains to 
be elucidated, the pathophysiological mechanisms probably consist of a combination 
of genetical and environmental factors. Activation of the immune system, involving 
Th1 lymphocytes and several monocyte derived cytokines, has been shown to play 
an important role in RA. Bi-directional interactions between the immune system and 
the hypothalamic-pituitary-adrenal axis (HPA-axis) have been identified (1,2). In 
animal studies it has been shown that the proinflammatory cytokines interleukin- 1  ß ( 
IL-1 ß), interleukin- 6  (IL-6 ) and tumour necrosis factor a (TNFa) are able to increase 
the activity of the HPA-axis (3,4). Conversely, cortisol influences cytokine production 
and inhibits several cytokines, including TNFa.
TNFa is a proinflammatory cytokine, and in the joints of RA patients high levels of 
this cytokine have been detected, suggesting a crucial role for TNFa in the 
inflammatory process in RA. Inhibition of TNFa has clearly been shown to reduce 
disease activity in RA, and recent development of anti-TNFa treatment has been a 
major break-through in the treatment of RA (5-8). This treatment causes a rapid 
objective and subjective clinical improvement, which already occur on the first day 
after injection. The only other treatment of RA by which such a rapid improvement of
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disease activity can be achieved is by treatment with corticosteroids. Considering the 
close interaction between the HPA-axis and cytokines, the question arose, whether 
the rapid effect of anti-TNFa treatment could be mediated through the HPA-axis. 
Relatively low plasma levels of cortisol have been reported in patients with RA, which 
are considered low regarding their level of active inflammation, suggesting a 
decreased activity of the HPA-axis in RA (9-11). If TNFa is involved in maintaining 
these reduced plasma cortisol levels, anti-TNFa treatment might restore these levels, 
resulting in clinical improvement.
However, in animal studies i.v. administration of TNFa has been shown to activate 
the HPA-axis resulting in raised glucocorticoid levels (3,4). Blockade of TNFa could 
therefore be expected to lower cortisol levels and the rapid improvement in response 
to this treatment must be due to other factors than raising plasma cortisol levels.
The aim of our study was to examine whether anti-TNFa treatment affects the activity 
of the HPA-axis in patients with RA.
Patients and Methods
Patients
Eighteen patients with RA, who participated in two different studies with a TNF- 
neutralising agent, were studied before and after an intravenous (i.v.) injection with the 
TNF-neutralising agent or placebo. The protocols were approved by the hospital’s 
ethical committee, and written consent was obtained from all patients.
All patients fulfilled the American College of Rheumatology criteria for RA, and had 
active disease, as defined by a Disease Activity Score (DAS) > 3.2 (12). The use of a 
stable low dose of prednisone with a maximum of 2  mg daily was permitted, but 
patients were excluded if they had used oral corticosteroids in a dose above 2  mg daily 
in the previous year, or if they had received an intramuscular injection with 
corticosteroids in the previous 3 months. Patients using oral contraceptives or other 
drugs that are known to influence the HPA-axis were also excluded. The use of non­
steroidal anti-inflammatory drugs (NSAIDs) was allowed.
Study design and measurements
Five patients were treated with the TNFR:FC receptor fusion protein Ro 45-2081 (F. 
Hoffmann-La Roche, Basel, Switzerland), and received an intravenous injection with 20 
mg Ro 45-2081 before 12:00 a.m. Eight patients were treated with the human 
monoclonal antibody adalimumab (Knoll AG, Ludwigshafen, Germany) in a dose of 1.0 
mg/kg (n=4), 3.0 mg/kg (n=3) or 5.0 mg/kg (n=1). This was administered before 12:00 
a.m. by a slow intravenous injection. Five patients received an injection with placebo in 
the latter study.
In the week before the injection, blood was drawn at 9:00 a.m. for the determination of 
plasma ACTH, plasma cortisol and ESR, and a joint examination was performed in 
order to determine DAS. Blood for measurement of ACTH was immediately placed on 
ice and transported to the laboratory. Urine was collected for the determination of 24 
hours cortisol excretion. Salivary samples were collected every 4 hours during 24 hrs
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for the determination of the circadian cortisol rhythm, starting at 8:00 a.m. On the first 
day after the injection, all of these measurements were repeated.
Laboratory assays
Plasma cortisol levels were measured by radioimmunoassay (RIA) using an 
antiserum raised in rabbit against a cortisol-2 1 -hemisuccinate-bovine serum albumin 
conjugate (13). The sensitivity of the assay was 0.02 ^mol/l. The within- and 
between-assay coefficients of variation were 6.9% and 7.3% at 0.208 ^.mol/l and 
4.2% and 5.6% at 1.03 ^mol/l. Plasma ACTH was measured by an 
immunoradiometric assay (IRMA) based on two polyclonal antibodies 
(EuroDiagnostics, Arnhem, The Netherlands). Salivary cortisol as well as 24-hour 
urinary cortisol (i.e. extractable by organic solvents) were measured by RIA after 
previous extraction and paper chromatography (14).
Statistical analysis. Results are expressed as mean ± standard deviation (SD). 
Statistical comparisons were made within the RA group with paired Student's t-test, 
using a significance level of p < 0.05. The area under the curve (AUC) was calculated 
for the cortisol measurements in salivary samples during 24 hours. The small number 
of patients in the placebo group did not allow statistical analysis, but their results are 
described in the text and shown in the tables.
Results
The characteristics of the two treatment groups are shown in table 1. Thirteen 
patients were treated with a TNF-neutralising agent and 5 with placebo. All patients 
had active disease, with a DAS of 5.09 ± 1.18 (mean ± SD) in the treatment group 
and 4.87 ± 0.74 in the placebo group. ESR was 34 ± 24 mm/hr. in the treatment 
group and 31 ± 13 mm/hr. in the placebo group.
Table 1. Baseline patient characteristics.
Anti-TNFa (n=13) Placebo (n=5)
Age (yrs) 54 ± 14 55 ± 14
Male/female 7/6 0/5
Rheumatoid factor positive 11 5
Disease duration (yrs) 11 ± 5 19 ± 15
DAS 5.09 ± 1.18 4.87 ± 0.74
ESR 34 ± 24 31 ± 13
NSAIDs 12 5
Use of prednisone 2 mg daily 1
All values are expressed as mean ± SD or number of patients
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In the treatment group, a significant improvement of disease activity was seen on the 
day after the injection with anti-TNFa, as shown by a significant decline of the 
disease activity score which was 5.09 ± 1.18 before and 4.48 ± 1.21 after injection (p 
< 0.05) (table 2). In the placebo group these figures were 4.87 ± 0.74 and 4.80 ± 0.57 
respectively, showing no improvement. No effect was seen on ESR in both groups.
Table 2. Clinical and HPA-axis variables before and after treatment.
Anti-TNFa_____________________ Placebo
clinical DAS
ESR (mm/hr)
Before 
5.09 ± 1.18 
34 ± 24
After 
4.48 ± 1.21 * 
33 ± 24
Before 
4.87 ± 0.74 
31 ± 13
After 
4.80 ± 0.57 
31 ± 13
serum ACTH (pmol/l) 
cortisol (^mol/l)
3.9 ± 2.7 
0.47 ± 0.19
4.1 ± 3.0 
0.45 ± 0.15
2.6 ± 0.8 
0.45 ± 0.29
2.4 ± 1.1 
0.51 ± 0.24
urine cortisol (nmol/24 hrs) 94.3 ± 110.6 82.3 ± 61.8 71.5 ± 17.4 Only 3 val
saliva cortisol AUC 
cortisol 8:00 (nmol/l)
4.3 ± 1.6 
11.1 ± 7.2
3.6 ± 1.8 
11.8 ± 7.4
3.3 ± 1.2 
6.6 ± 3.6
3.0 ± 1.1 
5.8 ± 4.1
All values are expressed as mean ± SD 
* P < 0.05 compared to before treatment
Cortisol
(nmol/l)
Time
Figure 1. Circadian cortisol levels measured in saliva (nmol/l) before and after treatment 
with anti-TNFa ; mean values ± SD.
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Baseline values of plasma ACTH, plasma cortisol and cortisol in 24 hours urine 
collection, were all in the normal range, and cortisol in salivary samples revealed a 
normal circadian rhythm with peak values at 8:00 am. (Figure 1). We did not find a 
significant change in any of these parameters before and one day after an injection 
with anti-TNFa treatment. Area under the curve calculated from the salivary cortisol 
rhythm also showed no significant difference before and after treatment. In the 
patients who received an injection with placebo, no change in these parameters 
before and after injection was observed either.
Discussion
At baseline patients with active RA had levels of ACTH and cortisol that were in the 
normal range. As mentioned earlier decreased levels of cortisol have been reported 
in RA, but also normal levels have been found in several studies. These normal 
levels however are considered inappropriately low for the degree of inflammation
(15). Seven of the 18 patients were men, which is due to the fact that patients using 
oral contraceptives were excluded, leaving relatively more men than women to be 
selected for this study.
A significant improvement of disease activity was seen in the treatment group on the 
day after the injection with the TNF-neutralising agent, and no improvement in the 
placebo group. Despite this improvement no change was seen in plasma ACTH or 
cortisol levels after injection, showing that blockade of TNFa does not affect the 
activity of the HPA-axis in patients with RA. As interactions between the HPA-axis 
and the immune system are complex, and probably involve several cytokines, which 
have been shown to stimulate the activity of the HPA-axis, blockade of one of them, 
TNFa, may be compensated by other cytokines, like I L-1 ß and IL-6 , resulting in 
unchanged HPA-axis activity.
Our findings show that the rapid and significant clinical improvement as observed on 
the first day after anti-TNFa treatment is not cortisol mediated. Probably the 
improvement is due to inhibition of local action of TNFa in the joints, where the 
highest TNFa levels are found. However, besides a clear decrease of pain and 
stiffness of the joints, patients also experience a general feeling of wellbeing and 
decrease of tiredness that cannot be explained by a local effect in the joints alone. 
This general improvement suggests that a systemic effect in response to anti-TNFa 
treatment takes place as well.
Patients who are treated with corticosteroids experience a similar effect, and one 
could speculate, knowing that corticosteroids inhibit cytokines, including TNFa, that 
inhibition of cytokines might play a role in the subjective improvement induced by 
corticosteroid treatment. However, corticosteroids have a wide range of action, and 
this might only be one aspect of the mechanism by which corticosteroids exert their 
effect.
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In conclusion our study shows that TNFa blockade does not affect the activity of the 
HPA-axis in patients with RA, and that the rapid improvement in response to anti- 
TNFa treatment is not a cortisol mediated effect.
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Chapter VII
Isolated digital vasculitis in a patient with rheumatoid arthritis: good response to
TNFa blocking treatment
Alfons A den Broeder, Frank HJ van den Hoogen, Leo BA van de Putte
91
Abstract
TNFa blocking agents are among the most promising new treatments for rheumatoid 
arthritis (RA). However, no data are present about the effect of these agents on 
extra-articular manifestations of RA. We describe a patient with small vessel 
vasculitis that repeatedly responded well to treatment with the soluble p55 TNFa 
receptor fusion protein Ro 45-2081 (lenercept).
Introduction
Symmetrical polyarthritis is the hallmark of rheumatoid arthritis (RA). In addition, 
pathology outside the joints can also be found. One of these so-called extra articular 
manifestations of RA is vasculitis. Vasculitis in RA usually affects small vessels and 
commonly involves the skin, causing nail-fold infarcts, and in more severe cases 
digital gangrene and leg ulcers (1). Less frequently, vasculitis of small and medium 
sized arteries complicates RA and causes damage to peripheral nerves and internal 
organs. Prevalence of vasculitis in RA varies from 1-5% but post-mortem studies 
show higher percentages up to 25% (2). Treatment of rheumatoid vasculitis depends 
on the size of the vessels affected and the impending organ damage. High doses of 
corticosteroids may be necessary, often in combination with immunosuppressive 
agents including azathioprine and cyclophosphamide to allow for long-term disease 
control and reduction of the corticosteroid dose. Treatment with these drugs is 
associated with considerable side effects.
In the last decade new agents have been developed for the treatment of autoimmune 
diseases. Among the most promising are TNFa blocking agents. Several agents that 
block TNFa have been developed and studied in patients with RA (3,4,5). TNFa 
blockade is achieved either with monoclonal antibodies against TNFI or with fusion 
proteins containing human TNF receptors bound to a Fc component of a human IgG 
antibody. Although excellent efficacy in treatment of RA has been reported for 
several of these agents, no reports have thus far addressed the effect of TNFa 
scavenging on extra-articular manifestations. We describe a chance observation in a 
patient with RA and nailfold lesions responding repeatedly to treatment with the anti- 
TNFa receptor fusion protein lenercept.
Case report
A 46 year old woman was diagnosed with rheumatoid factor positive, erosive RA in 
1982. From the beginning of her disease, ANA could be detected. Testing for disease 
specific autoantibodies was negative on several occasions. Her medical history was 
unremarkable. In the following years she was treated unsuccessfully with 
hydroxychloroquine, intramuscular gold salts, D-penicillamin, azathioprine, 
methotrexate, and a combination of sulfasalazine and methotrexate. Because of 
progressive joint destruction she received shoulder prostheses on both sides, an 
elbow endoprosthesis left, total knee joint replacement on both sides and a
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spondylodesis of the first and second cervical vertebra was performed. No extra- 
articular symptoms were present except for sicca complaints. Due to the 
uncontrollable disease she was included in 1994 in a study with Ro 45-2081, a fusion 
protein combining two p55 TNF receptors with the Fc component of an IgG human 
antibody (lenercept) (6 ). After a three months placebo controlled phase she was 
treated with 50mg lenercept intravenously every four weeks. Clinical response was 
impressive with swollen joint counts decreasing from 32 to 5 and C-reactive protein 
CRP levels declining from 95 at baseline to 20 after the first injection. Low disease 
activity was sustained for the following years. Besides lenercept, her medication 
consisted of oral prednisone 5 mg a day and occasionally paracetamol 500 mg.
In the spring of 1999 she first noticed nailfold lesion on the fingers of both hands. 
These lesions disappeared after every injection of lenercept and reappeared three 
weeks thereafter when the effect of lenercept was decreasing (figure 1A and 1B). 
Clinical response indicated by a drop in joint counts and CRP was present two weeks 
after each anti-TNFa injection.
Discussion
We describe a patient with RA and small vessel vasculitis manifested by nailfold 
lesions responding to treatment with lenercept. The response has been well 
documented during two cycles of anti-TNFa administration. Although the role of 
TNFa in RA and systemic vasculitis, such as Kawasaki disease (7) and Wegener’s 
granulomatosis (8 ), is well established, it’s role in vasculitis complicating RA is less 
clear. In one study TNFa levels were found to be increased in patients with small 
vessel cutaneous vasculitis without RA (9). Nailfold lesions in RA usually have a 
favourable outcome and generally do not require additional treatment. Thus far, little 
attention has been paid to extra-articular manifestations in studies examining the 
efficacy of anti-TNFa treatment in RA. The prompt disappearance of nailfold lesions 
after lenercept administration observed in our patient could be an indication that 
blocking of TNFa might be effective in more severe forms of vasculitis and possibly 
other extra-articular manifestations of RA, some of which are life threatening and 
currently treated with high doses of corticosteroids and immunosuppressive drugs.
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Figure 1.
Before (A) and two weeks after (B) injection with lenercept (Ro 45-2081, a sTNFR:Fc p55 
fusion protein). Small petechia and surrounding erythema are seen along the nailfold (A). 
After injection, the lesions are no longer present and the erythema has dramatically improved 
(B).
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Chapter VIII
Neutrophil migration and production of reactive oxygen species (ROS) during 
treatment with a fully human anti-TNFa monoclonal antibody in RA patients.
Alfons A den Broeder, Geert JA Wanten, MilanTjioe, Wim JG Oyen, Ton Naber, Piet
LCM van Riel, Pilar Barrera
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Abstract
Objective To evaluate the effects of therapy with a fully human, anti-tumour necrosis 
factor monoclonal antibody (anti-TNFa MoAb), on the production of superoxide and 
other reactive oxygen species (ROS) and on the migration capacity of neutrophils in 
patients with rheumatoid arthritis (RA).
Patients and methods A total of 29 patients with active RA and 25 healthy controls 
participated in these studies. Assessments were performed at baseline and two 
weeks after the first administration of anti-TNFa. The production of ROS was studied 
both in unstimulated conditions and after stimulation of receptor-dependent (serum 
treated zymosan, STZ) and receptor independent (phorbol mystrate acetate, PMA) 
pathways by luminol enhanced chemiluminescence. Additionally, the PMA-induced 
burst production of superoxide was measured using the cytochrome-c reduction 
assay. The ex-vivo migration capacity of neutrophils was studied using a modified 
Boyden chamber model. Potential changes in neutrophil migration to joints and to a 
non-target organ were assessed by scintigraphy with autologous leukocytes and by 
histological examination of the skin exposed to ultraviolet B (UVB) irradiation 
respectively.
Results The baseline production of ROS (both spontaneously and after STZ 
stimulation) and superoxide and the ex-vivo chemotaxis were similar in RA patients 
(n=25) and healthy controls (n=25) and remained unchanged after administration of 
anti-TNFa. The production of ROS after PMA stimulation was slightly higher in RA 
than in controls (P = 0.04) and this difference disappeared two weeks after the first 
dose of anti-TNFa (P < 0.05). The scintigraphic study showed that, a single dose of 
anti-TNFa, but not placebo, markedly decreased the influx of leukocytes to inflamed 
joints. In contrast, leukocyte infiltration in UVB irradiated skin was not affected by 
anti-TNFa therapy.
Conclusion In patients with RA, anti-TNFa therapy rapidly decreases the influx of 
neutrophils into inflamed joints but does not impair either neutrophil migration to non­
target organs or their chemotaxis and production of ROS.
Introduction
The efficacy of tumour necrosis factor alpha (TNFa) neutralising approaches in 
rheumatoid arthritis is nowadays well recognised (1,2). Despite the excellent 
efficacy/toxicity ratio of these agents, there are some still some concerns on the risk 
for infections (3-8) carcinogenesis (9-12) and autoimmune disorders (13,14) during 
TNF neutralisation. Some of these potential adverse effects could, at least partly, be 
related to an impaired function of neutrophils and other phagocytic cells, during TNFa 
neutralisation.
On the other side, modulation of the function of neutrophils and phagocytic cells 
could be beneficial in RA and other chronic inflammatory disorders. TNFa is involved 
in the priming, chemotaxis and production of reactive oxygen species (ROS) by 
neutrophils (15-17). These cells are abundant in RA synovial fluid and their
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production of ROS and other inflammatory mediators may induce cartilage damage 
(18,19). Reduction in neutrophil priming, ROS production and chemotaxis have been 
implicated in the mechanism of action of other rapidly acting antirheumatic drugs 
such as methotrexate, leflunomide (20-23) and steroids (24). Whether this also holds 
true for TNFa blocking agents is still unknown. In patients with RA, administration of 
infliximab, a chimeric anti-TNFa monoclonal antibody, has been reported to reduce 
the influx of neutrophils into joints and to increase their number in the circulation (25). 
It has been hypothesized that this could be due to a decreased expression of 
adhesion molecules (26,27). Interestingly, no increase in circulating neutrophils has 
been reported during therapy with etanercept, a TNFR-Fc fusion protein. Whether 
blocking TNFa alters the physiological migration of neutrophils to inflammatory foci in 
"non-target" organs has not been assessed yet. Still, such effect could be relevant for 
the risk of infections during TNFa neutralisation especially since this strategy is often 
combined with agents that alter neutrophil chemotaxis such as methotrexate and 
steroids (24,28).
Adalimumab (D2E7, Knoll-BASF, Germany) is a fully human, IgG1 monoclonal ant- 
TNFa MoAb developed using phage display techniques (29) which is now 
undergoing phase III studies in RA. Its efficacy has been demonstrated in thousands 
of patients (30-33) and can be measured within days from therapy initiation. In this 
study, we evaluated the impact of a single dose of adalimumab on neutrophil function 
in patients with active RA. To this aim, the production of ROS and the chemotactic 
capacity of neutrophils were assessed using ex-vivo assays. Furthermore, the influx 
of neutrophils into inflammatory foci, including the joints and a non-target organ such 
as the skin, were analysed in vivo.
Patients and methods 
Patients
Consenting patients with RA, enrolled in double blind, placebo-controlled studies with 
adalimumab monotherapy at our center were studied. All patients fulfilled the ARA 
criteria (34), had active disease, defined as a disease activity score (DAS) (35) > 3.2 
and had undergone a 4-week washout period for disease modifying antirheumatic 
drugs (DMARD). NSAIDs and steroids, up to 10mg daily, were kept stable four weeks 
prior to and during the study. Patients were randomised to initiate treatment with 
adalimumab subcutaneously (20 to 80mg dose) or placebo. Ex-vivo and in-vivo 
neutrophil function test and white blood cell (WBC) counts were assessed at baseline 
and at week 2. At this point, clinical response according to the EULAR criteria (36) 
was also assessed. All ex-vivo neutrophil function tests were also performed in age- 
and sex-matched healthy controls. The study was approved by the ethical committee 
of the University Medical Center Nijmegen, the Netherlands.
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Methods
Ex-vivo neutrophil function tests
All reagents used were from Sigma Chemicals (St Louis, MO, USA), unless 
otherwise. stated Neutrophils were isolated from heparinised blood (Vacutainer, 
Becton & Dickinson, Rutherford, NJ) as previously described (37). Briefly, whole 
blood diluted 1:1 in 0.4% trisodium citrate in PBS, was subjected to Percoll gradient 
centrifugation (5 = 1.076 g/ml, Pharmacia, Uppsala, Sweden, 700xg, 18 min, 25°C). 
The neutrophil containing cell-pellet was resuspended in 50 ml ice-cold isotonic lysis 
solution (155 mM NH4 G, 10 mM KHCO3  and 0.1 mM EDTA), centrifuged (5 min, 
400xg, 4°C) and remaining erythrocytes were lysed (lysis solution, 5 min). Cytospin 
and trypan blue staining showed > 97% neutrophils and > 99% viable cells in all 
procedures. Neutrophils (final concentration 2 x 106  cells/ml) were kept at room 
temperature until assay.
The "long-term" (120 min) spontaneous and stimulated respiratory burst were 
measured as the production of reactive oxygen species (ROS) that excite luminol 
(luminol-enhanced chemiluminescence or LECL). To this aim, 200 ^l neutrophils 
suspension (2 x 106cell/ml) and 20 ^l Luminol (5 x 10-4 M) per well, were incubated in 
96-well microplates at 37°C for 120 min in the absence or presence of a neutrophil 
stimulus. The latter consisted of serum treated zymosan (STZ), which induces ROS 
production through complement C3b receptor activation (39) or phorbol myristate 
acetate (PMA) which yields receptor-independent activation of protein kinase C. STZ 
and PMA were used at final concentrations of 1 mg/ml and 100 ng/ml respectively. 
Chemiluminescence was monitored every 30 seconds for 120 minutes using an 
automated LB96V Microlumat Plus plater luminometer (EG&G Berthold, Bad 
Wildberg, Germany). The integral area under the curve (AUC) over this period is 
expressed in relative light units (RLUs). The peak luminescence, expressed in per 
RLUs/second, was calculated using Winglow software (EG&G Berthold, Bad 
Wildberg, Germany).
The "short-term" burst production of superoxide (O2) was measured after stimulation 
with phorbol myristate acetate (PMA) for 5 minutes using the cytochrome-c reduction 
assay. The latter measures the superoxide dismutase inhibitable reduction of 
ferricytochrome c (38), which is expressed as the maximum rate of cytochrome c 
reduction (in nmol/minute/106 neutrophils at 550 nm) using 21.1 mM-1.cm-1 as 
extinction coefficient (39). The assay was performed at 37°C on a thermostatted 
spectrometer (Perkin-Elmer Lambda 12, Perkin-Elmer Corp., Norwalk, CT, USA). 
Neutrophil chemotaxis was evaluated using a modification of the Boyden chamber 
assay (40). Briefly, neutrophils (1 x 106 /ml, 400 |jJ per well) and N-formyl-methionin- 
leucin-phenylalanin (fMLP, 10-8 M, 600 ^l per well) were loaded in the upper and 
bottom chamber of MilliCell-PC culture plates separated by isopore polycarbonate 
membranes (12 mm diameter, 10 .^m thickness, 3 ^m pore size) and incubated at 37°C 
for 1 hour. The number of neutrophils that reached the bottom chamber was counted 
using a haemocytometer (Coulter counter, Coulter electronics, Mijdrecht).
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All ex-vivo neutrophil tests were simultaneously assessed in RA patients and age- and 
sex-matched healthy controls to correct for inter-assay variation.
Neutrophil function in-vivo
Scintigraphy with technetium-99 labelled autologous white blood cells (Tc-99m- WBC) 
Aliquots of 50 ml venous blood were drawn, mixed with 10 ml methylcellulose 
containing 0.33% acid citrate dextrose (ACD). Red blood cells were allowed to 
sediment for one hour. The WBC containing supernatant was centrifuged (10 min, 
150 g) and the resulting cell pellet was washed, centrifuged (10 min 150 g) and 
resuspended in 1.5 ml PBS with 1% human serum albumin (HSA). Thereafter, WBC 
were labelled with 1 GBq Tc-99m-hexamethylpropyleneamine oxide (HMPAO) at 
room temperature for 30 minutes. After centrifugation (10 min, 150 g), the WBC pellet 
was resuspended in 5% glucose and microscopically checked for cell integrity. 
Labelling efficiency (cell associated activity/total activity) was always > 75%.
A dose of 200 MBq Tc-99m- WBC was administered intravenously. Whole body 
scintigraphy was obtained 1 and 4 hours after injection, using a single head gamma 
camera equipped with a parallel hole low energy collimator (Siemens Orbiter, 
Siemens Inc., Hoffman Estate, IL). Joint uptake was scored semiquantitatively using 
a 0 - 2  scale ( 0  = no, 1 = equivocal, 2  = clearly increased uptake) by a blinded 
observer (41). The scored joints were the following: sternoclavicular, 
acromioclavicular and mandibular joints, shoulder, elbow, wrist, 
metacarpophalangeal joints, proximal interphalangeal joints, hip, knee, ankle joint 
(scored combined with subtalar joint), forefoot and metatarsophalangeal joints. For 
each patient, a total joint score was calculated by adding the values of all joint 
regions at baseline and this was set as 100%. Changes in scintigraphic scores at 
week 2  are expressed as percentage change from baseline.
UVB skin model
Physiological neutrophil migration to inflammatory foci in a non-target organ, was 
assessed using an ultraviolet light B (UVB) skin model. Briefly, a low dose UVB 
irradiation was administered to a rectangular skin area ( 2  x 2  cm) at the lower back, 
immediately before and two weeks after administration of the first dose of anti-TNFa 
MoAb. For each individual patient, the UVB dose was adjusted to encompass twice 
the so-called minimal erythema dose (2 MED). Punch biopsies of the skin were 
obtained before irradiation (control biopsy) and 24 hours after the first and second 
UVB irradiation. Biopsies were embedded in Tissue Tek OCT compound (Miles 
Scientific, Naperville, USA) and snap frozen.
Serial 7 .^M cryostat sections were fixed in 100% acetone, air dried, washed in PBS 
and stained with the following monoclonal antibodies (Dakopatts, Copenhagen, 
Denmark): anti-elastase (neutrophils), WT-14 (monocyte-macrophage), T-11 (T- 
lymphocytes) and T- 6  (Langerhans cells). This primary step was followed by 
incubation with normal horse serum and with biotinylated anti-murine IgG (Vecastain 
ABC kit, Vector Laboratories Inc, USA) for 30 min. Slides were then stained with an
101
avidin biotin complex solution, developed with 3-amino-9-ethylcarbazole (AEC, 
Calbiochem, USA), counterstained with haematoxylin and mounted in glycerol- 
gelatin. Incubation omitting the secondary antibodies was used as negative control. 
All areas of each section were randomly analysed by a blinded observer using a five 
point (0-4) semiquantitative scale (0 = no staining, 4 = marked staining).
Statistical analysis
Data are expressed as mean or median according to their distribution. Statistical 
analysis for paired observations was performed using Student’s t-tests and Wilcoxon 
signed rank tests as appropriate. Between-group comparisons were tested using the 
Mann-Whitney-U test. Correlation was tested using the Spearman rank correlation 
test. Analyses were performed using the Astute Base Module version 1.50 Package.
Results
Patients
A total of 29 patients enrolled in studies with adalimumab at our center, gave 
informed consent for different studies on the ex-vivo and in-vivo neutrophil function 
tests. After unblinding, 21 and 8  patients had been randomised to receive active 
treatment and placebo respectively. Baseline patient characteristics in these two 
groups were similar (table 1). Already two weeks after the first administration of anti- 
TNF MoAb 58% of the treated patients, but none of those receiving placebo, fulfilled 
the EULAR criteria for clinical response.
Ex vivo neutrophil tests
Ex vivo neutrophil function tests were performed in 25 patients with RA (18 receiving 
anti-TNFa and 7 placebo respectively) and 25 age- and sex-matched healthy 
controls. Total leukocyte counts and WBC subset counts in peripheral blood showed 
no significant increase in neutrophil counts 2  weeks after the first administration of 
anti-TNF MoAb (median neutrophil counts 5.86 x 109/L and 6.13 x 109/L at baseline 
and 2 weeks respectively P = 0.64).
Data on the capacity for ROS production and chemotaxis of neutrophils are shown in 
table 2. As shown, the production of ROS, including superoxide (O2), and the ex-vivo 
chemotactic capacity of neutrophils were largely similar in RA patients and healthy 
controls (Table 2). At baseline, only the peak production of ROS after PMA 
stimulation was slightly higher in RA patients than in controls (8 . 6  ± 3.2 versus 6 . 8  ±
2.5 RLU/sec, P < 0.05; patient/control ratio 1.46 ± 0.28). No such difference was 
observed 2 weeks after anti-TNFa administration. The chemotactic activity and the 
burst production of O2 after PMA stimulation did not change during the study (Table 
2 ).
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Table 1. Baseline patient characteristics
Percentage, mean ± SD or median (p25-p75) 
as appropriate
Adalimumab (n=21) Placebo (n=8)
Age (yrs) 55 ± 12 57 ± 10
Sex (%female) 62 75
Rheumatoid factor (%>10 IE) 100 100
Disease duration (yrs) 13 ± 8 9 ± 6
Number of previous DMARDs 6 (4-8) 5 (3-6)
NSAID use (%) 95 100
Prednisone use (% of patients) 71 75
Disease Activity Score 5.4 ± 0.8 5.3 ± 0.9
Swollen joints 44/66 * 18.8/21.6 25.5/20.3
RAI/Tender joints 68 * 25.3/37 25.5/29.3
CRP (mg/l) 53 ± 42 71 ± 32
ESR (mm/hr) 33 ± 25 32 ± 20
EULAR response after two weeks 58% 0%
* in study 1 Ritchie Articular Index and swollen 44 were measured, 
in study 2 swollen 66 and tender joints 68 were used.
No statistically significant differences were present at baseline.
In-vivo neutrophil function
Scintigraphic evaluation with radiolabeled leukocytes was performed in 4 patients 
which had been randomised to anti-TNFa (n = 2) and placebo (n = 2). At baseline, a 
polyarticular pattern of uptake mirroring the clinically inflamed joints was observed in 
all patients (Figure 1). Scintigraphic joint scores obtained at baseline (absolute values 
ranging from 6  to 18) correlated with swollen joint counts (within-patient values 
ranging from R = 0.3 to 0.64 ; P = 0.008 to <0.0001 ).
Scintigraphic images obtained two weeks after the first dose of anti-TNFa showed a 
markedly decreased uptake into inflamed joints (Figure 1). In the treated patients 
30% of the joints showing clearly increased leukocyte uptake (score 2) at baseline 
had became normal at week two (score 0) and 64% decreased to score 1. In 
contrast, no change from baseline values could be demonstrated in patients receiving 
placebo. Scintigraphic scores normalised for the baseline values were 53% and 33% 
in treated patients and 1 0 0  and 106% in the placebo group respectively.
The effect of anti-TNFa therapy on the physiological skin inflammatory reaction to 
UVB light was assessed in 12 patients all of whom had been randomised to anti- 
TNFa. Irradiation of the skin with UVB resulted in local erythema and, histologically, 
in a significant influx of neutrophils, lymphocytes and monocytes into the dermis (P = 
0.05; table 3). The minimal dose of UVB required to reach skin erythema (MED) was 
0.2 (0.1-0.2) Joules/cm2 at baseline and did not change during the study. 
Immunohistological examination of the UVB irradiated skin before and 2 weeks after 
the first showed that the influx of neutrophils into the dermis did not decrease after 
administration of anti-TNFa (Figure 2). The same was true for the lymphocyte and 
monocyte infiltration (table 3).
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Table 2. Neutrophil chemotaxis and ROS production, patients vs controls (n=25), treated (n=18) vs placebo (n=7).
Mean ± SD or median (p25-p75) Before
Patients
All patients Anti-TNFa Placebo
Controls
After
Patients
Anti-TNFa Placebo
Controls
Superoxide production 8.6 + 2.3 8.5 + 2.5 9.0 + 1.9 10.0 + 3.2 8.5 + 1.8 7.1 +2.6 9.7+ 2.5
Chemiluminescence Spont. AUC 5.7 (3.7-11.5) 6.4(3.1-11.6) 5.0 (3.8-7.2) 7.4 (4.5-10.8) 6.9(3.6-15.7) 6.5 (4.3-7.8) 9.4(5.6-15.9)
Spont. Peak 2.0(1.0-2.7) 2.1 (0.9-3.5) 1.4 (1.1-2.3) 1.8(1.2-3.1) 1.6(1.0-3.6) 1.6(1.0-2.3) 2.5 (1.6-4.5)
STZ AUC 25.8 + 10.1 23.5 + 8.6 31.6 + 12.0 26.3+10.9 22.4 + 5.7 27.3 + 6.1 24.7 + 7.5
STZ Peak 12.5 + 3.9 12.2 + 3.5 13.4 + 5.0 12.4 + 4.3 10.8 + 1.8 12.6 + 4.4 11.2 + 1.9
PMA AUC 11.6 + 3.7 11.2 + 3.5 12.8 + 4.8 10.8 + 4.0 9.8+ 3.5 f 11.3 + 4.9 10.4 + 4.2
PMA Peak 8.6 + 3.2 8.5 + 3.4 9.7+ 4.2 6.8 + 2.5 t 7.1 +2.6 f 8.9+ 4.4 6.8 + 2.5
Chemotaxis 53.6 + 18.5 49.1 ± 18.8 61.4 + 18.8 49.9 + 17.6 39.6 + 25.3 46.2 + 12.2 42.5 + 20.0
Superoxide production is expressed as nmol/minute/106 neutrophils, chemiluminescence is expressed as RLU/sec for peak value and AUC of 
the RLU/sec for AUC, chemotaxis is expressed as percentage of cells that passed the membrane. STZ serum treated zymosan 
$ P < 0.05, patients compared to controls at baseline
t  P < 0.05, comparison patient/control ratio after treatment vs before treatment and treated patients vs placebo group
Table 3. UVB induced inflammation in the dermis before and after treatment with 
adalimumab (n=12)________________________________________________________
Median (p25-p75) Control biopsy Baseline Day 14
Neutrophils 0.0 (0.0-0.3) 1.0 (1.0-1.8) t 1.0 (1.0-1.0)
Lymphocytes 1.0 (1.0-2.0) 3.0 (2.0-3.0) t 2.3 (2.0-3.0)
Monocytes 2.0 (2.0-2.0) 3.0 (2.3-3.0) t 2.5 (2.0-2.9)
Langerhans cells 2.0 (1.0-2.3) 2.0 (1.3-2.0) 2.0 (1.0-2.0)
Cell counts are expressed on a semi quantitative scale from 0-4 
t  p<0.05, compared to control biopsy
No significant differences were found between baseline and day 14
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Figure 1.
Scintigraphic image of a hand taken 4 hours after administration of Tc-99m labeled 
autologous leukocytes in a patient with RA. Before treatment (A) uptake is seen in the 
wrists (closed arrows) the second metacarpophalangeal joint of the left hand and several 
proximal interphalangeal joints (open arrows). Two weeks after the first injection of anti- 
TNFa (B), the activity in the wrists almost normalized and the increased leukocyte uptake 
in the in the finger joints disappeared.
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Figure 2.
Skin biopsies after UVB irradiation in a patient with RA before (A) and after (B) the first 
administration of anti-TNFa. Staining for elastase (neutrophils) is performed. Irradiation 
with UVB leads to increased presence of neutrophils after 24 hours. This effect is 
maintained after treatment with anti-TNFa.
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Discussion
Our results show that treatment with adalimumab drastically reduces leukocyte 
migration into synovial joints shortly after therapy initiation without inducing an 
increase in neutrophils in peripheral blood. The decreased homing of neutrophils to 
the target organ is not the result of a downmodulation in leukocyte function. 
Adalimumab does neither impair the production of ROS nor the chemotactic capacity 
of neutrophils ex-vivo or in-vivo. The physiological migration of neutrophils and 
mononuclear cells to an acute inflammatory focus in a non-target organ was not 
hampered by anti-TNFa therapy.
In our study, the reduction of neutrophil homing to the joints, was observed using 
scintigraphy with radiolabeled WBC. This is a sensitive method for assessing joint 
inflammation and correlates with clinical signs (42,43), in our case especially with 
joint swelling scores. Although only a limited number of patients were studied, the 
scintigraphic results were consistent (observed only in treated patients and not in the 
placebo group) and concomitant with the clinical response and the decrease in acute 
phase reaction (data not shown). Moreover, similar findings have been reported with 
another anti-TNFa MoAb (25). The decreased joint influx of neutrophils after anti- 
TNFa may be mediated through deactivation of the synovial endothelium, as 
suggested by the decrease of local and systemic levels of adhesion molecules 
(26,27) or by a decreased local production of chemoattractants such as IL- 8  (44,45). 
In view of the results in our study, a direct effect on the intrinsic chemotactic capacity 
of neutrophils seems very unlikely.
In contrast to the scintigraphic results, the acute inflammatory reaction in a non-target 
organ was not impaired by therapy. The acute skin model that was chosen for our 
study shares several features with a chronic inflammatory reaction such as that found 
in RA. An enhanced production of TNFa (46), upregulation of chemokines (e.g. IL-8 ) 
and adhesion molecules play a pivotal role in both processes. In spite of these 
similarities, TNF neutralisation does not hamper this acute reaction. Potential 
explanations for this paradox could be either that the production of TNFa exceeds 
the blocking capacity of the locally present anti-TNFa or that TNF-independent 
pathways play a major role in acute inflammation (47). Nonetheless, our results put 
forward the fact that in vivo TNFa blockade in therapeutic dosages does not interfere 
with the physiological inflammatory response.
The findings described here have several potential consequences. Firstly, it does not 
seem probable that suppression of neutrophil function or motility is implicated either 
in the mechanisms of action or in some of the potential adverse events of anti-TNFa 
therapy. This is especially true for the susceptibility to bacterial infections since the 
killing of these microorganisms by neutrophils and other phagocytes is largely 
dependent on the production of reactive oxygen metabolites.
Secondly, the knowledge that TNF blockade does not downregulate neutrophil 
functions can be used to design combination therapies with synergistic effects. In this 
context, several studies do suggest that some anti-rheumatic drugs such as steroids,
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leflunomide and methotrexate and certain NSAIDs can modulate neutrophil ROS 
production and migration (20-23).
Some other observations in our study deserve further mention. Comparison of the 
neutrophil ROS production and migration between RA patients and healthy controls 
did not show important differences. Only the peak production of ROS after 
stimulation by receptor-independent pathways (PMA) was slightly higher in RA than 
in controls. This difference was not apparent two weeks after the first administration 
of anti-TNFa and was also not detected using time-integrated measures (AUC) or by 
the cytochrome-c reduction assay. Our findings suggest the neutrophil function in RA 
patients is not impaired and corroborates findings in several previous studies (48). 
Potential bias due to concomitant therapies cannot be definitively ruled out but these 
remained unchanged during the whole study period.
One potential limitation of the present study might be the short follow-up period. 
Therefore, these observations cannot be directly extrapolated to the situation during 
long-term TNF neutralisation. Nevertheless, the effect of this anti-TNFa MoAb and 
other TNF blocking agents is extremely rapid and the drug half-life of adalimumab is 
approximately 12 days (49). Moreover the life span of neutrophils is only a few hours 
for non-activated neutrophils and somewhat longer under inflammatory conditions 
(50). This motivates the time-schedule used in our studies and the hypothesis that 
short- and long-term anti-TNFa treatment will not differ much concerning their effects 
on neutrophils.
In conclusion, we found that treatment with the human anti-TNFa MoAb adalimumab 
effectively suppresses neutrophil migration into inflamed joints in RA. This therapy 
does neither interfere with the physiologic response to acute inflammatory foci nor 
with other neutrophil functions such as oxidative burst and chemotaxis.
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Chapter IX
A nephrotic syndrome as complication of anti-TNFa in a patient with rheumatoid
arthritis.
Alfons A den Broeder, Karel JM Assmann, Piet LCM van Riel, Jack FM Wetzels
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Abstract
Monoclonal antibodies directed against Tumour Necrosis Factor a (TNFa) have been 
developed in recent years for the treatment of patients with rheumatoid arthritis. We 
describe a patient with RA who developed a nephrotic syndrome during treatment 
with a recombinant human monoclonal antibody against TNFa. The proteinuria 
disappeared spontaneously after cessation of anti-TNF treatment. Upon rechallenge, 
the nephrotic syndrome reappeared, pointing to anti-TNFa as the culprit. Renal 
biopsy disclosed a membranous glomerulopathy. Clinically, the nephrotic syndrome 
was characterised by a highly selective proteinuria and immediate responsiveness to 
steroid treatment, more compatible with a diagnosis minimal lesions glomerulopathy 
than with membranous glomerulopathy. This is the first report of a glomerulopathy as 
adverse effect of anti-TNFa treatment. The potential mechanisms of this side effect 
of anti-TNFa are discussed.
Introduction
TNFa is a proinflammatory cytokine that plays a pivotal role in the inflammation in 
rheumatoid arthritis (RA). Increased levels of TNFa were found in the synovial fluid of 
patients with RA and in several animal models, the abrogation of TNFa activity was 
associated with a decrease of joint inflammation. These and other findings have 
stimulated the development of anti-TNFa strategies. Blocking the action of TNFa 
either with monoclonal antibodies directed against TNFa or TNF receptor constructs 
has been shown to yield fast and impressive responses in patients with RA. (1-3). 
Adverse effects were usually mild and no specific side effects have been reported 
except for reactions during infusion and at the local injection site. Two anti-TNFa 
agents have now reached clinical practice. We describe a patient who developed a 
nephrotic syndrome as adverse effect of treatment with anti-TNFa.
Case report
Our patient was diagnosed with a rheumatoid factor positive, ANA negative erosive 
rheumatoid arthritis (RA) in 1982 at the age of 48 yrs. His medical history was 
unremarkable, except for the presence of Chronic Obstructive Pulmonary Disease 
(COPD). In the following years he was treated with D-penicillamin followed by 
parenteral aurothioglucose. This was stopped in 1984 because of proteinuria up to
1.5 g/l. After cessation of intramuscular gold administration, the proteinuria 
completely disappeared. DMARD therapy was continued with methotrexate, followed 
by aurothioglucose that was stopped in 1990 because of exacerbation of the RA. 
Proteinuria did not appear during this second episode of gold therapy nor did it later. 
Sulfasalazine treatment was initiated, later combined with methotrexate and 
prednisone. The latter combination therapy was stopped due to lack of efficacy. In 
light of the persistent disease activity the patient was recruited in May 1997 for a 
placebo-controlled phase I trial with a fully human monoclonal antibody against TNFa
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(adalimumab, Knoll/BASF, Germany). Treatment with anti-TNFa was started in a 
dose of 1.0 mg/kg body weight every two weeks i.v. and later increased to 3.0 mg/kg 
according to the protocol. Concomitant medication consisted of prednisone 1 dd 
10mg, diclofenac 2dd 75mg, alternating calcium and etidronic acid, omeprazol 2dd 
20mg, paracetamol as needed 500 mg, ipratropiumbromide 4dd 40^,g, salmeterol 
2dd 100^,g and doxycycline 1 dd 100mg. The latter drugs were prescribed for 
treatment of his COPD. There was an excellent clinical response to anti-TNFa 
treatment: the Disease Activity Score (DAS, a combined disease activity measure for 
RA) dropped from 5.89 to 2.41, swollen joint counts and tender joint counts (Ritchie 
Articular Index) decreased from 20 and 33 to 6  and 12 respectively, and C-reactive 
protein levels went from 142.8 to 24.2 mg/l. No serious adverse events were noted 
and treatment was continued uneventfully. Prednisone was gradually reduced to 2.5 
mg/day.
In April 1998, the patient developed rapidly progressive pitting oedema of both lower 
extremities. He also noticed facial oedema and a weight gain from 73 to 84 kg in 2 
weeks. Diuretic treatment was initiated but when his complaints worsened, he was 
admitted. On admission, blood pressure was 150/80 mmHg. Physical examination 
revealed bilateral leg oedema and evidence of pleural and peritoneal fluid. 
Laboratory investigations: serum creatinine 82 ^mol/l, serum albumin 15 g/l, 
cholesterol 7.0 mmol/l, haemoglobin 5.5 mmol/l. ANA negative, normal complement 
C3 an C4. Proteinuria averaged 16.7 g/24 hrs, selectivity index was 0.07 (highly 
selective).
A renal biopsy was performed. By light microscopy of silver stained sections all 
glomeruli demonstrated segmental irregularities of the glomerular basement 
membrane (GBM) suggestive for a membranous glomerulopathy, such as 
vacuolisation - especially on tangential sections -, spike formation or some ring-like 
structures. Podocytes, endothelial cells and mesangial areas were normal (figure 1, 
A and B). Congo red staining did not reveal amyloid. By immunofluorescence fine 
granular deposits of particularly IgG and C3 were present along the capillary wall in a 
characteristic membranous pattern. The granules were unevenly distributed in some 
capillary segments (figure 2). No AA amyloid deposits were found using a 
monoclonal antibody. By electron microscopy podocytes were hypertrophic and 
showed retraction of their foot processes (figure 3). In some segments of the GBM 
irregularly spaced subepithelial electron dense deposits accompanied by spike 
formation were observed. Other segments displayed a broad and abnormal GBM, 
incorporating many complexes that were less electron dense and resolving (figure 3). 
Several segments of the GBM, however, did not show any alterations or electron 
dense aggregates.
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Figure 1. Light microscopy of a part of a glomerulus. Some segments of the GBM show 
extensive vacuolisation (A; arrows), minor irregularities and spike-like conformations (B; 
arrows) on the epithelial side or bead like structures (B; arrowheads). A,B *900. Silver 
methenamine staining
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Figure 2. Direct immunofluorescence using FITC-labelled antihuman IgG antibody showing 
fine granular deposits of IgG along the capillary wall in a characteristic membranous 
pattern. In some capillary loops only a few granules are present (*400).
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The patient was treated with diuretics and an Angiotensine Converting Enzyme 
(ACE) inhibitor, and anti-TNFa treatment and diclofenac were withdrawn. The 
subsequent course is depicted in figure 4. The proteinuria remained difficult to control 
up to three month after cessation of diclofenac and anti-TNFa treatment but 
eventually disappeared. Interestingly, symptoms of RA, which had been mild before 
and during the phase that the nephrotic syndrome was active, relapsed in the same 
week the nephrotic syndrome disappeared. We then tried to find out if drug treatment 
was the cause of the nephrotic syndrome. Diclofenac was started, however, 
proteinuria did not reappear until after restart of anti-TNFa treatment. The patient 
was treated with prednisone 60mg daily and cyclophosfamide 100mg daily. Within 
one week, proteinuria had completely disappeared. Cyclophosfamide was stopped 
and prednisone quickly tapered to 10mg daily. At this timepoint, anti-TNFa was 
reintroduced. The nephrotic syndrome did not reappear until prednisone was reduced 
to a dose of 5 mg daily. Again, the patient responded to a higher dose of prednisone. 
Since December 1998, the patient is being treated with anti-TNFa in combination 
with 10mg prednisone daily. He has retained an excellent clinical response and 
proteinuria has remained absent.
Discussion
In our patient a nephrotic syndrome developed during treatment with anti-TNFa. 
Renal biopsy disclosed a membranous glomerulopathy. The clinical course strongly 
incriminated anti-TNFa as the culprit, since proteinuria disappeared after withdrawal 
of anti-TNFa treatment and reappeared upon rechallenge. Furthermore, we could 
exclude that the other likely candidate, the NSAID diclofenac, was the cause of the 
nephrotic syndrome. To our knowledge, this is the first report of a nephrotic 
syndrome as adverse effect of anti-TNFa treatment.
Membranous nephropathy has been frequently reported in patients with RA. In a 
series of 110 biopsies in patients with RA, membranous nephropathy was observed 
in 19 (17%) (4). In most patients with RA and membranous nephropathy, treatment 
with gold salts or D-penicillamin has been incriminated as the cause. However, 
recent reports have suggested that patients with RA may be prone to the 
development of membranous nephropathy, even in the absence of gold or D- 
penicillamin treatment (5). It is however unclear if in these latter patients the use of 
NSAIDs as causative agents was excluded, as also an association between NSAIDs 
and membranous nephropathy was recently found (6 ).
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Figure 3. Electron microscopy reveals subepithelial electron dense deposits in some 
segments of the GBM (A; arrows) In other segments of the capillary wall the GBM is 
thickened and extensively altered with incorporation of many resolving deposits showing 
variable lesser electron density (B,C; arrows). Extensive retraction of the foot processes 
of the podocytes (P) is present. A,B,C; *17000.
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Figure 4. Clinical course of the patient. Proteinuria is depicted over time. Injection of anti- 
TNFa is indicated by the arrows. There is a clear relationship between the level of 
proteinuria, the use of anti-TNFa and lowering of prednisone.
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Our patient may represent a case of membranous nephropathy caused by anti-TNFa 
treatment. One might speculate on the mechanism of action of this side effect. TNFa 
has been incriminated in glomerular diseases. In vitro studies have shown that TNFa 
can increase glomerular permeability, possibly by inducing oxygen radical production 
(7). Glomerular visceral epithelial cells can produce TNFa (8 ). Of particular interest 
for our case are the observations of Neale et al (9). These investigators have 
demonstrated the unique presence of TNFa in the visceral epithelial cells and in the 
subepithelial deposits in patients with membranous nephropathy. TNFa was not 
found in other forms of glomerular disease. Since membranous nephropathy is the 
result of an interaction between antibodies and antigens present on the surface of the 
glomerular epithelial cells (1 0 ), one can speculate that in our patient the membranous 
nephropathy was caused by interaction of the anti-TNFa antibodies with TNFa 
present on visceral epithelial cells. However, to the best of our knowledge, TNFa is 
only present in the cytoplasm of glomerular epithelial cells and an increased 
production is only found in patients with established membranous glomerulopathy. 
Furthermore, we found no evidence for TNFa in the glomerular basement membrane 
in our patient using biotin labelled IgG1 anti-TNFa MoAb or a polyclonal anti human 
TNFa by indirect immunofluorescence.
We feel that the clinical data points to an alternative explanation for the cause of the 
nephrotic syndrome. The clinical picture in our patient mimicked the nephrosis that is 
associated with minimal change nephropathy (11). Proteinuria was highly selective 
and there was an immediate and brisk response to treatment with steroids. In 
patients with established membranous nephropathy proteinuria disappears quite 
slowly if at all, even during treatment with immunosuppressive agents (12). In 34 
patients with membranous nephropathy who were treated with high dose prednisone, 
we never observed a complete remission of proteinuria within three months after start 
of treatment (13). Likewise, in patients with RA with membranous nephropathy 
caused by either gold or D-penicillamin proteinuria disappears gradually, in most 
patients the maximal proteinuria is even reached 1 - 2  month after stopping the 
offending drug (14). In such patients, treatment with prednisone apparently does not 
influence the duration of proteinuria (15).
The finding of subepithelial deposits certainly does not prove that the proteinuria is 
caused by the membranous nephropathy. In the rat model of membranous 
nephropathy, injection of monoclonal antibodies against the podocyte antigen 
megalin results in the formation of small subepithelial deposits that are not paralleled 
by the development of proteinuria (12). Likewise, a membranous nephropathy with 
subepithelial deposits in the absence of proteinuria has been observed in 
hypertensive patients treated with captopril (16). Notably, in the study mentioned 
above in patients with RA, three patients with membranous nephropathy were 
described with no proteinuria (4). Furthermore, it is well established that in patients 
with membranous nephropathy the deposits can remain visible after remission has 
occurred, even for many years (17). In our patient, many deposits seem to be old, 
incorporated in the GBM and dissolving, suggesting that they may have been caused
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by the previous gold therapy. Alternatively, the deposits may have been induced by 
the diclofenac treatment.
As noted, the nephrotic syndrome in our patient was highly steroid sensitive but also 
steroid dependent. A dose of 10 mg prednisone was able to prevent the 
reoccurrence of proteinuria. This latter aspect deserves attention. Since a 
considerable number of patients who receive anti-TNFa are concurrently being 
treated with prednisone, the potential of anti-TNFa to induce proteinuria may be 
masked. It remains to be established if this side effect becomes more frequent if anti- 
TNFa treatment is instituted in patients who do not receive steroids.
In conlusion, we have presented a patient with a nephrotic syndrome during 
treatment with anti-TNFa monoclonal antibodies. Clinically, the course of the disease 
closely resembled a steroid-dependent minimal change nephropathy
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Chapter X
Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis
patients treated with anti-TNFa.
Alfons A den Broeder, Marjonne CW Creemers, Anke M van Gestel, Piet LCM van
Riel
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Abstract
Background Anti-TNFa therapy yields high response rates shortly after institution of 
therapy, and on theoretical grounds large differences in the effective dose between 
patients can be expected. Together with the high costs, these differences warrant 
new approaches to the way patients are dosed.
Patients and methods We used the Disease Activity Score (DAS28), a composite 
disease activity index, to titrate the dose of anti-TNFa (adalimumab, D2E7, Knoll) in 
21 patients with low disease activity in an open extension study during 40 weeks. 
The dose of anti-TNFa was reduced stepwise and dosing intervals were kept stable. 
Disease activity and flares were assessed using the DAS28. Patients who flared 
received the previous effective dose.
Results Dose reduction was accomplished in 15 patients. The total amount of anti- 
TNFa given to the patients was reduced by 67 %. At study end the mean DAS28 had 
not changed and no patients dropped out due to persistent worsening of the RA. 
Conclusion Dose titration of anti-TNFa treatment using the DAS28 is feasible and 
leads to overall dose reduction while maintaining clinical efficacy. This approach will 
save costs and possibly prevent long-term side effects.
Introduction
Treatment of rheumatoid arthritis (RA) has traditionally been centred round the use of 
Disease Modifying Anti Rheumatic Drugs (DMARDs) as being the main agents to 
reduce disease activity and influence the course of the disease. Although effective, 
no single agent from this group is able to fully control the disease in the majority of 
patients. Furthermore, the use of DMARDs is often limited by toxicity, leading to dose 
adjustments or cessation of therapy (1). In recent years, the increased knowledge of 
the mechanism underlying the inflammation as seen in RA has led to the 
development of new agents. In contrast to conventional DMARDs, which have mostly 
been discovered empirically, these so-called biologicals have specifically been 
designed to block either the action of immune cells or the cytokines produced by 
these cells (2). A number of these agents have been developed and clinically tested, 
the most promising being the agents targeting TNFa. The latter are expected to 
dramatically change current therapeutic strategies to control RA due to their 
impressive efficacy and low toxicity profile, although its’ exact place in the treatment 
of RA has yet to be established (3).
TNFa blocking agents have unique properties, distinguishing them from conventional 
DMARDs. Firstly, clinical effects occur within days to weeks compared to DMARDs, 
in which responses are seen no earlier than after four weeks to three months. 
Secondly, due to dose dependant toxicity it is often not possible for DMARDs to 
reach the dose that is necessary to obtain optimal clinical efficacy. For anti-TNFa 
agents in general no dose dependant toxicity has been found, although a study with 
infliximab suggested more upper airway infections in the higher dose groups (4-7). A 
third important difference is the expected large variation between patients regarding
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the optimal dose of anti-TNFa. For conventional DMARDs the differences between 
the lowest and highest effective dose does not often exceed one order of magnitude; 
for example doses of methotrexate (MTX) range from 5 mg/week to 30 mg/week 
representing a 6 -fold increase. In vivo levels of cytokines often differ with one or 
several order of magnitudes between RA patients (8 ). TNFa blocking agents bind 
TNFa in a fixed ratio (9), therefore, it is conceivable that also large differences can be 
found in the required doses of these agents. For obvious reasons in randomised 
controlled trials a restricted number of fixed doses are being studied. The use of 
standard dosing schedules in daily clinical practice will however induce gross under­
and/or overtreatment. Prevention of the latter might reduce long-term side effects, 
since the first cases of diseases associated with impaired immune response have 
already been reported (1 0 ).
Tailoring treatment to the individual needs of the patient will also reduce the high 
costs, which are another hallmark of TNFa blocking agents compared to traditional 
DMARDs. The first TNFa blocking agent that has been approved for the treatment of 
RA (etanercept) is over 200 times more expensive than for example MTX (etanercept 
25 mg twice a week: 14,000 Euro a year; MTX: 15 mg/week, 60 Euro a year).
For titration of the dose of anti-TNFa based on disease activity, it is necessary to 
monitor disease activity continuously. The Disease Activity Score (DAS28) is a 
continuous composite index for measuring disease activity in RA, which has been 
well documented and validated (1 1 ,1 2 ).
In order to test the hypotheses that there is a large difference between patients in the 
required dose of anti-TNFa and that titration of anti-TNFa treatment is feasible, a 
dose titration regimen using the DAS28 in patients with RA, treated with anti-TNFa, 
was studied.
Patients and methods
Patients with RA, treated in a clinical trial with anti-TNFa in our centre, were studied 
for 40 weeks. Patients had originally been enrolled in a 6  week phase I study and 
had been treated subsequently in an extension study for two years with intravenously 
administered anti-TNFa (adalimumab, D2E7, Knoll). During the second year of this 
extension study, the patients had been treated with a fixed dose of 3.0 mg/kg. Dosing 
intervals were either every two or four weeks depending on the clinical effect in the 
first year of anti-TNFa treatment, but were fixed for each patient and remained 
unchanged in the second year and during the present study. All patients were 
responding to treatment and showed a stable level of relatively low disease activity in 
the second year preceding this study. Treatment with other DMARDs was not 
allowed. Steroids equivalent to up to 10 mg/day prednisone were accepted and kept 
stable during the study.
Patients were seen every eight weeks to evaluate disease activity and toxicity. 
Disease activity was measured using the DAS28 (11). This disease activity index 
ranges from 0 to 10 and includes the 28 tender and swollen joint counts, the ESR
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(Westergren, mm/hr) and the patients general health (or patients’ disease activity) 
measured using a Visual Analogue Scale (100 mm). A DAS28 > 5.1 means the 
patient has a high disease activity and a DAS28 < 3.2 means that the disease activity 
is low. A change in DAS28 > 0.6 constitutes a change greater than the measurement 
error of the DAS28. A change in DAS28 of > 1.2 (two times the measurement error) 
is a clinical significant change in the DAS28. Criteria for a disease flare were defined 
as an increase of the DAS28 of > 1.2 or an increase of the DAS28 of 0.6-1.2 if this 
resulted in a DAS28 > 5.1. The DAS28 is calculated as follows: DAS28 = 
0.56Vtender28 + 0.28Vswollen28 + 0.70LnESR + 0.014General Health.
Doses of anti-TNFa were decreased stepwise at every 8 -weekly visit from 3.0 to 1.0, 
0.5 and eventually to 0.25 mg/kg. In case a flare of the disease occurred, the dose of 
anti-TNFa was increased one step to the previous dose of anti-TNFa. In between the 
visits, the patients visited the outpatient clinic every two or four weeks for intravenous 
administration of anti-TNFa. A DAS28 was assessed during these drug 
administration visits only in case a patient reported a disease flare. This way, a 
prolonged flare of the RA was prevented.
The minimal individual required dose to sustain response was assessed using this 
protocol. The total weekly dose for each patient was calculated taking into account 
the different dosing intervals. A paired t-test was used to test DAS28 values at 
baseline and at the end of the study.
Results
Twenty-one patients were included in this study. Patient characteristics are shown in 
table 1. At start of the study the mean DAS28 was 3.5 (range 1.4-4.7). None of the 
patients had a high level of disease activity at the start of the study (DAS28 > 5.1).
Table 1. Patient baseline characteristics
N=21 Mean ± SD
Age (yrs) 54 ± 14
Sex (f/m) 15/6
Disease duration (yrs) 14 ± 10
Number of previous DMARDs 4.7 ± 1.9
Prednisone use (mg daily dose) 2.3 ± 3.5
Rheumatoid Factor>10iE/ml 96%
DAS28 at baseline 3.5 ± 0.8
In figure 1 the use of the DAS28 for titration of therapy is shown in one patient. At 
week 0 the dose of anti-TNFa was 3.0 mg/kg. This was lowered to 1.0 mg/kg at week 
8 . At week 16 the dose was further lowered to 0.5 mg/kg. This dose reduction 
resulted after two weeks in a flare with an increase of the DAS28 >1.2. The dose of
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anti-TNFa was increased again to 1.0 mg/kg and remained unchanged for the rest of 
the study. The DAS28 quickly returned to baseline level.
weeks 
LI------------- dose of anti-TNFa
__ 3 mg/kg □ 1 mg/kg □  0.5 mg/kg
Figure 1. DAS28 course and anti-TNFa dose titration in one patient. After a decrease in 
dose of anti-TNFa from 3.0 to 1.0 and subsequently to 0.5 mg/kg a flare of the disease 
occurs, reflected in an increase of the DAS28. After increasing the dose of anti-TNFa to 1.0 
mg/kg the DAS28 returns to the previous low level.
The results of the dose titration are shown in figure 2. Six out of 21 patients were 
placed back on the original dose of 3.0 mg/kg after flaring on 1.0 mg/kg whereas 9, 3 
and 3 patients respectively reached a dose of 1.0, 0.5 and 0.25 mg/kg. Required 
weekly doses of anti-TNFa ranged from 4.1 mg to 130 mg. The differences between 
the weekly required absolute doses of anti-TNFa were caused by differences in dose 
(3.0-0.25 mg/kg, factor 12), differences in dosing interval (every 2 or 4 weeks, factor 
2) and differences in bodyweight (53-90, factor 1.7). As a result of this dose 
reduction, the median of the calculated weekly dose of anti-TNFa administered to 
these patients was reduced with 67% from 97.5 mg/week (range 46.3-135) to 32.5 
mg/week (range 4.1-130). One protocol violation was noted: in one patient the dose 
was escalated while the increase of the disease activity did not meet the criteria for a 
disease flare with an increase of the DAS28 of 0.83 and a resulting DAS28 of 4.84. 
Eighteen patients flared during the study, with a mean increase of the DAS28 of 1.3. 
Eight of these patients reported a flare in between the regular 8 -weekly evaluations, 
the other ten patients were dose adjusted at the regular evaluation. Three patients
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did not experience a flare even on the lowest dose of 0.25 mg/kg anti-TNFa. At study 
end, one patient had a DAS28 that was > 1.2 higher than the DAS28 at baseline. No 
patients had dropped out during the study due to persistent increase of the disease 
activity. The mean DAS28 at study end was 3.8 (range 2.0-5.1), which was 
somewhat higher but not significantly different compared with the DAS28 of 3.5 
(range 1.4-4.7) at study start.
Mean DAS28 * 3.5 3.8
* This difference did not reach significance
Figure 2. Results of the anti-TNFa dose titration. The total weekly doses of the 
individual patients (n=21) before and after the dose titration phase are shown in 
mg/week. Medians are depicted with a horizontal bar. The differences before the dose 
titration study between individual patients are caused by differences in dosing interval 
(every 2 or 4 weeks) and differences in body weight.
Discussion
To our knowledge this is the first report of the use of a dose titration regimen to tailor 
anti-TNFa treatment in the individual patient. Although our study included only a 
limited number of patients, it demonstrates the Proof of Principle of dose titration and 
the advantages of this approach compared to the common ‘one size fits all’ standard 
dosing schemes.
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The importance of monitoring disease activity in daily clinical practice has recently 
been recognised and the first monitoring protocols are currently under investigation 
(13,14). To implement a dose titration regimen, measurement of the actual disease 
activity is necessary, preferably on a continuous scale. Improvement criteria like ACR 
and Paulus criteria are not suitable for this purpose as these criteria define response 
by a relative improvement, disregarding the actual disease activity (15,16). This 
hampers the use of these criteria in daily clinical practice, although these criteria 
have shown their value in randomised clinical trials.
A disease flare was defined using a reversed version of the EULAR criteria for 
response (12). The measurement error of the DAS28 is 0.6, therefor a change 
greater than two times the measurement error (1 .2 ) can be considered as a clinical 
relevant change. A DAS28 of > 5.1 indicates high disease activity according to 
clinical judgement of rheumatologists. Combination of these values leads to a 
definition of a disease flare as an increase in DAS28 with 1.2 in case of a low 
disease activity or an increase in DAS28 with 0.6 to 1.2 and a resulting DAS28 > 5.1 
(high disease activity).
The use of the DAS28 is feasible and time-effective using a pre-programmed 
calculator, spreadsheet or web-based calculator. One should take notice, however, 
that the cut-off levels for high and low disease activity mentioned in this report are 
calculated with the DAS28. The original DAS that is based on the Ritchie Articular 
index for tender joints and the 44 swollen joint count uses 3.7 as cut-off level for high 
disease activity and 2.4 for low disease activity instead. The measurement error is 
the same for both.
In spite of the relatively small number of patients, a large variation in required dose of 
anti-TNFa was found. Required doses ranged from 4.1 mg/week to 130 mg/week. 
Using the above described titration regimen, the median weekly amount of anti-TNFa 
given to these patients could be lowered with 67% from 97.5 mg/week to 32.5 
mg/week. Since no lower dose steps than 0.25 mg/kg were included, one could 
speculate that even further reduction is possible for individual patients. This is 
supported by the remarkable long duration of response seen in some patients after 
only one administration of anti-TNFa, documented for both adalimumab (up to 14 
weeks EULAR response) and infliximab (up to approximately 18 weeks Paulus 20 
response) (17,18). Because the patients in this study already had a stable and low 
disease activity on 3.0 mg/kg for one year, it was not necessary to include a higher 
dose of anti-TNFa in this titration regimen.
The other possible approach to dose titration is time-interval titration. In our centre a 
group of 12 patients with exceptionally refractory RA and high baseline disease 
activity (median number of used DMARDs of 6 , mean DAS28 at baseline 6.2) have 
been treated with infliximab infusions using a time-titration regimen based on the 
same flare criteria used by the present study. Infusions were delayed until a disease 
flare occurred. The new time-interval was based on the time to flare derived from the 
last infusion, with a minimum time interval of 4 weeks and a maximum of 16 weeks. 
Even in this selected group of patients with severe RA substantial differences in
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required dosing intervals could be demonstrated (median time interval 5.1 weeks, 
range 4-7 weeks). The calculated weekly required doses were between 24 mg/week 
and 76 mg/week (factor 3.2). It is possible that some patients might have benefited 
from an even shorter dosing interval, but this was not allowed by the study protocol.
A drawback of a step down dose titration is the inevitable disease flare in the titration 
phase. Eighteen out of 21 patients experienced a flare of the disease, but the mean 
DAS28 after the dose titration phase was not significantly higher than the DAS28 at 
start of the study. Moreover, no patients dropped out of the study due to a persistent 
flare. However, it should be noted that in case of an increase of the disease activity 
the dose of anti-TNFa could be adjusted at a drug administration visit (every 2 or 4 
weeks). This way, prolonged deterioration of the RA was prevented.
In conclusion, dose titration of anti-TNFa treatment using the DAS28 is feasible and 
leads to a substantial median dose reduction while maintaining clinical efficacy. A 
large variation in the individual dose of anti-TNFa needed to maintain clinical efficacy 
is found. This approach will save costs and possibly prevent long-term side effects.
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Summary
Rheumatoid Arthritis (RA) is a common disease, characterised by a symmetric 
chronic polyarthritis. Treatment traditionally consists of second line antirheumatic 
agents (or Disease Modifying Anti Rheumatic Drugs, DMARDs) in combination with 
NSAIDs and steroids if needed. The second line antirheumatic drugs are a 
heterogeneous group of chemical drugs. These agents have limited efficacy in some 
patients and frequently side effects are seen.
In the last decade, the knowledge about the pathogenesis of RA has increased. This 
is especially true concerning the role of proinflammatory cytokines like Interleukin ß 
(IL-1 ß) and tumour necrosis factor a (TNFa) and other soluble mediators of 
inflammation. Based on these insights, new agents have been designed to 
specifically block the action of TNFa or IL-1 ß. TNFa blockade can be accomplished 
using monoclonal antibodies or with TNF receptor fusion proteins. These agents bind 
with TNFa, prevent its binding to membrane receptors and neutralise therefore the 
biological activity of TNFa. Both approaches have been shown to be effective in the 
treatment of RA and have found their way to the clinics in recent years.
The first monoclonal anti-TNFa antibodies that were clinically tested contained both 
human and murine protein sequences. The use of such, so-called, chimeric or 
humanised antibodies is potentially limited by the formation of human anti-chimeric 
antibodies (HACA) which may lead to a shortened half-life and therefore shortened 
effect or to adverse reactions. To circumvent these drawbacks, a fully human anti- 
TNFa antibody (Adalimumab (D2E7, Knoll) has been developed which is now being 
studied in phase III rheumatoid arthritis clinical trials.
The subject of this thesis is the evaluation of several aspects of the short and long­
term treatment of patients with RA with adalimumab, a human anti-TNFa MoAb 
adalimumab and lenercept, a p55 receptor fusion protein [Ro 45-2081, lenercept, 
Roche]). These aspects include among others the efficacy, mode of action, safety 
and the use in daily clinical practice of this biological agent.
Chapter II
In this chapter the current state-of-the-art in disease assessment in rheumatoid 
arthritis is reviewed. To study the effects of any therapeutic intervention in patients 
with RA, the disease activity needs to be measured. There is however no "golden 
standard" for disease assessment in RA. Therefore, a wide variety of variables have 
been used in rheumatoid arthritis clinical trials, which of course hampers the 
comparison of results obtained in different studies. In the last decade, much effort 
has been directed towards improving and standardising disease assessment. 
Consensus has been reached on a minimum - so-called core set - of variables that 
should be measured in clinical trials. This consensus is based on the validity and 
sensitivity to change of these variables. The methods that should be used to 
measure these variables (for instance which type of joint counts should be used or 
which questionnaire is more suitable to assess a certain aspect of the disease) have 
however not yet been standardised.
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Using this core set of variables, improvement criteria have been developed. These 
are the American College of Rheumatology improvement criteria (ACR criteria) and 
the European League Against Rheumatism (EULAR). ACR criteria are dichotomous 
improvement criteria based on all coreset variables. The EULAR response criteria 
are based on the Disease Activity Score (DAS). The DAS is a combined disease 
activity index that is calculated using the number of swollen and tender joints, the 
Erythrocyte Sedimentation Rate (ESR) and the patient’s judgement of global health. 
This results in a numerical value that may range from 0-10. Using the EULAR 
response criteria, patients can be classified as good, moderate or no responder. Both 
the ACR and EULAR criteria have proven to be powerful response criteria that can 
be used to assess the response to a given treatment.
The use of the aforementioned coreset and response criteria was studied in recently 
published clinical studies. To this aim, clinical studies comparing two or more 
interventions that have been published in 1999 in leading journals were reviewed. To 
our surprise, it was found that the majority of the studies used incorrect or incomplete 
disease activity variables or response criteria. Possible causes for these 
inconsistencies and suggestions for future improvement are discussed.
Chapter III
In chapter three the short-term efficacy and toxicity of intravenous treatment with 
increasing doses of a fully human anti-TNFa antibody were studied in a randomised, 
placebo-controlled study in 120 patients. These patients suffered from a longstanding 
disease and had been previously treated with a large number of DMARDs. They 
were randomly assigned to one of five dose groups or placebo. The ACR and the 
EULAR response criteria were used to judge individual response percentages at the 
timepoints day 1 and week 1 to 4. Our results show that single doses of adalimumab 
up to 10 mg/kg were well tolerated. The pharmacokinetics properties of adalimumab 
could best be fitted to a non-compartment model. The mean half-life was 
approximately 12 days. The efficacy ranged from 70 to 100% response according to 
both ACR and EULAR response measures for doses from 1.0 mg/kg or higher (in the 
group receiving placebo the response was of 27%). The dose group of 0.5 mg/kg 
showed less efficacy. These data demonstrate the short-term safety and efficacy of 
adalimumab.
Chapter IV
Radiologic progression is an important outcome variable in RA. The first reports on 
the effect of TNFa blocking strategies on this variable show that radiologic 
progression is retarded with these therapies. Radiologic damage can however only 
be judged after a prolonged period of time and this induces an undesired delay in 
therapeutic decisions. Therefore, there is a need for markers that can predict 
radiologic outcome at an early timepoint.
We studied the effect of long-term treatment with anti-TNFa on radiological outcome 
in 47 patients. Patients that had been treated with anti-TNFa for two years were
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compared with patients that dropped out earlier because of toxicity or lack of efficacy 
and were treated with other DMARDs. Furthermore, a number of biological markers 
were measured at baseline to assess their predictive value for radiologic progression. 
These markers were chosen either for their relation with bone and cartilage turnover 
(HC gp-39, COMP and the metalloproteinases 1 and 3) or based on their 
involvement in endothelial activation (sE-selectin and sICAM-1), which plays an 
important role in the inflammation that characterises RA.
Our results show that the proportion of patients who showed radiologic progression 
was smaller in those that were treated with anti-TNFa during the whole study period 
compared to the patient group that dropped out during the study. In addition, we 
found that the time-integrated measurements of disease activity during the study 
were correlated to the radiological damage. Less disease activity resulted therefore 
in less radiological damage. The radiological outcome can to a certain extend be 
predicted using baseline sICAM-1 and COMP levels.
Chapter V
The exact mode of action of TNFa blockade in RA is not yet fully understood. Studies 
with another IgG1 anti-TNFa monoclonal antibody (infliximab) showed that blockade 
of TNFa reduces the acute phase reaction and decreases the local and systemic 
levels of adhesion molecules in RA patients. Whether these therapies also 
downregulate the synovial expression of the key proinflammatory cytokines IL-1 and 
TNFa in RA has not been fully elucidated yet, although some data supports this 
theory.
In this chapter, the effects of the first dose of adalimumab or placebo on the 
homeostasis of the two most important pro-inflammatory cytokines IL-1 ß and TNFa 
were studied. This was assessed both systemically (n=50) and at the level of the 
inflamed joint (n=25) using percutaneously obtained knee biopsies.
Two weeks after the first dose of anti-TNFa a clear decrease in acute phase related 
factors was seen (CRP, IL-6 , IL-1ra, circulating TNF receptors). The level of IL-1 in 
the circulation was low and did not change in this period. The systemic level of TNFa 
was low before treatment but increased after administration of anti-TNFa. This is 
probably due to the formation of TNFa:anti-TNFa complexes. Despite a clear 
reduction in joint swelling and pain already 2  weeks after therapy initiation, no clear 
changes with respect to the expression of proinflammatory cytokines and 
inflammatory cells were seen in synovial biopsies. The expression of TNFa and IL-1 
and the number of inflammatory cells were correlated within individual biopsies but 
demonstrated large inter-individual variation.
The short-term clinical effects of anti-TNFa can therefore not be explained by 
changes at the synovial level but seem to be caused by systemic effects of anti- 
TNFa.
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Chapter VI
The Hypothalamic-Pituitary-Adrenal axis (HPA-axis) could play a role in the 
mechanism of action of anti-TNFa. Although acute TNFa or IL-1 administration is 
known to stimulate the HPA-axis, the HPA axis does not seem to be activated in 
patients with RA. We hypothesised that TNFa could have a suppressive effect on the 
HPA axis in a chronic inflammatory state. In this scenario, blockade of TNFa could 
lead to an increased activity of the HPA axis. The latter would be concordant with the 
rapid clinical and laboratory effects of anti-TNFa treatment that mimic treatment with 
corticosteroids.
The effect of treatment with anti-TNFa on the HPA axis was assessed in eighteen 
patients receiving adalimumab (n=8 ), lenercept (n=5) or placebo (n=5). Several 
variables that reflect the activity of the HPA axis were measured, including ACTH 
levels and levels of cortisol in serum and saliva. In order to measure the effect of 
anti-TNFa on the HPA axis and not the effects of prolonged disease ameliorating 
during therapy, all assessment were performed at baseline and one day after the first 
administration of anti-TNFa.
Results show that the disease activity, measured using the DAS, had significantly 
decreased already one day after the first does of anti-TNFa. However, all HPA axis 
related variables remained unchanged in this period and no correlation was found 
between these variables, acute phase reaction, and clinical parameters. Therefore, it 
can be concluded that HPA axis modification is not part of the short-term mechanism 
of action of anti-TNFa treatment.
Chapter VII
Except for involvement of synovial joints, extra-articular pathology can also 
accompany RA. Vasculitis is one of the more frequent occurring extra-articular 
manifestations of RA. It usually affects small vessels, ranging from nail-fold infarcts to 
more severe digital gangrene and leg ulcers. Vasculitis can also affect larger vessels 
leading to organ damage. The effect of TNFa-blockade on RA related vasculitis is 
unknown.
Chapter 7 describes the positive effect of treatment with lenercept (a p55:IgG1 fusion 
protein) on skin vasculitis in one patient with RA. This patient had persistent nailfold 
lesions that disappeared within days after administration of anti-TNFa. This 
phenomenon was repeatedly observed during several cycles of anti-TNFa 
administrations. This is the first report on the effect of TNFa blocking agents on extra 
articular manifestations of RA.
Chapter VIII
Neutrophilic granulocytes (neutrophils) play an important role in the inflammation that 
characterises RA. These cells are abundantly present in RA synovial fluid and 
increased production of reactive oxygen species (ROS) by these cells can induce 
cartilage damage. Modulation of neutrophil functions could therefore be beneficial in 
RA. TNFa is involved in the in-vivo priming of neutrophils and in the induction of ROS
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production and chemotaxis. It has been suggested that reduction of neutrophil 
priming and ROS production may be implicated in the mechanism of action of several 
antirheumatic drugs, including methotrexate and leflunomide. Whether this also holds 
true for TNFa blocking agents is still unknown.
In contrast, modification of neutrophil activity by TNFa blocking agents could yield 
adverse effects. Data derived from experimental animal models suggest increased 
susceptibility for infections and impaired clearance of (pre) malignant cells after 
TNFa neutralisation. These adverse effects are partially mediated through an 
impaired function of phagocytic cells, including neutrophils.
Neutrophil ROS production and chemotactic capacity were measured ex-vivo in RA 
patients and healthy controls (n=29). Moreover, two in vivo models were used to 
study neutrophil migration in RA patients. Migration into the synovial joints was 
measured using scintigraphy with radiolabelled autologous leukocytes (n=4). 
Neutrophil migration to a non-target organ (the skin) was assessed using an 
ultraviolet type B skin inflammation model (n=12).
Our results show that ROS production in RA patients was only slightly increased 
compared to healthy controls and this difference disappeared two weeks after the 
first injection of anti-TNFa. Ex-vivo measured chemotaxis did not change after 
treatment. The scintigraphic studies revealed a reduction in neutrophil migration into 
inflamed joints of approximately 50% compared to baseline in patients treated with 
anti-TNFa, whereas placebo treated patients remained unchanged. The normal 
migration of neutrophils and other inflammatory cells to the skin after UVB radiation 
induced acute inflammation was not significantly influenced by anti-TNFa treatment.
In conclusion, anti-TNFa therapy rapidly decreases the influx of neutrophils into RA 
joints. However, the physiological migration of neutrophils to a non-target organ, such 
as the skin, and their chemotaxis and ROS production are not significantly impaired 
after treatment.
Chapter IX
No clearly related specific adverse effects of anti-TNFa treatment have been 
reported yet. In this chapter a patient is described that develops a nephrotic 
syndrome during treatment with anti-TNFa. The proteinuria disappeared 
spontaneously after cessation of anti-TNF treatment. After rechallenge, the nephrotic 
syndrome reappeared, establishing a causal relationship with anti-TNFa treatment. 
Renal biopsy disclosed a membranous glomerulopathy but clinically, the nephrotic 
syndrome was characterised by a highly selective proteinuria and immediate 
responsiveness to steroid treatment. This clinical picture is more compatible with a 
minimal lesion glomerulopathy. The potential pathofysiology of this side effect of anti- 
TNFa is discussed.
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Chapter X
Although two anti-TNFa agents have recently reached clinical practice, their exact 
place in the treatment of RA has yet to be established. Anti-TNFa strategies possess 
some distinct characteristics compared to traditional antirheumatic drugs. The onset 
of action is very rapid, especially after intravenous administration. In addition, it is 
conceivable that the inter-individual variation in effective dose of anti-TNFa is large. 
This conception is based on the blocking characteristics of these agents -  blocking 
TNFa with a fixed ratio - and the large inter-individual variation in cytokine levels in 
patients with RA. This large inter-patient variation could theoretically result in gross 
over- or undertreatment when standard dosing schedules are applied. Moreover, in 
view of the high costs, individual dosing is warranted.
We developed a treatment protocol to find the minimal effective dose of anti-TNFa for 
each individual patient that can be used in daily clinical practice. This protocol was 
tested for 40 weeks in 21 patients that had been treated with intravenously anti-TNFa 
every 2 or 4 weeks for two years and had stable disease activity. The disease activity 
was monitored using the Disease Activity Score (DAS28), a combined disease 
activity index, ranging from 0-10. A disease flare was defined using a reversed 
version of the EULAR response criteria. An increase in DAS28 greater than 1.2 or an 
increase between 0.6 and 1.2 but a resulting DAS28 higher than 5.1 were considered 
a disease flare. The dose of anti-TNFa was lowered every eight weeks in steps from
3.0 through 1.0, 0.5 to 0.25 mg/kg. When a patient had a flare of the disease that 
fulfilled the flare criteria, the dose was increased to the previously effective dose. The 
dosing intervals were kept unchanged.
At study end, three patients remained on the highest initial dose whereas nine, three 
and three patients could be downtitrated to 1.0, 0.5 and 0.25 mg/kg respectively. The 
highest individual total weekly dose of anti-TNFa was 130 mg, the lowest 4 mg, more 
than 40 times lower. No patients dropped out from the study due to a persistent flare 
of the disease activity.
It can be concluded that inter-individual variation in effective anti-TNFa dosages is 
high. Dose titration of anti-TNFa treatment using the DAS28 is feasible in daily 
clinical practice and leads to overall dose reduction while maintaining clinical efficacy, 
thus saving costs.
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Chapter XII
Nederlandse samenvatting
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Reumatoïde artritis ("chronisch reuma” in de volksmond, RA), is een ziekte die 
gekenmerkt wordt door een chronische ontsteking van meerdere gewrichten. Naast 
de stijfheid en pijn die dit veroorzaakt, kan de ziekte op den duur ook leiden tot 
beschadiging en functieverlies van gewrichten. Bij de medicamenteuze behandeling 
van RA spelen naast ontstekingsremmende pijnstillers (NSAIDs) en 
bijnierschorshormonen (b.v. prednison) de langzaam werkende antireumatische 
middelen (DMARDs) de belangrijkste rol. Van deze medicijnen is het gunstig effect 
op de RA meestal bij toeval ontdekt, zij werden hiervoor niet specifiek ontwikkeld. 
Hoewel behandeling met DMARDs de RA vaak positief beïnvloedt is dit niet bij alle 
patiënten het geval. Ook wordt behandeling met DMARDs vaak bemoeilijkt door het 
ontstaan van bijwerkingen.
In de afgelopen jaren is er meer bekend geworden over de mechanismen die ten 
grondslag liggen aan de ontsteking die bij RA plaatsvindt. Bepaalde cytokinen, 
eiwitten die geproduceerd worden door cellen en die andere cellen aanzetten tot het 
vormen van een ontsteking, lijken hierbij een belangrijke rol te spelen. De 
belangrijkste hiervan bij RA zijn interleukine-1 en tumor necrose factor a (TNFa). 
Gebaseerd op deze kennis zijn medicijnen ontwikkeld die zeer specifiek deze stof 
neutraliseren.
In het menselijk lichaam kunnen de effecten van TNFa op verschillende manieren 
worden geblokkeerd. Dit kan worden gedaan met antistoffen die specifiek binden aan 
TNFa. Ook kunnen voor dit doel TNF receptoren worden gebruikt. De eerste 
gepubliceerde resultaten van beide benaderingen laten een goed effect zien op RA. 
De antistof tegen TNFa die in deze onderzoeken werd bestudeerd, is een eiwit dat 
een combinatie is van mensen en muizeneiwit. Dit is op theoretische gronden minder 
aantrekkelijk dan een geheel menselijk eiwit. Niet-menselijke eiwitten zouden 
namelijk na toediening aan de mens allergische reacties zouden opwekken. 
Adalimumab is een antistof gericht tegen TNFa dat geheel uit menselijke eiwitten 
bestaat. Het is ontwikkeld door Knoll BASF. Vanaf 1997 wordt dit middel bij patiënten 
met RA getest. In dit proefschrift worden diverse aspecten van de behandeling van 
patiënten met RA met adalimumab belicht. De werkzaamheid, veiligheid en 
onderliggende werkingsmechanismen worden bekeken.
Om de werkzaamheid van een behandeling bij patiënten met RA te kunnen meten, 
moet de activiteit van de ziekte gemeten worden. Omdat er niet één gouden 
standaard is waarmee de ziekteactiviteit in RA gemeten kan worden, werd in het 
verleden een veelheid aan variabelen gemeten die met de ziekteactiviteit 
samenhangen. Hieronder vallen bijvoorbeeld het aantal pijnlijke en gezwollen 
gewrichten, de duur van de ochtendstijfheid, de grijpkracht van de handen et cetera. 
In de laatste jaren is onder meer door onze groep veel werk verricht om de meting 
van de ziekteactiviteit betrouwbaarder en beter vergelijkbaar te maken. In hoofdstuk
2 wordt de huidige stand van zaken op dit gebied geïnventariseerd. Ook wordt 
bestudeerd of de bestaande richtlijnen in wetenschappelijke publicaties worden 
gevolgd.
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Er blijkt overeenstemming te bestaan over welke variabelen minimaal gemeten 
zouden moeten worden in patiënt gebonden onderzoeken om de ziekteactiviteit bij 
RA vast te stellen. Twee gecombineerde respons criteria (criteria, die een aantal van 
voornoemde variabelen combineren in één maat) zijn ontwikkeld in de afgelopen 
jaren. Dit zijn de ACR criteria en de EULAR criteria. De laatstgenoemde zijn 
gebaseerd op de DAS. Dit is een gecombineerde ziektemaat voor RA, die berekend 
wordt uit het aantal gezwollen en pijnlijke gewrichten, de bezinking en de 
ziekteactiviteit volgens de patiënt zelf. De schaal loopt van 0 tot 10. Zowel de EULAR 
als de ACR criteria zijn goed bruikbaar voor het vastleggen van welke individuele 
patiënten met RA goed reageren op een behandeling. Over een aantal zaken is 
echter nog geen duidelijkheid, bijvoorbeeld met welke gewrichtscore het aantal 
aangedane gewrichten geteld zou moeten worden.
Bij revisie van de medische literatuur blijken de bovengenoemde richtlijnen bij opzet 
en verslaglegging van onderzoek nog onvoldoende of incorrect gebruikt te worden. 
Van 12 klinische studies die in 1999 werden gepubliceerd gebruikt het grootste deel 
onjuiste of onvolledige ziektematen. Deze ontwikkeling zal in de toekomst 
nauwlettend gevolgd dienen te worden.
De effectiviteit en veiligheid van een éénmalige toediening van verschillende 
doseringen adalimumab in 120 patiënten wordt in hoofdstuk 3 beschreven. Deze 
patiënten waren eerder zonder succes behandeld met andere middelen tegen RA, 
maar hadden nog niet adalimumab gekregen. Verschillende doseringsgroepen, 
waaronder ook een placebogroep (een niet werkzaam medicijn), worden met elkaar 
vergeleken.
Doseringen van 1 tot 10 mg per kilogram lichaamsgewicht blijken goed verdragen te 
worden door alle patiënten en effectief te zijn bij ongeveer 70% tot 100% van de 
behandelde patiënten. De dosering van % mg per kilogram heeft echter een lagere 
effectiviteit na éénmalige toediening. Na toediening van placebo laat slechts 27% van 
de patiënten een verbetering zien. De halfwaardetijd bedraagt ongeveer 12 dagen. 
Op de korte termijn is behandeling met adalimumab veilig en effectief.
Bij patiënten met RA is, naast het behandelen van de huidige klachten, het 
voorkomen van kraakbeen- en botschade op de langere termijn en daarmee gepaard 
gaande verlies aan functionaliteit een belangrijk doel van de behandeling. De gouden 
standaard voor het vervolgen van deze schade zijn de röntgenfoto’s van handen en 
voeten. Het aantal beschadigingen op deze foto’s kan worden geteld en zo kan de 
röntgenschade in getal uitgedrukt worden. Deze informatie is echter altijd pas 
achteraf beschikbaar, en het zou aantrekkelijker zijn uit het oogpunt van behandeling 
om hierover eerder geïnformeerd te kunnen worden. Hoofdstuk 4 laat de effecten 
van twee jaar behandeling met anti-TNFa op de röntgenschade in 47 patiënten met 
RA zien. Ook wordt de voorspellende waarde van zes verschillende bloedbepalingen 
(metalloproteinasen, adhesiemoleculen, COMP en HC gp-39) op het ontstaan van
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röntgenschade na twee jaar onderzocht. Deze variabelen zijn uitgekozen op basis 
van hun (mogelijke) relatie met kraakbeenschade.
De patiënten die de gehele periode zijn behandeld met anti-TNFa ontwikkelen 
minder röntgenschade na twee jaar dan patiënten die gedurende de studie stopten 
en met andere middelen behandeld werden. Ook is de gemiddelde ziekteactiviteit 
gedurende deze 2  jaar gerelateerd aan de uiteindelijke röntgenschade, dat wil 
zeggen: minder ziekteactiviteit, minder schade. Aangezien behandeling met anti- 
TNFa de gemiddelde ziekteactiviteit duidelijk verminderd, pleit deze bevinding voor 
een positief effect van behandeling met anti-TNFa op het ontstaan van 
röntgenschade. Het beloop van de röntgenschade in patiënten groepen kan tot op 
zekere hoogte worden voorspeld middels de COMP en de sICAM-1 spiegels aan het 
begin van de studie.
Het werkingsmechanisme van TNFa blokkade in patiënten met RA is nog niet geheel 
opgehelderd. Er is nog zeer weinig bekend over het effect van deze behandeling op 
de hoeveelheden van de belangrijkste ontsteking cytokines (TNFa en IL-1 ß) in het 
bloed en in de gewrichten. Hoofdstuk 5 beschrijft de effecten van een éénmalige 
toediening van anti-TNFa op de hoeveelheid en productiesnelheid van TNFa en IL- 
1ß en hun natuurlijke tegenhangers (IL-1ra en TNF receptoren) in het bloed van 50 
patiënten met RA. Ook wordt in 25 patiënten met behulp van kniebiopten het effect 
van deze behandeling op het aantal ontstekingscellen en de aanwezigheid van TNFa 
en IL-1 ß in het kniegewricht bestudeerd.
De behandeling met anti-TNFa leidt tot een duidelijke daling in het bloed van 
factoren die gerelateerd zijn aan ontsteking (CRP, IL-6 , IL-1 ra, TNF receptoren). De 
hoeveelheid IL- 1  ß in het bloed blijft laag en onveranderd; de aanmaak van IL- 1  ß 
neemt echter wel af. De concentratie TNFa is voor behandeling laag en neemt toe na 
behandeling. Dit is het gevolg van het binden van TNFa aan de antistof in het bloed. 
Ondanks duidelijke afname van gewrichtspijn en zwelling en de algemene 
ziekteactiviteit waren in het weefsel van de knie bovengenoemde effecten niet 
aantoonbaar. De hoeveelheden TNFa, IL-1 ß en ontstekingscellen in één biopt blijken 
wel duidelijk aan elkaar gerelateerd. Allen worden echter niet beïnvloed door twee 
weken behandeling met anti-TNFa. De klinische effecten van een éénmalige 
toediening van anti-TNFa lijken derhalve niet verklaard kunnen worden door 
beïnvloeding van IL-1 ß en TNFa lokaal aanwezigheid in het gewricht maar eerder 
door systemische activiteit van anti-TNFa.
Hormonale regelsystemen kunnen ook een rol spelen bij het effect van anti-TNFa. 
Ofschoon een acute toediening van TNFa de natuurlijke productie van 
bijnierschorshormoon productie activeert, wordt in patiënten met RA geen verhoogde 
of juist een verlaagde productie gezien. Van bijnierschorshormoon is bekend dat het 
een sterk onderdrukkend effect heeft op de TNFa productie. Het zou zo kunnen zijn 
dat patiënten met RA een relatief verlaagde bijnierschorshormoon productie hebben. 
Omgekeerd is het mogelijk dat TNFa de bijnierschorshormoon productie verlaagd bij
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de chronische ziekte RA. Blokkade van TNFa zou dan leiden tot toename van de 
bijnierschorshormoon productie. Dit zou goed kunnen passen bij één van de 
belangrijkste kenmerken van anti-TNFa behandeling, het snelle optreden van het 
klinisch effect. Dit wordt namelijk eveneens gezien na behandeling met bijnierschors 
hormonen (prednison).
In hoofdstuk 6 wordt bestudeerd of toediening van anti-TNFa effect heeft op de 
regulatie van de productie van bijnierschorshormoon (de zogenaamde hypofyse 
bijnier as). Bij 18 patiënten (13 anti-TNFa en 5 placebo) worden een aantal 
bepalingen verricht die een maat zijn voor de activiteit van de eigen 
bijnierschorshormoon productie, zoals ACTH en cortisol in het bloed, en cortisol in 
het speeksel en in de urine. Deze bepalingen worden herhaald op de eerste dag na 
toediening van de eerste dosering anti-TNFa.
Er wordt geen verschil gezien tussen de resultaten voor en na behandeling en tussen 
patiënten die placebo of anti-TNFa krijgen. Ook het klinisch effect van anti-TNFa is 
niet gerelateerd aan de hoogte van bijnierschorshormoon productie of uitscheiding. 
Geconcludeerd kan worden dat de het snelle klinische effect van anti-TNFa niet te 
maken heeft met beïnvloeding van de bijnierschorshormoon productie.
Naast de gewrichtsontsteking die wordt gezien bij patiënten met RA, kunnen ook 
ziekteverschijnselen buiten de gewrichten optreden, zogenaamde extra-articulaire 
symptomen. De bekendste hiervan zijn de onderhuidse reumanoduli 
(“reumaknobbels”). Ook kunnen ontstekingen van de kleine bloedvaatjes optreden 
(vasculitis). De gevolgen van het laatste kunnen variëren van kleine wondjes aan de 
huid tot grote beschadigingen van inwendige organen zoals longen en nieren. Er is 
weinig bekend over de effecten van behandeling met anti-TNFa op extra articulaire 
manifestaties van RA.
In Hoofdstuk 7 wordt één patiënt beschreven die een typische ontsteking aan de 
kleine bloedvaatjes van de vingertoppen heeft. Deze patiënt laat herhaaldelijk een 
goede reactie zien op toediening van anti-TNFa, waarbij de verschijnselen van de 
vasculitis eveneens verdwijnen. Deze waarneming suggereert dat behandeling met 
anti-TNFa extra-articulaire verschijnselen zoals vasculitis van de huid of andere 
organen gunstig kan beïnvloeden
Naast de werkzaamheid van een nieuw medicijn speelt de veiligheid ervan ook een 
belangrijke rol. Van blokkade van TNFa in proefdieren is bekend dat er een 
verhoogde gevoeligheid voor bepaalde infecties kan ontstaan. Dit wordt mede 
veroorzaakt door afgenomen activatie van neutrofiele segmentkernigen, een soort 
witte bloedcellen. Deze cellen hebben belangrijke functies bij de afweer tegen micro- 
organismen. Zij kunnen zich naar de ontstekingshaard verplaatsen (chemotaxie) en 
micro-organismen onschadelijk maken middels de aanmaak van bepaalde stoffen 
(zuurstofradicaal productie). Of deze functie beïnvloedt worden door behandeling 
met anti-TNFa is nog niet geheel duidelijk. Dit mogelijke effect van de behandeling
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zou een deel kunnen zijn van het werkingsmechanisme maar ook de gevoeligheid 
voor infecties kunnen doen toenemen.
In hoofdstuk 8 worden de effecten van een éénmalige dosering anti-TNFa op de 
aanmaak van zuurstof radicalen en chemotaxie door neutrofielen beschreven in 29 
patiënten met RA. Aansluitend hierop wordt in enkele patiënten door middel van 
beeldvorming bekeken, of de instroom van deze witte bloedcellen in ontstoken 
gewrichten afneemt na behandeling. Tenslotte wordt middels een huidonderzoek na 
UVB belichting in 12 patiënten onderzocht of ook buiten de gewrichten een 
verandering van instroom van neutrofielen wordt gezien.
De resultaten laten zien dat de zuurstofradicaal productie door neutrofielen bij 
patiënten met RA slechts iets hoger is dan bij gezonde vrijwilligers. Dit verschil 
verdwijnt echter na toediening van anti-TNFa. De instroom van witte bloedcellen in 
de gewrichten neemt wel duidelijk af na behandeling. Het vermogen tot chemotaxie 
van de cellen zelf blijft echter onveranderd na behandeling. In de huid wordt geen 
effect gevonden. Dit leidt tot de conclusie dat er geen grote beïnvloeding van 
neutrofiel functie door behandeling met anti-TNFa bestaat. De afname van de 
instroom van cellen in de gewrichten wordt waarschijnlijk veroorzaakt door afname 
van ontstekingsfactoren in het gewricht, niet door functieverlies van de bloedcellen 
zelf.
In hoofdstuk 9 wordt een patiënt beschreven met een nog niet eerder beschreven 
bijwerking van behandeling met anti-TNFa. Enkele maanden na de start van 
behandeling met anti-TNFa ontwikkelde deze patiënt een nieraandoening, die 
gekenmerkt wordt door verlies van eiwit via de urine. Na staken van de behandeling 
met anti-TNFa verdween dit zogenaamde nefrotisch syndroom binnen een aantal 
weken. Herstart van de toediening van anti-TNFa resulteerde in een hernieuwde 
opvlamming van het nefrotisch syndroom, zodat de oorzakelijke relatie met de anti- 
TNFa behandeling duidelijk werd. De anti-TNFa behandeling werd voortgezet, omdat 
het nefrotisch syndroom goed reageerde op een lage dosering prednison.
De mogelijke onderliggende mechanismen van dit nefrotisch syndroom veroorzaakt 
door anti-TNFa worden belicht.
De behandeling van RA met anti-TNFa verschilt in belangrijke mate van de 
behandeling met conventionele DMARDs. Het effect van anti-TNFa treedt snel op en 
is sterk. Daarnaast valt op basis van de grote verschillen in TNFa spiegels en 
productie tussen patiënten een groot verschil in werkzame dosering te verwachten. 
Ook gezien de zeer hoge kosten die verbonden zijn aan behandeling met anti-TNFa 
is het van belang om per individu de juiste dosering te kunnen vaststellen. In 
hoofdstuk 10 worden 21 patiënten bestudeerd waarbij met behulp van de DAS 
score de individueel benodigde dosis anti-TNFa wordt bepaald. Terwijl elke acht 
weken een DAS score wordt bepaald (en eventueel vaker wanneer de ziekteactiviteit 
toeneemt), wordt de dosering anti-TNFa verlaagd van 3.0 naar 1.0, 0.5 en tenslotte 
0.25 milligram per kilogram lichaamsgewicht.
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De resultaten laten zien dat het mogelijk is middels de DAS score de behandeling per 
patiënt te optimaliseren. De gemiddelde wekelijkse dosering van anti-TNFa kon 
worden gehalveerd zonder duidelijke toename van de ziekteactiviteit. De doseringen 
die nog effectief waren varieerden tussen patiënten met een factor 40. Hieruit blijkt 
dat er grote verschillen tussen patiënten bestaan in behoefte aan anti-TNFa.
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